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The work presented in this thesis looks at using multi-component crystallisation techniques to 
impart solid form control to pharmaceutically relevant systems. In this thesis solid form 
encompasses both different polymorphic forms of the same material as well as the chemical and 
physical stability of a non-polymorphic single component compound.  The work emerges as part as 
the EPSRC Future Manufacturing Hub in Continuous Manufacturing and Advanced Crystallisation 
(CMAC); an academic-industrial collaboration set up to aid the adoption of continuous 
manufacturing processes into an industrial setting. 
Chapters 3-5 explore the use of incorporating a second molecular component into the 
crystallisation process, termed a template in this work, in order to direct the formation of 
metastable polymorphic forms. Chapter 3 investigates this templating effect on the formation of 
the metastable form (II) of paracetamol (PCM) in a small scale batch crystallisation environment; 
PCM-II displays enhanced compressibility and solubility in comparison to the stable PCM-I. A 
number of structurally similar and size-matched template molecules are investigated for their 
templating effects, with the most success observed with the structurally similar metacetamol 
(MCM). Possible mechanistic insights into the action of the template molecules are also 
investigated.  In Chapter 4, the conditions for the templated production of PCM-II with MCM at the 
100 ml scale are optimised through use of a Design of Experiments analysis. Identification of 
optimal conditions for the production of PCM-II are then used in further batch scale-up experiments 
at the 800 ml scale, monitored with process analytical technologies.  
Chapter 4 also describes initial transfer to continuous crystallisation platforms, investigating 
production in a periodic mixed suspension mixed product removal (PMSMPR) crystalliser, with 
Chapter 5 describing flow crystallisation experiments in the continuous oscillatory baffled 
crystalliser (COBC) and the kinetically regulated automated input crystalliser (KRAIC). The use of the 
COBC resulted in the successful continuous crystallisation of PCM-II; however elimination of an 
impurity proved problematic. The use of the PMSMPR platform resulted in the first ever successful 
continuous crystallisation of phase pure samples of PCM-II. 
Chapter 6 describes obtaining solid form control of reactive pharmaceuticals through incorporation 
inside benign host molecules. Investigations focussed on two hosting systems whereby the APIs 
thiamphenicol and α-lipoic acid were hosted within γ- and β- cyclodextrin, respectively. Full NMR 
analysis to elucidate host-guest stoichiometry was performed, with the transfer to cooling 
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1 Introduction – Crystallisation of molecular 
products 
1.1  Context of research 
With over 80 % of marketed pharmaceuticals delivered in a crystalline form, crystallisation is a key 
step in the manufacture and production of pharmaceuticals and fine chemicals. The ability to 
control the solid form of active ingredients, in terms of their polymorphic form, crystal size and 
shape or crystal size distribution is of paramount importance in the crystallisation process and much 
research has been directed towards it in recent years. The transfer of these systems from small 
scale discovery environments into large scale batch crystallisation settings is critical for adoption 
into an industrial setting. The work presented here emerges from the EPSRC Future Manufacturing 
Hub in Continuous Manufacturing and Advanced Crystallisation (CMAC); an academic-industrial 
collaboration between seven UK universities and a number of industrial partners set up to aid the 
adoption of continuous manufacturing processes into an industrial setting, paving the way for more 
efficient processes for the manufacture of fine chemicals and pharmaceuticals with greater control 
over particle attributes. 
1.2 Supersaturation 
Supersaturation is considered to be the thermodynamic driving force of crystallisation; the method 
of crystallisation will determine how this supersaturation is generated (outlined in section 1.6). A 
solution is considered supersaturated when it contains more dissolved solute than is dictated by 
the solubility curve at a given temperature and pressure (i.e. the equilibrium solubility); for this 
reason it is sometimes referred to as supersolubility. Relative supersaturation (σ) is dimensionless 
and can be described as the difference between the chemical potential of a molecule in its 
supersaturated state (µss) and its equilibrium state (µeq), as outlined in Equation 1.1. 
𝝈 =  
µ𝒔𝒔− µ𝒆𝒒
𝒌𝑻
                     Equation 1.1 
Supersaturation is more commonly expressed in terms of concentrations (c, solution concentration 
and c*, equilibrium concentration), introducing a supersaturation ratio (S), which quantifies the 
extent to which a solution of a certain concentration exceeds the equilibrium solubility, outlined in 
Equation 1.2 and Equation 1.3. 
𝑺 =  
𝒄
𝒄∗
                                    Equation 1.2  
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𝝈 =  
𝒄− 𝒄∗
𝒄∗
= 𝑺 − 𝟏               Equation 1.3  
In order to design any crystallisation process, knowledge of the solubility of the system is crucial. 
Figure 1.1 shows a typical concentration-temperature solubility diagram, with three main regions 
highlighted. The solid black line represents the equilibrium solubility curve and the dotted line 
represents the metastable limit under a given set of conditions; the region between these is known 
as the metastable zone width (MSZW).  
When the composition of the solution lies below the equilibrium solubility line, the solution is 
undersaturated and in this region any remaining crystals will dissolve. Utilising the undersaturated 
region aids experiments such as temperature cycling to allow dissolution of fine particles and using 
the supersaturation generated by this for growth of larger particles. The region between the 
solubility line and the metastable limit is termed the metastable zone width. Within this region any 
existing crystals will grow and secondary nucleation can occur, however primary nucleation is not 
possible. Knowledge of the metastable zone width is needed to aid the design of seeded 
crystallisations. However, factors such as cooling rate, scale of crystallisation and presence of 
impurities can alter the metastable zone limit significantly, and so this should not be considered a 
definite, fixed quantity. Above the metastable limit is the supersaturated region which is dominated 
largely by uncontrolled, spontaneous primary nucleation.  
1.3  Nucleation 
Nucleation is a step that refers to the assembly of molecules within a supersaturated solution to 
form a new solid phase. It is a key step in determining the outcome of a crystallisation process, 
dictating properties such as crystal size distribution and polymorphic form. Nucleation can be 




broadly categorised as either primary or secondary and the former as either homogeneous or 
heterogeneous (detailed in Figure 1.21). 
Homogeneous nucleation is spontaneous and does not require external stimuli; supersaturation, 
as outlined above, drives this process. Secondary nucleation, which is by its nature heterogeneous, 
requires a surface on which to nucleate, which can be an additive, an impurity or a seed crystal of 
the desired product. The presence of this additional surface, on which to nucleate, lowers the value 
of free energy of the assembling system, hence allowing nucleation at lower values of 
supersaturation than those required for spontaneous homogeneous nucleation.2 
There are two nucleation pathways that are currently accepted within the crystallisation 
community: classical nucleation theory (CNT) and two-step nucleation. The differences between 
these are highlighted schematically in Figure 1.3.  
 
 
Figure 1.2: Nucleation classification (adapted from Beckmann1) 
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Figure 1.3: The two commonly accepted nucleation pathways: classical nucleation theory (top) and two-step nucleation 
(bottom)3 
Classical Nucleation Theory (CNT) was originally postulated by Volmer4 in the early 1900’s. In CNT, 
it is proposed that there are density and order fluctuations within a supersaturated solution. These 
various fluctuations result in the formation of clusters, with the packing within each of these 
clusters representing each of the polymorphic forms of the material being crystallised. The 
nucleation rate (J), defined as the number of crystalline particles that form per unit of volume and 




]     Equation 1.4  
Where  B/ln2S = W/kT and is described as the energy barrier to nucleation. 
It is clear that the nucleation rate displays an inverse relationship to the supersaturation ratio of 
the solution: increasing the supersaturation ratio by even a fraction, results in large decreases in 
the nucleation rate. 
Two- step nucleation was originally proposed by Vekilov5 and is a mechanism commonly seen in 
the crystallisation of proteins; the molecules come together in a disordered liquid phase before 
establishing order within that liquid phase and then forming a crystal. The main distinction between 
this theory and CNT is the appearance of crystalline order over time compared to immediate 
establishment of crystalline order in clusters in CNT. 
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1.3.1 Thermodynamics of nucleation 
The thermodynamics of nucleation consider the total free energy required to form a cluster of a 
critical size; it is the sum of the free energies associated with the formation of a surface (with an r2 
dependence and is positive and hence unfavourable) and with the bulk volume effect (with an r3 
dependence and is negative and so is favourable). The combination of these two free energies 
produces a curve like that shown in Figure 1.4, with the surface energy dominating initially until rc 
is reached and the volume free energy dominating after, resulting in the favourable negative ΔG. 
The negative volume free energy effect is associated with the decrease in free energy observed 
when a molecule within a supersaturated solution is transferred from the solution to the solid state; 
this change is favourable as the solid state is more stable under these conditions. The positive 
surface free energy effect is associated with the formation of new crystal surfaces and contains an 
interfacial tension term characteristic of each crystal surface formed. At small cluster sizes, the 
energy associated with the formation of a new surface dominates, whilst at larger cluster sizes the 
bulk free energy dominates; this gives the characteristic curve shape shown in Figure 1.4. As such, 
there is a critical cluster size (rc) where the gain in bulk free energy and reduction in interfacial free 
energy from formation of a new surface balances. After this point, the growth of clusters is 
thermodynamically favourable, with total free energy amounting to a negative value. The value for 
rc can be calculated using Equation 1.5.  
𝒓𝒄 =  
𝟐𝝎𝜸
𝒌𝑻𝒍𝒏(𝑺)
      Equation 1.5  
Figure 1.4: A free energy diagram for the formation of a cluster (a) at low 
supersaturation, (b) at high supersaturation 
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Where ω = molecular volume, γ = surface energy, k = Boltzmann constant and T = temperature. 
Figure 1.4 shows the dependence of rc on supersaturation, with Equation 1.5 quantifying this 
dependence. Simply, as supersaturation increases the barrier associated with the formation of a 
cluster of critical size, rc, decreases. The size of this free energy barrier is characterised by the 
constant B in Equation 1.4, and will vary depending on whether the nucleation is homogeneous or 
heterogeneous.   
1.3.2 Kinetics of nucleation 
Whilst the B term in Equation 1.4 is accounted for through thermodynamic considerations, the A 
term describes the kinetics of the nucleation process. Considering the Szilard-Farkas model 6, which 
considers nucleation as a series of attachments and detachments to form clusters, the  
pre-exponential factor A can be described by Equation 1.6. 
𝑨 = 𝒛𝒇∗𝑪𝟎    Equation 1.6  
Where z is the supersaturation dependent Zeldovich factor, f* is the attachment frequency of 
building units to a nucleus and C0 is the concentration of nucleation sites. Monte Carlo type 
computer simulations model this nucleation process well and so can be helpful in simulating 
nucleation rates. 
As an example, lysozyme in a solution of aqueous sodium chloride solution has a value of A of the 
order of magnitude of 108; this fast nucleation rate is often exploited in demonstrations as the 
crystals grow visibly within seconds. In comparison, paracetamol in water has an A value of the 
order of magnitude of 103.  
1.3.3 Heterogeneous nucleation 
As mentioned above (section 1.2), the presence of a surface on which to nucleate lowers the free 
energy barrier to nucleation. The degree to which the barrier is lowered is dependent on the 
structural similarity of the impurity to the crystallising substance.7 The use of additives and their 
effects on nucleation rates has been examined for a range of materials including ice8, potassium 
dihydrogen phosphate9 and polyhydroxybutyrate.7  Heterogeneous nucleation has been utilised to 




1.3.4 Secondary nucleation 
Heterogeneous nucleation that occurs due to the presence of a seed particle of the crystallising 
substance is known as secondary nucleation. This nucleation tends to occur at much lower 
supersaturations than homogeneous or heterogeneous nucleation induced by a foreign body. Seed 
crystals are added within the metastable zone width to ensure no spontaneous nucleation (more 
details in section 1.5.3); as such, tight control over particle size distributions and polymorphic form 
output are achievable.  
Methods of generating these secondary nuclei in the reaction vessel are varied: they can be added 
deliberately to the crystallisation process either dry or in suspension, they can come from 
encrustation on vessel walls or they can be a result of particle breakage due to shear from an 
impellor, often observed with brittle needle crystals. 
1.4  Crystal Growth 
Once formation of initial nuclei has occurred, supersaturation within the reaction mixture is 
depleted to aid the growth of these nuclei into larger crystals. There are a number of mechanisms 
that have been proposed for crystal growth, some of which are outlined in this section. 
1.4.1 Crystal faces 
Nuclei in a supersaturated solution can be considered to be in equilibrium; growth units are 
constantly arriving at the surface and if they have the correct interactions to bind they will stay and 
if not they will leave. When the flux to the surface is higher than those leaving, crystal growth 
occurs.  Hartmann and Perdock12 introduced a classification system in order to define how growth 
units can be classified depending on how many interactions they make with the crystal face: a 
surface in which three bonds are possible is a kinked face, a surface in which two bonds are possible 
is a stepped face and a flat face is a surface with which only one bond is possible (Figure 1.5). 
Figure 1.5: The classification of crystal faces according to Hartmann and Perdock12 
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Assuming the crystal growth rate from a certain face is proportional to the number of attachments 
and hence the binding energy of that surface, it can be concluded that kink faces are the fastest 
growing faces and flat faces are the slowest growing faces. As such, the morphology of the crystal 
will be defined by the slowest growing, flat, F faces. Therefore, the basis of crystal growth theory is 
in the mechanisms through which these F faces grow. 
Differences in concentrations between bulk supersaturated solutions and the growth surface, and 
the corresponding diffusion effects of these concentration gradients, to allow transport of growth 
units to the surface, also affect crystal growth and should be considered. Berthoud and Valeton13 
proposed a two-step mechanism for the mass transport of growth units to a surface: diffusion from 
bulk to solid surface followed by a first order reaction whereby growth units arrange and 
incorporate themselves into the crystal lattice. Mathematically, the overall crystal growth rate 
coefficient (kG) can be expressed in terms of the diffusion coefficient (kD) and the integration of the 









     Equation 1.7 
There are energy barriers that must be overcome within the diffusion process to allow crystal 
growth to occur and these are shown in Figure 1.6. When in solution, the growth units are solvated 
and so must be partially desolvated to allow diffusion (ΔGdesolv). Next, the growth unit must diffuse 
from the bulk solution to the surface, to a position where it is able to adsorb (ΔGD). Finally, the 
growth unit must be incorporated itself into the crystal lattice at the crystal surface (ΔGr).  




1.4.2 Birth and spread model 
In discussion of the thermodynamics of nucleation, it was shown that clusters must reach a critical 
size before further growth can occur (section 1.2.1). The combination of this nucleation theory with 
growth in two dimensions on a flat surface leads to the birth and spread model14 and is illustrated 
in Figure 1.7. 15 
As this model incorporates nucleation kinetics, it has a high dependency on the supersaturation of 
the system, quantified by Equation 1.8.  
𝑹 = 𝑨𝝈
𝟓
𝟔 𝐞𝐱𝐩 (− 
𝑩
𝝈
)     Equation 1.8  
This suggests that at low values of supersaturation, no growth will occur, with a sharp rise in growth 
rates with fractional increases in supersaturation, owing to the negative inverse exponential term. 
1.4.3 Burton Cabrera Frank (BCF) model  
In practice however, growth rates are observed at low values of supersaturation; this can be 
attributed to small dislocations or defects in the crystal surface. Of particular interest is the screw 
dislocation as this can provide a step for continuous growth in a spiral fashion (Figure 1.8); these 
screw dislocations are particularly common when growth has occurred on an external surface such 




Figure 1.7: Schematic of the birth and spread model15  
Figure 1.8: The development of spiral growth, originating from a spiral dislocation13  
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Once a screw dislocation has formed, growth is no longer occurring on a flat face and therefore 
further nucleation is not needed to continue the growth process. Therefore, growth can continue 
at much lower supersaturations than are possible by the simple birth and spread model. The spiral 
growth shown in Figure 1.8 has been directly observed in a number of materials including NaCl and 
KCl16 and L-arginine trifluoroacetate17 using techniques such as atomic force microscopy (AFM) 
(shown in Figure 1.9). 
As with the birth and spread model, a mathematical expression is used to show the growth rate (R) 
of the crystal (Equation 1.9). 
𝑹 = 𝑨𝝈𝟐 𝐭𝐚𝐧𝐡 (
𝑩
𝝈
)        Equation 1.9 
1.4.4 Rough interface model 
Since, without the presence of screw dislocations, growth on flat faces is an energetically 
unfavourable process, sites with higher interaction energies such as steps or kinks need to be 
generated. A dimensionless parameter, α (Equation 1.10), or the surface entropy factor can be 
introduced, which defines the ease with which a surface is able to form these new sites with 
multiple binding interactions. 
𝜶 =  
𝜻∆𝑯𝒇
𝑹𝑻
        Equation 1.10  
Where ζ is the anisotropy factor and is related to the number of nearest neighbour sites.  
Limits and boundaries exist for the value of α that defines the type of growth that will occur under 
certain conditions. For values of α<3, continuous growth is observed; the surface will contain many 
kink and step sites to ensure multiple binding interactions are possible. Therefore, every growth 
unit that arrives at the surface will find a growth site and the growth rate is linearly proportional to 
supersaturation. For values of α between 3 and 5, there are fewer surfaces for multiple binding 
interactions. As such, not every growth unit arriving at the surface will find a growth site; those that 
Figure 1.9: Spiral growth in L-arginine trifluoroacetate crystals, 
visualised using AFM 
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do not find a growth site will either diffuse back into solution or agglomerate to other adsorbed 
units to form surface islands. These islands result in steps and kinks on the original crystal surface, 
providing more binding interactions. The growth rate takes the form of Equation 1.8 and so growth 
obeys the birth and spread model outlined above within this α range. For values of α>5, the growth 
obeys that of the BCF model outlined above and spiral growth occurs.  
1.5  Crystal morphology 
The overall shape of the crystal, often termed habit or morphology, is an important parameter to 
consider in the manufacture of fine chemicals and is a property that is controlled through the 
crystallisation process. It is common practice to distinguish between the equilibrium and kinetic 
morphology: the former is the morphology the crystal adopts when the reaction has reached 
equilibrium, and corresponds to the crystal structure that minimises the surface free energy, while 
the latter is the morphology adopted when the crystal is formed under kinetic control. Crystal 
morphology has significant effects on a variety of downstream processing steps such as flowability 
and filtration. Figure 1.10 compares the filtration of block and plate crystals; it can be seen that 
with the block crystals, the solution is able to flow freely through the crystals, whereas with the 
plate crystals, they pack in an impermeable layer and hence cause problems with filtration by 
blocking solution flow. 
There exist methods that can be used in order to predict crystal morphology, however many of 
these are based on the crystal structure alone and will not take into account the effect of external 
factors such as choice of solvent or presence of additives. Both these factors have been shown to 
have considerable effect on the morphology of crystals produced from crystallisation experiments. 
The effect of solvent on the morphology of a variety of compounds is well reported in the literature, 
including but not limited to ibuprofen18, p-aminobenzoic acid19, meta-nitroaniline20 and 
paracetamol. 21 Similarly, the effect of additives on the morphology of crystals is also well reported 
Figure 1.10: Filtration of block-like crystals (left) and plate-like crystals (right) 
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in the literature and has been demonstrated for a variety of compounds including succinic acid22, 
urea23 and paracetamol. 24 
1.6  Crystallisation methods 
In order for crystallisation to occur, a method of generating supersaturation within the system must 
be found. Crystallisation from solution is the most commonly employed method within the 
pharmaceutical industry.25 Melt crystallisation is an alternative; however this is rarely employed 
owing to the low thermal stability of many active pharmaceutical ingredients (APIs). 
1.6.1 Cooling crystallisation 
During a cooling crystallisation experiment, knowledge and understanding of the solubility is 
crucial.  Figure 1.11 shows a typical cooling profile used within a cooling crystallisation experiment. 
In the absence of any seed crystals, a period of cooling occurs in order to transform the process 
from the undersaturated region (1) to the supersaturated region (2). At point 2, nucleation will 
occur with a corresponding drop in solution concentration upon formation of crystals precipitating 
out of solution. With this drop in concentration, the system will move into the region defined by 
the metastable zone width (MSZW) (2→3). If the system is then cooled within the metastable zone, 
either through a stepped cooling profile or tracing the lower solubility curve, only growth and no 
further primary nucleation will occur. Designing a cooling profile as outlined above will help to 
produce a product with consistent particle attributes, namely particle size distribution and 
polymorphic form. 
Figure 1.11: A typical solubility diagram showing the variation of concentration with temperature during a cooling 
crystallisation experiment 
It is important to note that the metastable limit varies substantially under different crystallisation 
conditions. The presence of additives or impurities can alter the metastable zone width as well as 
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factors such as cooling rate. Faster cooling rates often do not allow equilibrium to be reached and 
hence nuclei form under kinetic rather than thermodynamic control; the crystals do not have time 
to rearrange into the most stable arrangement. Hence, faster cooling rates give rise to wider 
MSZWs. As such, operating the system close to equilibrium will favour the formation of more stable 
solid forms; metastable polymorphs are more likely to be formed through faster cooling rates. 
Cooling crystallisation is the basis of many continuous crystallisers (see section 1.7). 
1.6.2  Evaporative crystallisation 
Evaporative crystallisation is commonly employed if there is not a significant change in system 
supersaturation upon cooling. In an evaporative crystallisation experiment, the supersaturation of 
a system is generated through solvent evaporation. In a small-scale environment, an 
undersaturated solution is left at a certain temperature which causes evaporation of the solvent  
(1, Figure 1.12), thus increasing the saturation of the solution. When enough solvent has 
evaporated, the solution will cross the metastable zone width, to point 2 (Figure 1.12), and enter 
the supersaturated region. This induces spontaneous nucleation into the system.  
As crystallisation proceeds, the concentration of the solution will consequently decrease (2→3), 
however further evaporation of solvent will increase this again (3→4). Therefore the concentration 
will vary along the red line indicated in Figure 1.12 depending on the solvent and temperature at 
which evaporation is occurring.  
Figure 1.12: A typical solubility diagram showing the variation in temperature during an 




Traditionally, in terms of pharmaceuticals and fine chemicals, evaporative crystallisation is useful 
for small-scale, discovery crystallisations. The main barrier to implementation of evaporative 
crystallisation into the pharmaceutical industry is the inability to control the supersaturation in a 
system sufficiently carefully, which can lead to inconsistent particle attributes. However, industrial 
scale evaporative crystallisers are marketed, many of which are steam heated, such as the Oslo-
Krystal evaporating crystalliser and the wetted-wall evaporative crystalliser.26 
1.6.3 Antisolvent crystallisation 
In antisolvent crystallisation, a solvent, in which the solute displays poor solubility, is added to an 
undersaturated solution of the solute in order to increase the level of supersaturation within the 
system. The antisolvent added works to decrease the solubility of a substance in solution, hence 
resulting in crystallisation.  
Antisolvent crystallisation is a commonly used method to produce solubility enhanced forms of 
Biopharmaceutics Classification System (BCS) Class II and IV drugs (low solubility-high permeability 
and low solubility-low permeability respectively). In particular, there are numerous examples of the 
use of antisolvent crystallisation to produce nanoparticles of poorly water-soluble drugs; these 
micronised nanoparticles are shown to increase the dissolution rate by a significant increase in the 
relative surface area and hence increase the bioavailability of these drugs.27-30 Antisolvent 
crystallisation has also been used to obtain metastable polymorphs; examples include 
indomethacin31, abecarnil32 and L-histidine33.  




1.6.4 Reactive crystallisation 
Reactive crystallisation occurs when two or more compounds react within the solution phase to 
give a product that is less soluble than the parent compounds in the particular solvent system 
chosen. This decrease in solubility, or increase in saturation, results in crystallisation. The rate at 
which supersaturation is generated in the system is dependent on the rate of reaction between the 
two components. Within the pharmaceutical industry, a common approach to reactive 
crystallisation is  by changing the pH.34 
1.6.5 Seeded crystallisation 
As nucleation has a stochastic nature, many processes look to avoid spontaneous nucleation by 
introducing seed crystals into the crystallisation process, limiting nucleation to secondary 
nucleation at lower values of supersaturation. As such, seeding is commonly employed in order to 
obtain greater control over the solid form produced during crystallisation and obtain narrower 
particle size distributions. Seed crystals of the desired product are introduced when the growth 
solution is in the metastable zone (Figure 1.14); the solution is then cooled in line with the lower 
solubility curve. As a general rule, seeds are introduced one third of the way into the metastable 
zone; any higher in temperature (closer to the solubility line) and the seeds will dissolve, any lower 
in temperature (further into the MSZ) and there is a chance spontaneous nucleation will occur.  The 
right of Figure 1.14 shows a typical temperature-time profile for a seeded crystallisation. Once the 
seeds are added, there is a hold period in order to ensure no dissolution of the seeds. 
Addition of seeds can be through a suspension or as dry seeds. Adding the seeds dry can cause 
problems with particle dispersion and agglomeration, especially if the seeds are particularly 
hydrophobic, however if trying to crystallise a metastable form where slurrying in solvent will cause 
conversion to a more stable form, addition of dry seeds may be desirable. Addition of seeds in a 
Figure 1.14: A typical solubility curve showing the change in concentration with temperature during a seeded 
cooling crystallisation (left) and a typical seeded crystallisation temperature profile (right) 
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suspension mitigates the problems with dispersion experienced with dry seeds. They can be added 
in a saturated solution in the same solvent as the crystallisation or as an antisolvent. The use of 
suspensions is particularly beneficial in continuous processes where a suspension can be continually 
pumped in throughout the course of the crystallisation.  
There are a number of examples of the use of seeding within the pharmaceutical industry to gain 
polymorphic control within the system. 35-39 Abu Bakar et al 39 coupled seeding with temperature 
cycling in order both to gain polymorphic control and obtain a narrow particle size distribution of 
the antibacterial drug sulfathiazole. The use of temperature cycling results in faster dissolution of 
fines (very small crystalline particles of undesirable morphology) and accelerated growth of larger 
particles on cooling, increasing the kinetics of Ostwald ripening (the process whereby smaller 
crystals dissolve and the generated supersaturation aids the growth of larger crystals). This allows 
for tighter control of the particle size distribution. 
1.6.6 Monitoring the crystallisation process 
It is clear that control is one of the most critical elements of a successful crystallisation process. In 
order to exert such control most effectively, it is important to monitor crystallisation processes, to 
diagnose conditions and allow for these to be optimised throughout the process. The most effective 
way of monitoring the crystallisation process is through the use of inline process analytical 
technology (PAT); examples include focussed beam reflectance measurements (FBRM), infrared (IR) 
spectroscopy, UV-Vis spectroscopy, Raman spectroscopy and particle visualisation measurements 
(PVM). The experimental details of the techniques used in this work are outlined in Chapter 2.  
Monitoring of the crystallisation process allows real-time analysis of the product being produced 
and allows necessary adjustments to the operating conditions in order to obtain specific product 
attributes. 
UV-Vis and IR spectroscopy are both techniques used to monitor the concentration of a particular 
species throughout the crystallisation process. In multi-component systems, where the different 
species have different spectra, specific peaks characteristic of each component can be tracked 
throughout the crystallisation process, enabling the formation or disappearance of the various 
components to be studied. 
Raman spectroscopy is also commonly employed in the monitoring of crystallisation processes. It 
has the benefits of being an in-situ, non-destructive technique that requires little sample 
preparation and is relatively insensitive to aqueous solutions. The use of Raman spectroscopy is of 
particular use in the identification of polymorphic forms and transitions throughout a 
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crystallisation; examples include the non-steroidal anti-inflammatory (NSAID) drug flufenamic 
acid40, the anticonvulsant drug carbamazepine41 and the amino acid L-cysteine42. Raman 
spectroscopy has also been combined with thermal techniques such as differential scanning 
calorimetry (DSC) and hotstage microscopy (HSM) to aid in the monitoring of thermally-induced 
polymorphic transitions.43-44 
Commonly, a number of PAT techniques are combined to monitor changes during crystallisation. 
The cooling crystallisation of paracetamol has been monitored simultaneously with IR and  
FBRM.45-46 Both techniques confirm a solution mediated phase transition (see section 1.8.2) from 
form II to form I upon nucleation. FBRM analysis shows a decrease in the number of counts 
attributed to fines within the system and a consequential increase in larger particles. 
Photomicrographs show the change from a needle-like morphology (characteristic of paracetamol 
form II) to octahedral morphology (characteristic of paracetamol form I). Subtle differences in the 
IR spectra of the two polymorphic forms can be seen when tracking the IR signal throughout the 
crystallisation. 
A similar analysis was undertaken with the anticonvulsant carbamazepine, which has four reported 
polymorphs. 47 Here, FBRM, ATR-FTIR and Raman spectroscopy were used to monitor polymorphic 
changes during a cooling crystallisation. FBRM combined with microscopic images helped to show 
polymorphic changes based on clear differences in crystal morphologies. ATR-FTIR and Raman 
microscopy were used to complement these techniques as each polymorph has significantly 
different IR and Raman spectra. Similarly, FBRM, PVM, PXRD and Raman spectroscopy were used 
to monitor the polymorphic changes of D-mannitol from the metastable δ form to the 
thermodynamically stable β form. 48 
1.7  Continuous crystallisation 
Traditionally, crystallisation of active pharmaceutical ingredients (APIs) has been undertaken in 
large, stirred batch tank reactors which can suffer from poor heat and mass transfer upon scale-up 
from the laboratory to industrial scales. As such, there has been a large amount of industry and 
academic interest in moving these processes into a continuous environment.49-52 Continuous 
crystallisation offers the advantages of more effective heat and mass transfer as well as reduced 
downtime between batches, less batch-to-batch variation and greater control over particle 
attributes such as particle size distribution and polymorphic form. Due to the nature of most 
continuous crystallisers, they also make the scale-up from laboratory to industry easier. The main 
advantages and disadvantages of continuous crystallisation techniques are outlined in Table 1.1.  
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Table 1.1: The advantages and disadvantages of continuous manufacturing of crystalline fine chemical products 
Advantages Disadvantages 
Improved and heat mass transfer High capital costs 
Reduced reactor downtime between  batches 
Manufacturing sites already have batch 
equipment installed, however possibility of 
modification 
Better control over particle attributes such as 
polymorphic form and crystal size distribution 
No ‘one size fits all’  -  equipment used will 
depend on system being studied 
Reduced space requirements  
Reduced batch-to-batch variation  
 
A number of different continuous crystallisation platforms are available; those utilised in this work 
will be explained further in Chapters 4 and 5, however an overview will be given here. A simple 
batch crystalliser can be modified into a single-stage mixed suspension mixed product removal 
(MSMPR) crystalliser. In this, there is a continual addition and removal of solution/slurry; a feed 
vessel is often present, set at a higher temperature than the MSMPR to allow for a cooling gradient 
to be established and for crystallisation to occur. MSMPRs are often employed with more vessels; 
this will increase residence time and means smaller vessels can be used for the same total reaction 
volumes. Having smaller vessels will mitigate problems with mixing and heat transfer often 
experienced in large stirred tank reactors. Transfer between vessels in a multi-stage MSMPR can be 
via peristaltic pumps or as more recently demonstrated through vacuum transfer53; the former can 
often cause damage to particles, while the latter can cause problems with solvent evaporation. An 
MSMPR design can be further modified to give a periodic mixed suspension mixed product removal 
(PMSMPR) system. Unlike the continuous addition and removal of solution in conventional 
MSMPRs, PMSMPRs are characterised, as the name suggests, by the periodic addition and removal 
of solution from a single or multi-stage cascade54; this periodic nature allows for periods of dwelling 
within the reaction vessel to increase residence time within the crystalliser. The use of MSMPRs for 
the continuous crystallisation of a variety of compounds has been demonstrated including 
paracetamol form I54-55, albuterol sulfate56, cyclosporine53 and preferential crystallisation of the 
enantiomers of threonine.57  
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Although vessels used in MSMPR designs tend to be smaller than batch crystallisation vessels, they 
will still experience problems with the uniformity of mixing and heat transfer throughout the course 
of the crystallisation. As such, over recent years there has been much interest in the use of 
oscillatory flow reactors (OFRs) as a method of continuous crystallisation58-61, in particular 
continuous oscillatory baffled crystallisers (COBCs).49, 62-63  A typical COBC set-up is shown in 
Figure 1.15 and will be described fully in Chapter 5.  
In OBRs, a series of equally spaced baffles are present contained within a jacketed straight; these 
baffles result in the generation of eddies within the system which provides efficient mixing. Due to 
their relatively small internal diameters (typically 15 mm, but some have been developed that are 
smaller64), the heat transfer from the jackets is highly efficient and the mixing throughout the 
crystalliser is more uniform.  
Continuous crystallisation has been demonstrated in the COBC of β-L-glutamic acid65, a co-crystal 
of α-lipoic acid and nicotinamide66, lactose62 and a proprietary compound in production49. Although 
possessing a relatively small internal diameter, the volume of the COBC can be high, depending on 
the overall length of the crystalliser; this is ideal for industrial scale production, but less suitable for 
lab-scale production. As such, there have been reports of the development of lab-scale flow devices 
which operate with much smaller reaction volumes. One example is the kinetically regulated 
automated input crystalliser (KRAIC)67 developed at the University of Bath; this is an open tubular 
crystalliser that operates on the principle of segmented flow (a more detailed overview is given in 
Chapter 5). 
Figure 1.15: A typical COBC set-up65 
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1.8  Polymorphism 
Polymorphism is the ability of the same molecule to adopt different packing arrangements in the 
solid state; analogous to elemental allotropes. Approximately 80 % of marketed pharmaceuticals 
display polymorphic behaviour68, with different polymorphs often displaying markedly different 
physical properties. Broadly, polymorphism can be subdivided into packing and conformational 
polymorphism; packing polymorphism arises from different bonding motifs resulting in different 
molecular packing arrangements, whilst conformational polymorphism arises from different 
molecular conformations often caused through rotation within the molecule. 5-methyl-2-[(2-
nitrophenyl)amino]-3-thiophenecarbonitrile, also known as ROY owing to its red, yellow and orange 
crystalline forms, has 10 polymorphic forms and is an extreme example of conformational 
polymorphism. ROY adopts different conformations in each of its polymorphs due to the variation 
of the angle marked θ in Figure 1.16. 69 
The different properties often displayed by polymorphs can have substantial benefits in terms of 
favourable physical properties such as solubility70-72, of importance for Active Pharmaceutical 
Ingredients (APIs) and other solid molecular materials. The case of the anti-HIV drug Ritonavir73 
provides a prime example to why knowledge of polymorphism and the ability to control this 
polymorphic form is of utmost importance in all stages of drug development; loss of control over 
production of the more soluble (less stable) polymorphic form of this compound had serious 
consequences for its manufacture (see Chapter 3). There are multiple accounts of methods of 
controlling the stable polymorphic form of APIs74-76; however the deliberate targeting of metastable 
polymorphic forms, with enhanced physical properties, is largely unreported, and has rarely been 
achieved on scale. Much previous work in targeting metastable polymorphic forms has focussed on 
small-scale discovery environments (mg quantities) 77-79, and where scale-up has been attempted, 
sample stability has been poor; for example the use of polymer additives to obtain paracetamol 
Figure 1.16: The molecular structure of ROY 
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form II gave samples stable for only five hours80 and spray drying of acedapsone gave samples stable 
for only six hours.81 
1.8.1  Thermodynamics of polymorphism 
The relative stabilities of different polymorphs relate to the free energy; the polymorph with the 
lowest free energy, under a given set of experimental conditions, is termed the stable polymorph 
and any other polymorphs with higher free energies are metastable (Figure 1.17).  Metastable 
forms often display enhanced physical properties such as solubility or compressibility70, 82-83, 
however the system will have a tendency to reduce its free energy through transformation to the 
stable form, obeying Ostwald’s Law of Stages (see section 1.8.2 below). 
Different polymorphic forms will have different crystal lattices, with the non-covalent interactions 
being the predominant difference; it is these differences in non-covalent interactions that result in 
different packing arrangements in the solid state. Due to the differences in non-covalent 
interactions, different polymorphs will display different molar heat capacities (Cm). Integration of 
these heat capacities at constant pressure with respect to temperature gives the enthalpy (HT1) and 
entropy (ST1) of the system at a given temperature T1 (Equations 1.11 and 1.12).84 
𝐻𝑇1 =  ∫ 𝐶𝑚,𝑝𝑑𝑇 +  𝐻
0 =  𝑈𝑇1 + 𝑃𝑉 =  𝐸𝐿𝑎𝑡𝑡𝑖𝑐𝑒−𝑒𝑛𝑒𝑟𝑔𝑦




             Equation 1.11 





𝑑𝑇 + 𝑆0            Equation 1.12 
The internal energy of the system (UT1) is made up of contributions from both lattice energy and 
zero-point energy. In 1979, Burger and Ramberger85 applied Equations 1.11 and 1.12 to 
polymorphic systems; polymorph A is more stable than polymorph B at absolute zero in this 
Figure 1.17: The energy landscape of stable and metastable polymorphs 
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consideration. These allow for the differences in enthalpy (∆𝐻𝐵→𝐴
𝑇1 ) and entropy (∆𝑆𝐵→𝐴
𝑇1 ) between 
two polymorphs to be calculated (Equations 1.13 and 1.14). 
∆𝐻𝐵→𝐴
𝑇1 =  ∫ ∆𝐶𝑚,𝑝 (𝐵→𝐴)𝑑𝑇 +  ∆𝐻𝐵→𝐴
0𝑇1
0
          Equation 1.13 
∆𝑆𝐵→𝐴






0               Equation 1.14 
The third law of thermodynamics states that at absolute zero the entropy of a perfect crystal is zero 
and so the ΔS term will vanish. Similarly, if the polymorphs display packing polymorphism rather 
than conformational polymorphism the ΔH term will be dictated by the difference in lattice energy 
as the difference in zero-point energy will be small. As such, the difference in Gibbs free energy 
between the two polymorphs can be expressed as in Equation 1.15. 
∆𝐺𝐵→𝐴
𝑇1 =  (∫ ∆𝐶𝑚,𝑝 (𝐵→𝐴)𝑑𝑇 +  ∆𝐻𝐵→𝐴
0𝑇1
0





𝑑𝑇)              Equation 1.15 
Equation 1.15 assumes a monotropic relationship between the two polymorphs (i.e. no phase 
transition has occurred between T1 and absolute zero). If the two polymorphs are enantiotropically 
related, extra terms will be included in the enthalpy and entropy changes to account for this, 
however the expression in Equation 1.15 would hold up to the point of the polymorphic 
transformation. Equation 1.15 is useful as it shows the difference in free energy between 
polymorphs can be calculated using heat capcity (Cm) and enthalpy; both of these can be measured 
through calorimetry methods.  
Plotting the change in free energy with temperature gives an indication as to whether two 
polymorphs are enantiotropically or monotropically related (Figure 1.18). Two polymorphs are said 
to be enantiotropically related if there exists a transition point at which one polymorph converts to 
the other in a solid state transition. This transition temperature must be below the melting 
temperature of the two polymorphs for the polymorphs to be enantiotropically related. Similarly, 
two polymorphs are monotropically related if this transition point does not exist (the one noted in 
Figure 1.18 is a ‘virtual transition temperature’). 
41 
 
A quick way to determine whether two polymorphs are enantiotropically or monotropically related 
is through consideration of their solubility curves. In a monotropic system, the two solubility curves 
of each polymorph do not cross. In enantiotropic systems, the relative solubility of each polymorph 
is temperature dependent and the two solubility curves will intersect; the point of intersection is 
the phase transition and the temperature at which this occurs is the transition temperature 
(Figure 1.19). 
1.8.2 Solution mediated phase transitions 
Polymorphic systems in solution will adhere to Ostwald’s Rule of Stages86; the least stable 
polymorph will nucleate first, which will then dissolve and the stable polymorph will crystallise. The 
process of dissolution and crystallisation is known as a solution mediated phase transition, the 
kinetics of which are discussed in detail below. 
Figure 1.18: Gibbs free energy changes with temperature for monotropically (left) and enantiotropically (right) 
related polymorphs 
Figure 1.19: Concentration-temperature diagrams for a monotropic and an enantiotropic system 
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Figure 1.20 shows a phase diagram for a monotropic system (or equally an enantiotropic system in 
which the transition temperature falls such that the two solubility curves do not cross); phase 1 
represents the stable polymorph and phase 2 a metastable polymorph. At a given temperature, a 
solution with a composition such that the solubility is xB is only supersaturated with respect to the 
stable phase 1, whereas a solution with a composition such that the solubility is xA is supersaturated 
with respect to both phase 1 and phase 2; as such either phase can crystallise. Ostwald’s Law of 
Stages states that the metastable polymorph (phase 2) will be the first to crystallise. At this point, 
the solution composition drops to x1 which corresponds to the solubility of phase 1. However, 
although the majority of the nuclei formed will be of the metastable phase 2, it is plausible that 
some nuclei of the stable phase 1 will have formed as the solution has been supersaturated with 
respect to this phase throughout the crystallisation so far. The formation of these nuclei start the 
transformation process; as these nuclei grow, the solution concentration drops to that of x1 which 
corresponds to the solubility of the stable phase 1 and becomes undersaturated with respect to the 
metastable form 2. The resultant effect is the dissolution of phase 2 crystals, which generates the 
necessary supersaturation for the growth of phase 1. This dissolution/growth process continues 
until the composition of solution is entirely phase 1. The total transformation can be considered as 
a sum of growth time (τG) and dissolution time (τD) (Equation 1.16). 
τ = τG + τD                                                  Equation 1.16 
There exist two extremes: where τD >> τG the solution mediated phase transition is under dissolution 
control and where τG >> τD the solution mediated phase transition is under growth control. 
Measurement of the desupersaturation profile over the course of the crystallisation can help with 
Figure 1.20: Phase diagram 
43 
 
kinetic interpretation. Most solution mediated phase transitions can be classified by one of four 
main trends (Figure 1.21 ). 87 
In scenario (a), once there is any conversion to the more stable polymorph, the supersaturation 
profile starts to decrease immediately. This indicates that growth of the stable phase is faster than 
dissolution of the metastable phase and so is termed as a ‘dissolution controlled polymorphic 
transformation’. This is often the case when the solid-liquid surface area is much smaller for the 
metastable form (larger particles take longer to dissolve) in comparison to the stable form. The 
opposite would be true for a seeded system.  In scenario (b), the supersaturation plateaus at the 
solubility of the metastable form before a drop; this plateau in supersaturation represents an 
equilibrium being established between the amount of metastable material dissolving and the 
amount of material needed for growth of the stable form. The drop in supersaturation is seen when 
very little metastable solid remains in suspension. This is termed a ‘growth controlled polymorphic 
transition’.  This scenario has been shown to hold for the solution mediated phase transition of 
carbamazepine.87 Scenarios (c) and (d) are similar to (a) and (b) respectively with the addition of an 
induction time to the onset of nucleation of the stable form. The difference between the plateau 
region seen in scenario (b) is that very little is occurring in this plateau as there is no transformation 
to the stable form. In scenario (c), once the stable form has nucleated, it follows the same path as 
scenario (a) and is called a ‘nucleation-dissolution controlled polymorphic transformation’. This 
scenario has been observed in the system of tolbutamide.88 The same is true for scenario (d) with 
regards to the plateau region and after this it follows the same pattern as scenario (b), hence being 
Figure 1.21: The four observed trends in solution mediated phase transitions (black – supersaturation, red – 
metastable polymorph, blue – stable polymorph)  
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termed a ‘nucleation-growth controlled polymorphic transformation’.  This scenario has been 
shown for piracetam87 and famotidine. 89 
1.8.3 Solid state polymorphic transformations 
Polymorphic transitions are also possible in the absence of solvent, taking place in the solid state. 
The kinetics of this type of transformation have been outlined in detail by Cardew and Davey in 
198390 , building on the work of Avrami91; the latter assumed ‘germ nuclei’ to be randomly 
distributed throughout the solid which then grow within the metastable phase until the 
transformation is complete. It was concluded that ratio of growth rate and nucleation rate (τG/τN) 
is key in determining the kinetics of the solid state polymorphic transformation. The work by Avarmi 
holds for large values of this ratio, while the work by Cardew and Davey expands this for low values 
of this ratio. As such, it is often the case that the presence of the more stable polymorph in the solid 
can seed the conversion from metastable to stable form in the solid state. In early work this was 
seen for the polymorphic transformation from form IV→III for ammonium nitrate and the 
calcite→argonite transition in calcium carbonate.92 More recently, this relationship has been 
observed for the form II→I transformation of paracetamol. 93 
Any two polymorphs displaying an enantiotropic relationship will undergo a solid-state phase 
transformation upon heating or cooling or with the addition of pressure. Often thermal analysis 
techniques such as differential scanning calorimetry (DSC) are used to observe these changes. 
Reported examples of solid-state polymorphic transitions include: caffeine94, sulfamerazine95, API 
CG396 and agomelatine. 97 
1.9 Multicomponent crystallisation 
The use of second components within the crystallisation process can seem counterintuitive; 
crystallisation is a process used to help purify a compound and introducing a second component is 
counteracting this. More recently, however, second components are increasingly being included in 
the crystallisation process to help improve physicochemical properties of active ingredients: this 
can be achieved either by forming a molecular complex (co-crystal) with enhanced physical 
properties98-101 or by helping to direct formation of a solid form with a certain property such as a 
preferred polymorph102-104 or morphology. 22, 105-106 The design of multicomponent crystallisation 
processes, in which the two molecular components are chosen due to the likelihood that they will 
interact, is often aided by consideration of the approach of crystal engineering. 
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1.9.1 Crystal engineering 
Crystal engineering can be described as ‘the rational design on functional molecular solids’.107 
Knowledge of a variety of intermolecular interactions, alongside computational tools and 
algorithms, allows for the prediction of possible bonding motifs to design solids that may have 
desirable physical properties. In the context of crystallisation, the same principles can be used to 
predict likely intermolecular interaction between components. The use of hydrogen bonding 
remains at the forefront of crystal engineering strategies, however the development of strategies 
employing alternative intermolecular interactions such as halogen bonding has become more 
prevalent within recent years.108-109 
Crystal engineering is used in the design of a variety of materials for different applications including 
ensuring protein incorporation into crystal lattices 110, the design of crystals with non-linear optical 
applications 111 and the design of metal organic frameworks for use in gas storage.112-113 
  Hydrogen bonds 
Due to their strength and directionality, hydrogen bonds are the most commonly employed 
intermolecular interaction exploited in crystal engineering. Their ubiquitous nature is 
demonstrated in the fact that hydrogen bonds are responsible for the double-helical structure of 
DNA114-115, the crystal structure of ice116 and the structure of fabrics such as nylon117-119 and 
cotton.120 
A hydrogen bond (A-H…B) is an electrostatic interaction that occurs when a hydrogen atom is bound 
to an electronegative atom such as O, N or F. This induces a partial positive charge on the hydrogen, 
resulting in an attraction to an atom that displays a partial negative charge or a free-bonding lone 
pair of electrons (B). The atom attached to the hydrogen (A) is the hydrogen bond donor and the 
atom that forms the interaction with the hydrogen is the hydrogen bond acceptor (B). 
Table 1.2 highlights the properties of hydrogen bonds that classify these interactions as strong, 
moderate or weak hydrogen bonds; in strong hydrogen bonds, not discussed in this work, there is 





Table 1.2: Hydrogen bond properties (adapted from121) 
 Strong Moderate Weak 
A-H…B interaction Largely covalent Largely electrostatic electrostatic 
Bond lengths A-H ≈ H…B A-H < H…B A-H << H…B 
A…B (Å) ~2.2-2.5 ~2.5-3.2 ~3.2-4.0 
Bond angles (°) 175-180 130-180 90-150 
Bond energy (kJmol-1) 62-167 16-62 4-16 
Exploitation of crystal engineering is facilitated by the availability of a range of capabilities geared 
towards its use. For example, the Mercury program within the Cambridge Crystallographic Data 
Centre (CCDC) software has a range of tools available to aid in the prediction of possible hydrogen 
bonding motifs. The IsoStar option analyses the Cambridge Structural Database and protein data 
bank to find common interactions for a fixed central group and varying contact groups. These 
interactions are overlaid to form a scatter plot which highlights the propensity of functional groups 
to form certain interactions. However, IsoStar only considers individual functional groups rather 
than whole molecules.122  Information from IsoStar can then be used to produce a full interaction 
map (FIM), which considers multiple functional groups in an entire molecule. These FIMs also take 
into account steric and environmental factors of the whole molecules involved in the crystal 
structure. FIMs are helpful when considering the relative stabilities of polymorphs. This is illustrated 
for the API sulfathiazole in Figure 1.22 . The FIM generated for a metastable polymorph (form I; 
SUTHAZ01) of sufathiazole shows that not all predicted hydrogen bonding interactions are satisfied 
by an area of electron density; the circled hydrogen bonding interaction is one such interaction that 
does not correlate with an area of predicted electron density. In comparison, the FIM for the stable 
polymorph (form V; SUTHAZ05) of sulfathiazole shows all interactions satisfied by areas of electron 
density (the same intermolecular hydrogen bonding interaction as for Form I is circled for 
comparison).   
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Similarly, analysis of the hydrogen bonds within the metastable polymorphic form of Ritonavir 
could have predicted the likely presence of a more stable polymorphic form as was indeed 
discovered after the drug was in production.73, 123 In the stable Form II, all strong donors and 
acceptors have been satisfied, indicating its favourable stability.  
  π-π interactions 
Although weaker than hydrogen bonds, π-π interactions (or pi-stacking) are also important 
intermolecular interactions. For example, the aromatic rings in amino acids undergo multiple π-π 
interactions in RNA binding. 124 Hunter and Sanders proposed a simple model of two interacting π 
systems; each π system consists of a positively charged σ-framework sandwiched between two 
negatively charged π-electron clouds. 125 The possible interactions that these two systems can have 









Figure 1.22: Full interaction maps for sulfathiazole form I (left) and form V (right); the greyed out molecules are formed 
through hydrogen bonding interactions. Generated from CSD references SUTHAZ01 and SUTHAZ05, respectively. 
Figure 1.23: The different types of electrostatic interactions between two aromatic systems 
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The model proposed by Hunter and Sanders states that when one of the two systems possesses a 
strongly electron-withdrawing group, the preferred packing will not be edge to face. In this case, 
the electron-withdrawing group draws the electron density away from the core; hence, there is a 
central area of electron deficiency, promoting face to face packing in preference (Figure 1.24). 
In the case of alternating electron-rich and electron-poor aromatics, there is the possibility of a 
charge transfer absorbance band. 126 Analogous to energy levels within molecules, the highest 
occupied molecular orbital (HOMO) of the system can be considered to be located mainly on the 
electron rich aromatic and the lowest unoccupied molecular orbital (LUMO) located mainly on the 
electron poor aromatic. Hence, excitation of an electron from the HOMO to the LUMO can occur. 
As the HOMO-LUMO gap between the two aromatics is smaller than that in each of the individual 
aromatics, a longer wavelength absorbance is often seen. This results in a shift from UV absorbance 
to visible absorbance; the origin of colour in this type of system can be partially attributed to π-π 
stacking. 
 Supramolecular synthons 
To define the control of intermolecular interactions in a manner analogous to covalent bonds in 
organic synthesis, Desiraju coined the term supramolecular synthon to describe the ‘structural units 
within supermolecules which can be formed and/or assembled by known or conceivable synthetic 
operations involving intermolecular interactions’.127 These synthons can either be composed of two 
identical functional groups (homosythons) or two different functional groups (heterosynthons), as 




Figure 1.25: (a) a supramolecular homosynthon in the form of a carboxylic acid dimer, (b) a 
supramolecular heterosynthon in the form of an amide-carboxylic acid dimer 
Figure 1.24: Attraction through face to face packing when one of the systems contains 
an electron withdrawing group 
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The hydrogen bonding patterns present in molecular packing arrangements can become 
complicated to describe, with often many interactions present. Graph set notation, developed by 
Etter, can be used to aid the description of hydrogen bonding motifs in three dimensions.128  The 
notation is based on the number of proton donors and acceptors, subscripts and superscripts 
respectively, within the motif and whether the hydrogen bonds are intramolecular (S) or 
intermolecular; the latter can be distinguished as finite (R and D) or infinite (C). As an example, the 
dimer motifs in Figure 1.25 can each be described by the 𝑅2
2(8) graph set. 
  Co-crystallisation 
Crystal engineering facilitates the design of new molecular materials enabling the possibility of 
enhancing a variety of physicochemical properties. One method of crystal engineering is through 
the use of co-crystallisation; this is a method whereby intermolecular interactions are used to ‘join’ 
an active ingredient such as a pharmaceutical with a benign co-former molecule with 
complementary functional groups chosen to enable interactions such as hydrogen bonding. In this 
use of crystal engineering, incorporation of the co-former molecule into the crystal structure is used 
to direct the structure towards more favourable packing arrangements. 
Co-crystallisation has been used to a significant degree in the pharmaceutical industry; and in this 
context there are other multiple component systems that are commonly exploited; these include 
simple salts of the API. A co-crystal comprising two molecular components can, of course, also form 
a salt, in the case where there is, for example, proton transfer between the two, leaving each 
charged. For molecular co-crystals, the definition of the terms co-crystal and salt and the continuum 
that exists between the two is a highly debated topic throughout academia and industry. 129 For the 
purposes of this work a co-crystal can be defined as ‘solids that are crystalline single phase materials 
composed of two or more different molecular and/or ionic compounds generally in a stoichiometric 
ratio which are neither solvates nor simple salts’.130 The same work highlights the FDA classification 
of salts as ‘any of numerous compounds that result from replacement of part or all of the acid 
hydrogen of an acid by a metal or a radical acting like a metal; an ionic of electrovalent crystalline 






By the use of crystal engineering it is possible to predict possible structures through a variety of 
criteria such as analysis of common hydrogen bonding motifs. The nature of these hydrogen bonds 
(and whether proton transfer is likely to have occurred between the two molecular moieties 
involved) can also be predicted using the generally accepted pKa rule. This rule can be used to 
predict whether a salt or co-crystal will form; that is a salt will form (proton transfer favoured) if 
ΔpKa (pKa (base) – pKa (acid)) is greater than three, and a co-crystal will form if ΔpKa <0. 131 The 
area between this gives rise to the salt – co-crystal continuum. Although ΔpKa is strictly speaking a 
solution property, predictions from the pKa rule have been found to have some validity and to be 
a useful tool.  
Co-crystallisation is a tool which allows physical properties of an active material to be tuned such 
as colour for a variety of optical applications 132, or to provide enhanced physical properties for 
active pharmaceutical ingredients (APIs). The latter can include enhancement of solubility, 
compressibility, dissolution rate, thermal stability and flowability, with a few examples outlined 
below. 
Alpha lipoic acid (ALA) is an antioxidant that has uses in the treatment of diabetes and chronic 
fatigue. The disulfide bond in its structure is susceptible to cleavage when exposed to light or 
elevated temperatures above its melting point of 65 °C. Co-crystallisation with the Generally 
Regarded As Safe (GRAS) co-former nicotinamide has produced a molecular complex with enhanced 
thermal stability and solubility relative to the ALA starting material, whilst retaining the therapeutic 
properties of ALA. 133 
Loperamide hydrochloride is used in the treatment of diarrhoea and displays low solubility at the 
pH of the gastrointestinal tract where it is absorbed. An improvement in this solubility would 
Figure 1.26: A co-crystal of theophylline and paracetamol (CSD REF: KIGLUI) and a salt of 4-
aminopyridine and 5-acetylamino salicylic acid (CSD REF:CELXOI), with proton transfer from the 
carboxylic acid to the pyridine nitrogen 
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improve its efficacy.  Bruni et al showed that by co-crystallising loperamide hydrochloride with 
glutaric acid, an increase in solubility of a factor of six (from 10.1mg/100ml to 63.5mg/100ml) can 
be achieved. 134 Multiple other examples of co-crystallisation for solubility increase have been 
reported throughout the literature.135-139 
Co-crystallisation has also been used to alter a variety of mechanical properties of active 
ingredients. Co-crystallisation of caffeine with 4-chloro-3-nitrobenzoic acid has shown the 
possibility to use this method to increase the tensile strength of brittle active ingredients. 140 
Materials with greater flexibility generated through methods such as this could be used in 
applications such as photovoltaic materials and chemical sensors. In another example of the 
altering of mechanical properties, co-crystallisation of paracetamol with the co-former 
trimethylglycine has resulted in increased compressibility upon tabletting.141 Furthermore, the 
possibility to engineer co-crystals that display a layered arrangement of molecules within the crystal 
structure could allow for improved compressibility. 
1.9.2 Hydrates 
Solvated forms of crystal structures are found when a solvent from the crystallisation step is 
incorporated into the crystal lattice through the formation of intermolecular interactions. Owing to 
its small molecular size and ability to form multi-directional hydrogen bonds, water is often 
incorporated into the crystal structure, resulting in the formation of a hydrate.142 It is estimated 
that one third of all pharmaceutical solids can form hydrates. 143 The formation of hydrates in the 
pharmaceutical industry can be both advantageous and disadvantageous.  
In aqueous solvent systems, hydrated forms are often the most stable, displaying reduced solubility 
in comparison to their anhydrous counterpart.144 They also pose the risk of dehydration in storage, 
risking loss of crystallinity or change in crystal form and efficacy. 145 Furthermore, hydrated forms 
of pharmaceuticals can also result in different crystal morphologies, potentially complicating 
downstream processing steps if these were to suddenly appear in manufacture. 
However in the case of a polymorphic system whereby reliable formation of individual polymorphs 
was problematic, hydrate formation could offer a route to solid form control. 
1.9.3 Additives within crystallisation 
Over recent years there has been an increased interest in the use of additives included within the 
crystallisation process in order to direct specific particle attributes such as polymorphic form and 
particle morphology. Here an additive encompasses either small, size-matched molecules or 
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polymers. In contrast to the case of co-crystallisation, additives are often not incorporated into the 
solid product structure, and are often able to be used at very low concentrations. 
In polymorphic systems, additives can work to hinder solution mediated phase transitions or to 
promote or hinder growth of a certain polymorphic form. The use of structurally similar additives 
has been well explored in the control of polymorphism in l-glutamic acid. 146-150 The metastable α 
form has been produced with a variety of amino acids146, 148; the presence of bulky side chains in l-
phenylalanine and l-tyrosine were shown to be key in the stabilisation of the α-polymorph. 
Monomeric and polymeric derivatives of 5-aminoisophthalic acid were also used as additives to 
inhibit the growth of the stable β-polymorph. 149 Davey et al reported the stabilisation of the 
metastable α-form through conformational mimicry through a combination of modelling and 
experimental techniques. 150 The effect of additives on solution mediated phase transitions has 
been examined for carbamazepine151-152 and a proprietary compound153. Here, the additives are 
thought to increase the solubility of the stable form, reducing the driving force for the 
transformation process from the metastable to stable form. Many new or previously elusive 
polymorphic forms have been discovered using attempted co-crystallisations, these forming in 
preference to the target co-crystal; examples include felodipine103, 154, fluconazole79, nicotinamide 
and isonicotinamide.78 
Additives have also been used to alter the morphology of crystals whilst maintaining the 
polymorphic form. Klapwijk et al recently investigated the effect of a polymer additive on the 
crystallisation of succinic acid.22 It was found at low polymer concentrations the polymer inhibited 
the growth of certain faces of the crystal, resulting in a more block-like morphology; this block 
morphology is more desirable for downstream processing than the traditional plate-like 
morphology usually adopted from crystallisation from water. Similarly, Simone et al investigated 
the effect of benzoic acid on the crystallisation of ortho-aminobenzoic acid.155 It was found that 
benzoic acid acts as a growth modifier, resulting in a change from prisms to needles upon increasing 
concentration of benzoic acid. 
The use of insoluble additives for heterogeneous nucleation and their effect on polymorphism has 
also been investigated widely in the literature; for example silica particles and carbon powder were 
used in order to ascertain the most stable form of an unnamed active ingredient156. Polymorph 
control through heterogeneous nucleation has been investigated in isonicotinamide, by employing 
a number of porous and regular surfaces11, and in paracetamol10. Other systems studied where 
different additive approaches have been used include the use of spherical agglomerates in the 
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crystallisation of paracetamol157 and the use of nanoscopic pores and polymers in the crystallisation 
of aspirin.158 
1.10 Aims of research 
The overarching theme of this work will be the use of multi-component crystallisation techniques 
to control the solid form of pharmaceutical materials. The ability to control the solid form of 
pharmaceutical materials and to be able to develop robust crystallisation processes to impart this 
control is of great interest to both academia and industry. The work presented in this thesis will 
investigate two different techniques to exert solid form control through crystallisation.  
The first, and main, focus of the work will look at obtaining metastable polymorphic forms through 
multi-component templating techniques, using additives to promote formation of a desired solid 
form. Work will use the model system of paracetamol (PCM) and the distinction between its two 
main polymorphic forms, looking to design a large scale route to the metastable polymorph that 
displays enhanced physical properties. Previous work in this area has been limited to small scale 
evaporative crystallisation discovery environments. With this work emerging from the EPSRC 
Future Manufacturing Research Hub in Continuous Manufacturing and Advanced Crystallisation 
(CMAC), eventual aims will be to transfer systems into a variety of continuous crystallisation 
platforms set-up both at the University of Bath and within CMAC partner institutions.  
The second strand of the work presented here will look at hosting of pharmaceuticals that display 
poor stability, with the aim of increasing said stability through incorporation into a host molecule 
via intermolecular host-guest association. Although work has been done to investigate the use of 
host materials to increase the solubility of a variety of APIs, their use in controlling the stability of 








2 Experimental methods 
Experimental details specific to particular investigations carried out during this project are 
presented within the main results chapters (Chapters 3-6); however details of the theory and 
experimental procedure for commonly used methods are presented here. 
2.1 Solubility Measurements 
Solubility measurements were performed at the University of Strathclyde using the Technobis 
Crystal 16 (Figure 2.1). 
The technology employed within the Crystal 16 uses turbidity measurements to give clear and cloud 
points for the solution understanding. In the Crystal 16, up to 16 vials of the sample solution are 
subjected in parallel to a heating and cooling temperature programme. For each of the vials a 
temperature vs transmissivity vs time plot is generated and analysed in the CrystalClear software 
(Figure 2.2) in order to determine clear and cloud points. The clear point is where the solution 
allows for 100 % light transmission i.e. all particles having dissolved. The cloud point is where this 
transmittance no longer has a value of 100 % indicating precipitation of particles out of solution. 
From this, metastable zone widths (MSZW) can be determined and cooling crystallisation 
experiments designed; it is important to note that the MSZWs depend on a variety of crystallisation 
conditions including cooling rate, stirring and scale and so can only be used as a guideline for 
experimental design. 
Figure 2.1: The Technobis Crystal 16 
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As used in the present work, in general four 1.5 cm3 vials of varying concentrations of the compound 
to be measured were heated from 20 °C to 75 °C and then cooled from 75 °C to 5 °C, via a peltier 
thermoelectric device, at a rate of 0.1 °C min-1 with a magnetic bottom stirring speed of 800 rpm. If 
a lower boiling point solvent such as ethanol (bpt = 78 °C) was used, the cooling profile was adjusted 
accordingly to prevent vaporisation of solvent, which would reduce the accuracy of the 
measurements. Data were processed using CrystalClear v.1.0.1.614 from Avantium Technologies.  
2.2 Cooling crystallisations  
Cooling crystallisation experiments were carried out using the Polar Bear Plus crystalliser from 
Cambridge Reactor Design (Figure 2.3). The Polar Bear Plus crystalliser provides a platform for 
simultaneous controlled cooling of up to 28 1.5 cm3 vials in a temperature range of 150 °C to -40 °C 
via a peltier thermoelectric device with bottom magnetic stirring. It has interchangeable inserts 
that allow gradual scale up of systems from 1.5 cm3 vials to 20 cm3 vials up to 250 cm3 round-
bottomed flasks (RBFs). 
Overhead stirring can be implemented in conjunction with larger scale experiments in RBFs utilising 
a separate motor and shaft (detailed in Chapter 3) in order to provide more effective mixing at 
Figure 2.2: A temperature vs transmissivity vs time plot for a vial in a Crystal 16 experiment 
Figure 2.3: The Polar Bear Plus with interchangeable inserts (right) 
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these larger scales. Full details of cooling profiles employed for experiments are given in the 
relevant Chapters. 
2.3 Single crystal X-ray diffraction (SCXRD) 
2.3.1 The crystalline state 
In order to study the key physicochemical properties of crystalline materials such as 
pharmaceuticals, a fundamental understanding of the underlying solid-state crystal structure is 
necessary. Broadly, the area of crystallography is the study of the atomic structure of ordered 
materials. A crystalline solid can be defined as a highly ordered, symmetrical lattice consisting of 
identical points (lattice points) arranged in a periodic manner in three dimensions; the lattice points 
form a highly regular arrangement which underpins the regularity of crystal structures. Joining 
together eight neighbouring lattice points forms a three-dimensional parallelogram (the unit cell). 
The unit cell is defined by three sides (a, b, c) and three angles (α, β, γ) as shown in Figure 2.4. The 
unit cell is the smallest repeating volume of the lattice that is representative of the crystal. The 
crystal is assembled by repeating the unit cell and its contents by translation along all three spatial 
dimensions. 
There are four types of unit cells dictated by the positioning of the lattice points, in particular the 
possible inclusion of additional lattice points: primitive (P), body-centred (I), base-centred (C) and 
face-centred (F) (Figure 2.5). 
 
 
Figure 2.4: The unit cell  axes showing the length and angle parameters 
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Reflection and rotation symmetry elements result in constraints on the geometry of the unit cell 
and these constraints give rise to the seven crystal systems. The combination of the four unit cell 
types and the seven crystal systems gives the 14 Bravais Lattices.  
Table 2.1: The restraints on the seven crystal systems that result in the 14 Bravais lattices 159 
Crystal system Unit cell parameters Lattice types 
Triclinic a ≠ b ≠ c ; α, β, γ ≠ 90° P, I, F 
Monoclinic a ≠ b ≠ c ; α = γ = 90°, β ≠ 90° P 
Orthorhombic a ≠ b ≠ c ; α = β = γ =90° P 
Tetragonal a = b ≠ c ; α = β = γ =90° P, I 
Rhombohedral a = b = c ; α = β = γ ≠ 90° P, I, F, C 
Hexagonal a = b ≠ c ; α = β = 90° ; γ = 120° P, C 
Cubic a =b = c ; α = β = γ = 90° P 
 
Whilst joining the lattice points in three dimensions results in formation of a unit cell, a two-
dimensional array can be defined to produce lattice planes which can be indexed in two ways; using 
Weiss indices or Miller indices. Weiss indices are the intercepts of these planes with the cell axes 
and so can be fractions. Miller indices are the inverse of Weiss indices and are described as integers. 
In three dimensions, each Miller index (h, k, l) corresponds to a set of parallel planes with a 
characteristic plane spacing, ‘dhkl’.  
In a crystal structure, there are also symmetry elements internal to the unit cell which add to the 
structure defined by the lattice symmetry. Six symmetry element types are possible; four non-
translational and two translational; these act on the unit cell contents and define the internal 
symmetry. The translational elements are glide planes and screw axes. Glide planes consist of a 
reflection followed by translation; this can result in more efficient packing of molecules in 
comparison to a simple reflection. This is because the translation results in a half a repeat unit 
displacement of the mirror images in comparison to simple reflection where images are directly 
opposite one another where repulsive forces dictate a minimum separation distance of these 
images. A screw axis consists of rotation followed by translation and similarly can maximise packing 
efficiency with respect to a simple rotation. These symmetry elements act upon the smallest 
Figure 2.5: The four types of unit cell. Each lattice point is represented by a filled circle 
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volume of highest symmetry within the unit cell, termed the asymmetric unit, to generate the unit 
cell contents.  
The combination of these six symmetry elements with the 14 Bravais lattices result in the 
generation of 230 possible arrangements, each of which is termed a space group. The 230 space 
groups are unevenly distributed across the fourteen Bravais lattices and they represent the only 
ways in which identical objects can be packed within a crystal structure. In practice, for the type of 
molecular systems relevant to pharmaceutical crystallisation, only a small number of these space 
groups, usually those of relatively low symmetry, are relevant. 
2.3.2 X-ray diffraction 
X-rays lie on the electromagnetic spectrum, with wavelengths of the same order of magnitude as 
typical interatomic spacings. Hence, X-rays are ideal for probing the internal structure of crystalline 
materials on the atomic scale.  
The electrons in an atom scatter the X-rays and the strength of scattering is dependent on the 
number of electrons in the atom, its atomic number. The scattering of X-rays from electrons is 
known as Thomson scattering.160 W. L. Bragg showed that X-ray diffraction can be regarded as a 
reflection from sets of parallel lattice planes, each of which contain a series of regularly distributed 
lattice points, analogous to the reflection of light by a mirror; as such the angle of incidence is equal 
to the angle of reflection. The Bragg construct shown in Figure 2.6 is used to derive Bragg’s Law 
(Equation 2.1) for constructive interference between waves reflected from parallel lattice planes 
and hence leading to measurable intensity when Bragg’s law is satisfied. 
path difference = 2dhklsinθ = nλ               Equation 2.1 
Figure 2.6: The Bragg construct used to show the diffraction of X-rays from sets 
of parallel lattice planes with a d spacing = dhkl 
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Bragg’s law defines the necessary conditions to observe a reflection intensity, however it is purely 
geometric and does not define the intensity of the reflection; the latter is obtained from 
experimental data and is related to the unit cell and crystal contents. In the Bragg interpretation, 
the resultant wave is formed through constructive interference of the scattered waves from 
electrons on the lattice planes. The variation in intensities within an X-ray diffraction pattern is due 
to the variation in these resultant waves, thus must be related to the scattering from the atoms and 
molecules in the unit cell – the molecular structure. 161 The atomic scattering factor, fj for the jth 
atom, gives the extent to which that atom will scatter X-rays; the intensity of this scattering will 
vary with angle within the diffraction pattern; different atoms have different electron clouds which 
will scatter X-rays differently. The atomic scattering factor at a Bragg angle of 0° is equivalent to the 
atomic number of the atom. At low Bragg angles, the scattering power of the atom is thus 
proportional to the number of electrons, however this relationship diverges at higher Bragg angles 
as the scattering power of the atom diminishes. 
An X-ray diffraction experiment measures the intensity of a series of reflections (diffraction spots) 
at varying positions. Each spot corresponds to diffraction from a set of Miller planes (h, k, l). 
Rearrangement of Bragg’s Law shows that there is an inversely proportional relationship between 
sinθ and d. A diffraction pattern is hence constructed in units of 1/d and so is said to be in reciprocal 
space; this concept is used in order to provide an understanding of the relationship between the 
position of spots and the unit cell. Simply, the distance of each spot on the diffraction pattern from 
the centre is proportional to sinθ and 1/d. Hence, materials with large unit cells, and hence larger 
d spacing, display compressed diffraction patterns and vice versa.  
The relationship between the diffraction spots and atoms and their positions in the unit cell can be 
examined through information about reflection intensities and how these relate to electron 
densities. The diffraction pattern produced through experimental methods is related to the position 
of atoms through Fourier transforms defining the quantity known as the structure factor, Fhkl 
(Equation 2.2). 
𝐹ℎ𝑘𝑙 =  ∑ 𝑓𝑗𝑒𝑥𝑝2𝜋𝑖(ℎ𝑥𝑗 + 𝑘𝑦𝑗 + 𝑙𝑧𝑗)
𝑗=𝑛
𝑗=1       Equation 2.2 
Where fj is the atomic scattering factor of the jth atom and (h,k,l) are the reciprocal space 
coordinates and (x,y,z) the direct coordinates of the jth atom, respectively. 
Fourier transformation of the structure factor (Equation 2.3) in turn produces an electron density 
map which allows for the location of atoms (particularly those with higher atomic numbers) to be 
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determined. The structure factor can be defined as ‘a mathematical function describing the 
amplitude and phase of a wave diffracted from crystal planes characterised by Miller indices’.162  
ρ (xyz) = 
1
𝑉
∑ 𝐹ℎ𝑘𝑙. exp [−2𝜋𝑖(ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧)]ℎ,𝑘,𝑙      Equation 2.3 
Where ρ(xyz) is the electron density at point x,y,z in direct space, (h,k,l) are reciprocal space 
coordinates and (x,y,z) are direct space coordinates. 
The magnitude of the structure factor Fhkl is the square root of the intensity of each spot in the 
diffraction pattern (Ihkl) (Equation 2.4). 
Ihkl = |Fhkl|2            Equation 2.4 
Equation 2.4 gives rise to the phase problem: the magnitude of Fhkl can be determined; however 
the sign or phase cannot be determined from the experiment. This is a problem as crucial 
information for the determination of electron density is contained within the phase, as is evident 
from Equation 2.3. The phase problem is overcome within the structure solution stage of X-ray 
structure determination; the method of overcoming the phase problem is dependent on the atoms 
present in the unit cell. Patterson methods are used when there is a heavy atom present in the 
structure. Here, the observed structure factors are squared to produce a Patterson map, which 
does not require knowledge of the phases; a Patterson map has peaks that correspond to vectors 
between pairs of atoms and so shows the positions of atoms relative to each other. The peaks are 
proportional to the square of the atomic numbers of the atoms present. Direct methods are used 
when lighter atoms are present, for example in purely organic materials. This process works on a 
‘best approximation’ to determine the phases through statistical relationships between 
combinations of reflections. A successful direct method structure solution used in the large majority 
of organic structure determination usually yields the location of most non-hydrogen atoms in the 
structure. Following this, Fourier recycling methods are used, together with structural refinement, 
to locate any missing atoms; for good quality data this will include the hydrogen atoms in the 
structure.  
Crystal structure refinement is carried out using least squares analysis. This procedure is based on 
the fact that once a set of approximate atomic identities and positions are known, defining the 
molecule within the crystal structure, a set of calculated structure factors can be obtained (from 
Equation 2.2). These can then be compared with the calculated structure factors, and a least 
squares process involving improving (refining) the atomic parameters/positions and atomic 
vibrations (thermal parameters) can be carried out, aiming to minimise the difference between 
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observed and calculated structure factors.  The R factor is a calculation of the agreement between 
the calculated and observed structure factors, evaluated through the structure factor magnitudes; 
defined in Equation 2.5, the value of which should decrease throughout the refinement process. A 




   Equation 2.5 
2.3.3 Experimental 
Single crystal X-ray diffraction experiments were performed using Rigaku Oxford Diffraction 
(formerly Agilent Technologies) instruments, utilising the set-up shown in Figure 2.7. Both a 
Supernova and XCalibur diffractometer were used in the work presented in this thesis; the 
difference is that the Supernova is dual source (able to operate with both Mo-Kα and Cu-Kα 
radiation) and has higher intensity through the use of microfocus beams, whilst the XCalibur only 
operates with Mo-Kα radiation. Both instruments are equipped with a graphite monochromator, 
four-circle kappa goniometer and an Eos S2 detector. The four circle allows for movement of the 
goniometer through all diffractometer positions (κ, ϕ, ω, 2θ) to provide collection of a complete 
set of diffraction data. Each diffractometer is equipped with an Oxford Cryosystems Cryostream 
700 series to provide a flow of liquid nitrogen to the sample for precise temperature control at both 
high and low collection temperatures. 
Data collection and processing were carried out using CrysAlisPro software.163 Diffraction data were 
processed through the XPREP software to verify the space group and eliminate poor reflections to 
allow a higher quality refinement.  All crystal structures were solved using direct methods (SHELXS  




for the crystal structure of PCM-II or SHELXD for the hosting complex outlined in Chapter 6) and 
refined with SHELXL in the WinGX interface.164  
2.4 Powder X-ray diffraction (PXRD) 
2.4.1 Theory 
Although extremely useful for telling the composition of individual single crystals, SCXRD is not a 
suitable method for the analysis of large quantities of polycrystalline material that would be 
generated from a large scale batch crystallisation experiment. Analysis of polycrystalline materials 
produced from such experiments is conducted using powder X-ray diffraction (PXRD) analysis. Every 
compound will have a distinct PXRD pattern making it a good fingerprinting technique to quickly 
elucidate what has been produced in a given experiment.  
In a powder sample, the varying arrangement of the micro crystals comprising the polycrystalline 
sample will result in differing orientations of the lattice planes. At any one detector angle, some of 
these lattice planes will be orientated at the correct Bragg angle to result in diffraction, as defined 
by Bragg’s Law. Due to the random orientations of the crystals in the samples, the diffraction from 
the sample is scattered in multiple directions, with diffraction from each set of lattice planes within 
a polycrystalline sample seen as a cone of diffraction (Figure 2.8). 
 
On a two-dimensional detector placed perpendicular to the X-ray beam, these diffraction cones will 
appear as a series of concentric rings (Debye rings). Plotting the 2θ angle against the integrated 
intensity of these rings leads to a one-dimensional diffraction pattern.159 
When comparing an experimental PXRD pattern to one calculated from a single crystal structure, 
the most important feature is the peak positions as these directly relate to the unit cell parameters 
and hence act as an ideal identifier of the crystal structure present. Peak intensities, which relate 
to the positions of the atoms in the unit cell, can often vary between experimental and calculated 
Figure 2.8: The cone of diffraction produced from a polycrystalline sample 
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patterns due to preferred orientation effects that can arise depending on the method of sample 
preparation used. Hence, unless full quantitative phase analysis is carried out using methods such 
as Rietveld refinement, the intensity can often only be used indicatively. 
2.4.2 Experimental 
Unless otherwise stated, PXRD data was collected at the University of Bath in flat-plate mode using 
a Bruker D8 Advance laboratory diffractometer equipped with monochromatic Cu-Kα radiation  
(λ = 1.54056 Å), the set-up of which is highlighted in Figure 2.9. 
A small amount of powder was placed on a glass slide and pressed down to form a flat layer, using 
another glass slide. The glass slide was mounted onto the sample holder using non-diffracting 
plasticine. Samples were scanned between 5 ° and 40 ° 2θ with a 0.01° step size, 0.3 secs per step 
and a rotation speed of 15 rpm; rotation of the sample holder was used to negate preferred 
orientation effects.  
2.5 Differential Scanning Calorimetry (DSC) 
2.5.1 Theory 
Differential Scanning Calorimetry (DSC) is a method of thermal analysis used to help provide 
qualitative and quantitative information on thermal events in a sample subjected to a set heat/cool 
profile. Both a reference pan (typically a closed empty aluminium pan) and a closed aluminium pan 
containing the sample are subjected to the same linear temperature programme. The difference in 
heat flow to the sample and to the reference at the same temperature is recorded as a function of 
temperature. This difference should remain the same until a thermal event occurs in the sample; 
an endothermic event would result in the rate at which the sample temperature would rise being 
Figure 2.9: The experimental set-up of the D8 Advance diffractometer, with 
key features labelled 
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lower than that of the reference and so heat needs to be applied to the reference in order to 
maintain a constant temperature profile and vice versa for an exothermic event. 165 DSC can monitor 
various thermal changes within the sample; the main events typically observed in such a scan and 
their appearance in DSC patterns are shown in Figure 2.10 (note: this plot shows exothermic events 
up). 
2.5.2 Experimental 
All Differential Scanning Calorimetry (DSC) studies, with exception of the examination of samples 
produced in the MSMPR work at AstraZeneca, were carried out using a Thermal Advantage Q20 
DSC from TA Instruments, equipped with Thermal Advantage Cooling System 90 and operated with 
a dry nitrogen purge gas at a flow rate of 18 cm3 min-1. The samples were placed in sealed Tzero 
aluminium pans and a heating rate of 5 °C min-1 was used. Data were collected using the software 
Advantage for Qseries (Ver. 5.40 software © 2001-2011 TA Instruments-Waters LLC). For the 
MSMPR samples DSC studies were carried out using a Thermal Advantage Q2000 from TA 
Instruments. Up to 3 mg of material was contained in an aluminium pan, fitted with a lid, and heated 
over the temperature range 25−200 °C at a constant heating rate of 5 °C min−1. Data were collected 
using the software Advantage for Qseries (Ver. 5.40 software © 2001−2011 TA Instruments-Waters 
LLC). 
Figure 2.10: Thermal events in a DSC trace showing (a) a glass transition (change in baseline 
level), (b) a desolvation/phase transition (endothermic), (c) a re-crystallisation (exothermic) and 
(d) a melt (endothermic) 
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2.6 Thermogravimetric analysis (TGA) 
2.6.1 Theory 
Thermogravimetric analysis (TGA) is a technique used to measure mass losses in a sample upon 
heating. A sample is weighed into a pan, with this weight being equivalent to 100 % mass. 
Percentage changes in mass from events such as loss of solvent or decomposition can be seen from 
a change in the % mass; correlation of this percentage mass loss to atoms within the molecule can 
aid with quantification of thermal events in a sample (Figure 2.11). For this reason, TGA is often 
combined with DSC in order to obtain a full picture of the thermal changes in a sample upon 
heating. 166-168 Crucially, TGA will not show melting events and so can be used to distinguish 
between events in a DSC that could theoretically be attributed to more than one event (e.g. 
distinguishing desolvation from melting).  
2.6.2 Experimental 
TGA data was obtained using a Perkin Elmer TGA 4000 Thermogravimetric Analyser. Analyses were 
performed using samples sealed in crimped aluminium sample pans. Data points were collected 
every second at a ramp rate of 5 ˚C min-1 in a flowing 40 mL min-1 argon stream. 
2.7 Raman Spectroscopy 
2.7.1 Theory 
Raman spectroscopy is a type of vibrational absorption spectroscopy whereby a monochromatic 
beam of radiation is shone at a sample and the energies of the scattered radiation are measured. 
Most of the radiation will pass through the molecule without being scattered, but a small 
Figure 2.11: A typical TGA trace, showing mass loss from a decomposition event 
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proportion will be scattered, without the scattered frequency being altered from the incident 
frequency, this is known as Rayleigh scattering. However a small amount of the scattered light will 
exchange energy with the sample (in vibrational Raman, gaining or losing energy to vibrational 
modes), thus will be scattered with a lower or higher frequency than the incident radiation. When 
the scattered radiation has a lower frequency (lower wavenumber) than the incident radiation it 
gives rise to Stokes lines, with a higher frequency (higher wavenumber) giving rise to anti-Stokes 
lines. 169 
Raman spectroscopy is another method, in addition to PXRD, often used to help distinguish 
different polymorphic forms of the same material. Differences in hydrogen bonding between 
polymorphic forms would result in different vibrational frequencies of the associated bonds, which 
can manifest as different Raman spectra. Similarly, changes between a single component and multi-
component material would be visible through Raman spectroscopy, owing to the different 
vibrational frequencies between hydrogen bonded moieties and free functional groups.  
2.7.2 Experimental 
Offline Raman spectra were acquired using a Renishaw InVia confocal Raman microscope using a 
red laser (λ = 785 nm) and a 4 second acquisition time. Experimental details for the Raman PhAT 
probe used in scaled batch crystallisation experiments are given in Chapter 4.  
2.8 Process analytical technologies (PAT) 
2.8.1 Focussed Beam Reflectance Measurement (FBRM) 
FBRM is a laser-based technique used to measure the chord length distribution of particles 
suspended within a liquid. The chord length correlates to the particle size, however is not a direct 
measure of particle size. Internal lenses within the probe focus the laser beam to a focal point. The 
focussed beam probes particles in solution by scanning in a circular path (Figure 2.12 (a)). As this 
beam scans individual particles in suspension, the backscattered light is detected by the probe; the 
length of this pulse corresponds to the size of the particle (Figure 2.12 (b)). The length of each 
backscattered pulse is multiplied by the scan speed in order to obtain the chord length of the 
particle. Thousands of chord lengths are measured per second and these are plotted against the 
frequency of each chord length (counts) to give a chord length distribution (Figure 2.12 (c)). 170 
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FBRM is a useful technique for detecting onset of nucleation in systems as well as providing crucial 
information when using seeding techniques. However, particle size information from chord length 
distributions should be treated with caution; chord length distributions can be significantly skewed 
by crystals that display a high aspect ratio, such as needles.  
Full experimental details for the FBRM used in scaled batch experiments are given in Chapter 4. 
2.8.2 Raman probe 
Raman probes apply the principles of Raman spectroscopy described above to monitor a 
crystallisation process non-invasively, giving real time information on the solid form produced 
throughout the process.  Probes can be immersion based (i.e. submerged in a solution like a FBRM 
probe) or non-contact based such as the PhAT probe employed in this work. 
One of the main benefits of monitoring crystallisation processes with a Raman probe is their 
insensitivity to aqueous solutions. However, other crystallisation solvents can swamp spectra, 
resulting in poor resolution of peaks from the product.  
2.9 SEM 
2.9.1 Theory 
Scanning electron microscopy (SEM) is a technique used to obtain high resolution images of solid 
particles in terms of their morphology, surface features and topography and is often used to 
Figure 2.12: The measurement of chord length distribution through FBRM (a) a focussed laser beam scanning in a circular 
path, (b) the measurement of suspended particles in the circular path, (c) the resulting chord length distribution 
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complement optical microscopy images. Electrons are emitted from an electron gun and 
accelerated towards the sample, which has been coated in a thin film of a metal in order to prevent 
charge build up on the surface. The electron beam hits the sample and can interact with the sample 
to generate backscattered electrons, secondary electrons or X-rays. Backscattered electrons have 
a similar energy to the incident electron beam, losing very little energy on interaction with the 
sample.  They originate from deep within the sample and provide compositional information. 
Secondary electrons have a lower energy than the incident electron beam, losing energy on 
interaction with the sample. They originate from within a few nanometres of the surface, and as 
such provide sensitive surface information. When interaction of the electron beam with the sample 
results in the ejection of an electron from the outer shell, the excess energy produced can be 
emitted as an X-ray. These give information about the elemental composition of the sample. 171 
2.9.2 Experimental 
As different SEMs were used depending on where the work was performed, full experimental 
details are given in the relevant Chapters.  
2.10 NMR 
2.10.1 Theory 
When a nucleus is placed in a strong magnetic field, the spin states of nuclei with a non-zero nuclear 
spin, such as 1H and 13C, can align themselves with or against the magnetic field resulting in a split 
in these normally degenerate energies. By applying an external radio-frequency (RF) field of correct 
frequency, the spin state of a nucleus can be changed from the stable state (aligned with the 
magnetic field) to the unstable state (aligned against the magnetic field); this is known as 
resonance. Depending on the local bonding environment of the nucleus (i.e. the local chemical 
environment), a slightly different external RF field frequency would be required to cause the 
nucleus to resonate; this is due to local shielding effects diminishing the effective magnetic field by 
a small amount. It is this difference in RF magnetic field that an NMR experiment measures. From 
the differences in frequency required for resonance, the chemical environment in which the 
nucleus sits can be determined.   
2.10.2  Experimental 
Routine NMR analysis was performed by dissolving the sample in D2O and using a Bruker Avance 
500 MHz spectrometer, with all spectra recorded at 298 K. Data were processed using ACD labs. 
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Chapter 6 details various different NMR methods used for host-guest complexes, the experimental 






















3 Small-scale batch crystallisation of 
paracetamol form II 
 
Some of the results presented in this Chapter have been published in a themed issue 
(Pharmaceutical Solids) of Chemical Communications: 
L.R. Agnew, D.L. Cruickshank, T. McGlone and C.C. Wilson, ‘Controlled production of the 
elusive metastable form II of acetaminophen (paracetamol): a fully scalable templating 
approach in a cooling environment’, Chem. Commun., 2016, 52, 7368-7371 
3.1 Introduction and Aims 
 
Paracetamol (PCM) (Figure 3.1) is a well-known antipyretic and analgesic active pharmaceutical 
ingredient (API) which has been studied extensively in the solid state.82, 172-174 It exists in five known 
polymorphic forms, two of which can only be accessed under high pressure conditions.175 Until 
recently, Form III (PCM-III) has been highly elusive, however recent work has shown the possibility 
to isolate PCM-III using Ostwald’s rule of stages.176  The work in this thesis focusses on the two main 
polymorphic forms of PCM: the thermodynamically stable form I (PCM-I, CSD REF:HXACAN30) and 
metastable form II (PCM-II, CSD REF:HXACAN31)). PCM-I crystallises in the monoclinic space group 
P21/n, with PCM-II crystallising in the orthorhombic space group Pbca. 
PCM-I and PCM-II are a prime example of packing polymorphism, with PCM-I adopting a 
herringbone packing arrangement and PCM-II adopting a layered structure (Figure 3.2). In both 
polymorphs, each paracetamol molecule forms four hydrogen bonding interactions: the hydroxyl 
group acts as both a donor and acceptor forming an O-H…O hydrogen bond to the carbonyl group 
and an O…H-N hydrogen bond to the amide N-H, with the amine and the carbonyl forming the 
complementary interactions.  




Figure 3.2: The crystal structures of PCM-I (left) and PCM-II (right), showing the clear difference in their packing 
arrangements 
The two polymorphs are easily distinguishable through powder X-ray diffraction (PXRD) analysis 
(Figure 3.3), their space groups and unit cell parameters producing entirely distinct patterns; in 
particular there is a low angle peak at 10° 2θ in PCM-II that provides rapid, easily observed, 
distinction between the two polymorphs. Raman spectroscopy can also be used to distinguish 
between polymorphs, which will be detailed further in Chapter 4. 
 
The two polymorphs display an monotropic relationship.177 However, in some samples produced in 
this work, a solid state conversion from form II to form I is observed upon heating in a temperature 
range of 130-140 °C. This transition is visible through differential scanning calorimetry traces, when 
carried out with a slow scan speed (Figure 3.4). This phenomenon has been observed and explained 
Figure 3.3: PXRD patterns for PCM-I and PCM-II 
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by Nichols and Frampton.172 They observed that when crystallised from the melt, the DSC trace 
shows one sharp endothermic peak at 157 °C, indicating the monotropic relationship of the two 
polymorphs. However, when crystallised from solution, a small endothermic peak at 157 °C, 
corresponding to a phase transition from PCM-II to PCM-I, followed by a sharp melt at 171 °C, 
corresponding to the melt of PCM-I, are observed. They postulate that solution based methods 
produce samples of PCM-II which are not polymorphically pure, with the presence of this small 
amount of PCM-I being responsible for the first endothermic event. Alternatively, the fast 
precipitation of PCM-II crystals from solution based methods could result in more defects on the 
crystal surface, which could induce the transformation between the two forms. 
Calculation of the Bravais-Friedel-Donnay-Harker (BFDH) morphology for each of the two 
polymorphic forms of PCM shows that PCM-I adopts equant block crystals with the herringbone 
arrangement growing perpendicular to the (002) plane, while PCM-II forms a more elongated 
diamond, again with the hydrogen bonded layers growing perpendicular to the (002) plane 
(Figure 3.5). It is commonly reported in literature that PCM-I adopts a block like morphology while 
PCM-II adopts a needle morphology. 
Figure 3.4: DSC trace of PCM, with the transition between 130 and 140 °C highlighted. This 




Figure 3.5: BFDH calculated morphology of PCM-I (left) and PCM-II (right) 
However, calculations of the BFDH morphology are based on crystallographic parameters and use 
only knowledge of the unit cell and corresponding symmetry operations; they do not take into 
account any external factors such as solvent, supersaturation or presence of additives or impurities, 
nor do they take account of the internal molecular arrangement. As such, a lot of work has been 
carried out to investigate the effect of different parameters on the morphology of PCM.  Prasad et 
al reported the change in morphology of PCM-I from columnar to plate-like upon increasing 
solution supersaturation.178  The effect of a variety of structurally similar additives, including p-
acetoxyacetanilide (PAA), methyl paraben (MP), 4-acetamidobenzoic acid (4-ABA), metacetamol 
(MCM) and orthocetamol (OCM), on the morphology of PCM-I has been  
reported178-179, with the effects being classified as blocking, docking or disrupting depending on the 
mechanism of action and uptake of the additive into the PCM crystal. For example, due to the extra 
steric bulk of the ester group, PAA is a good blocking molecule; it does not have a proton donor to 
continue the hydrogen bonded chain and so blocks growth along the (002) face. MCM is considered 
to be a good docking molecule, meaning it can be included within the crystal lattice due its 
complementary hydrogen bonds to PCM. PAA is also considered to have a disrupting effect on the 
emerging nucleus, reducing its stability and inhibiting growth. 
The differing morphologies of the two polymorphs has allowed for the use of in-line process 
analytical technologies to monitor the polymorphic transformation upon cooling a saturated 
solution of PCM. Here, focussed beam reflectance measurement (FBRM) was used to observe the 
change from a needle-like morphology (characteristic of PCM-II) to an octahedral morphology 
(characteristic of PCM-I), when crystallised from ethanol.180 
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The layering in PCM-II results in better compaction properties in comparison to PCM-I82 , while 
PCM-II  also displays increased solubility (Figure 3.6), as determined by the Technobis Crystal 16 (as 
outlined in Chapter 2). In light of these benefits of PCM-II in terms of solid state properties, it would 
be advantageous if a method could be established for the large scale production of PCM-II, 
producing samples that display good stability with respect to the transformation to the stable  
PCM-I; this has been the aim of this work.  
 
Previous routes to obtaining metastable form II include reaction coupling181, swift cooling182, 
enforcing Ostwald’s rule of stages183, use of polymer additives80, heterogeneous nucleation10 and 
multicomponent “templating” approaches.104  The last of these has shown the possibility to 
template form II with a variety of benzoic acid (BA) derivatives; in this context, a template is defined 
as a co-former included within the crystallisation process that leads to the adoption of a particular 
polymorphic form of an API, without itself being present in the final crystal structure. However, this 
was only achieved in an evaporative crystallisation environment. As the final goal is to transfer the 
production of PCM-II to continuous crystallisation platforms, many of which utilise cooling 
crystallisation, transfer to a cooling environment is a crucial first step. The work presented here 
looks at the production of metastable form II, with p-substituted halobenzoic acid derivatives (4-
bromobenzoic acid (4-BrBA), 4-chlorobenzoic acid (4-ClBA), 4-fluorobenzoic acid (4-FBA)) as 
templating molecules, in a cooling crystallisation environment. The p-substituted benzoic acid 
derivatives were shown to produce form II most reliably in evaporative studies and so were chosen 
as initial additives. Here, this designed approach is developed by also using a variety of structurally 
similar molecules (Figure 3.7), all only previously studied in the relation to their effect on the 
morphology of PCM-I, as potential templating molecules for PCM-II production. The structurally 
Figure 3.6: Solubility diagram showing the increased aqueous solubility of PCM-II 
over PCM-I, determined by turbidity measurements in the Technobis Crystal 16 
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similar molecules investigated include metacetamol (MCM), orthocetamol (OCM), p-acetanisidide 
(PACN), methyl paraben (MP), 4-acetamidobenzoic acid (4-ABA) and 3’-amino-4’-
methoxyacetanilide (3A4MA) as potential templating molecules for PCM-II production. 
3.2 Materials and methods 
PCM, 4-BrBA, 4-ClBA, 4-FBA, MP and 4-ABA were purchased from Sigma Aldrich. MCM, OCM, PACN 
and 3A4MA were purchased from TCI Ltd. All reagents were used without further purification. 
Laboratory grade solvents purchased from Sigma Aldrich and VWR were used throughout.  
3.2.1 Solubility measurements 
Solubility measurements of PCM, MCM, OCM, 4-FBA, 4-BrBA and 4-ClBA in 60:40 (v/v) H2O:IPA were 
carried out using the Technobis Crystal 16 at the 1 ml scale. Vials containing varying concentrations 
of each component were subjected to a heat-cool cycle at a rate of 0.5 °C min-1 with a magnetic 
bottom stirring rate of 800 rpm. Clear and cloud points were determined using the Crystal Clear 
software from Avantium Technologies.   




3.2.2 Cooling crystallisations  
Solubility analysis on paracetamol and the template molecules allowed for experimental design, in 
particular a cooling profile suitable for the system. The cooling profile used throughout all 
crystallisations is shown in Figure 3.8. 
Dwelling periods of one hour were used throughout the cooling profile, as shown in Figure 3.8, to 
allow for equilibration of solution and give more control over the crystallisation process; similar to 
how induction time measurements are performed, holding a saturated solution at a certain 
temperature for an extended period of time would allow for nucleation at higher temperatures and 
aim to reduce the likelihood of unwanted products ‘crashing out’. 
Cooling crystallisation experiments were performed using the Polar Bear Plus crystalliser from 
Cambridge Reactor Design. Small scale experiments were all performed with magnetic bottom 
stirring to agitate the solution, the speed of which was dependent on the template molecule used. 
Full details of concentrations and experimental parameters are given in sections 3.3, 3.4 and 3.5. 
Products at the end of the crystallisation were filtered and solids analysed through PXRD analysis. 
In each crystallisation performed, a control vial containing PCM in the absence of any template 
molecule was included. In all cases, the crystallisation carried out in this control vial resulted in the 
production of PCM-I. 
3.2.3 Seeding experiments 
Seeding experiments were performed in pure water as solvent in order to reduce the solution 
mediated phase transformation kinetics, with the aim of stabilising the metastable PCM-II. The 




cooling profile employed throughout these seeding experiments is shown in Figure 3.9. A 15 minute 
hold period was utilised after addition of seeds to check that the added seeds do not dissolve; such 
dissolution would trigger the solution mediated phase transformation hence resulting in the 
production of PCM-I. 
A PCM concentration of 35 mg/g of solvent was used throughout all experiments in a 50 ml volume, 
with an overhead stirring rate of 400 rpm. This concentration of PCM was chosen as it corresponds 
to a saturated solution of PCM-II in the water solvent system at a temperature of 35 °C. Dry form II 
seeds were added at the beginning of the hold period and any obvious dissolution observed by eye.  
3.2.4 Characterisation techniques 
SEM analysis of the solid product from the crystallisations of PCM in presence of 4-FBA and PCM in 
presence of MCM at small scale was used to visualise crystal morphology more accurately than 
microscope images. The samples were prepared by vacuum filtration and subsequent drying at 
room temperature. They were then mounted and stored under vacuum. A Quorum QT Chrome 
Coater (UK) with a film thickness of 20 nm was used to coat the samples. The images were then 
obtained via use of the FESEM (JOEL 6301F SEM (Japan) with a Saturn Imaging System (Belgium)). 
SEM analysis of PCM-II in the presence and absence of metacetamol hydrate was undertaken at 
AstraZeneca in Macclesfield. Samples were mounted on an aluminium stub with a carbon tab and 
were gold coated with a Quorum Q150R sputterer to a target film thickness of 10 nm. The images 
were obtained using a Hitachi TM-1000 with an accelerating voltage of 15 kV. 
Figure 3.9: The seeding profile employed 
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Variable temperature PXRD (VT-PXRD) analysis was carried out at AstraZeneca in Macclesfield. The 
samples were mounted on a silicon wafer mount and analysed using a Bruker D8 Advance 
diffractometer ( = 1.5418 Å) equipped with a LYNXEYE detector. Samples were measured in 
reflection geometry in  - 2 configuration over the scan range 4° to 40° 2  with a nominal 0.5 
second exposure per 0.02° increment.  The effective exposure per step was 96 seconds.  The X-rays 
were generated by a copper long-fine focus tube operated at 40 kV and 40 mA.  The sample was 
heated inside a TTK 450 sample chamber using a TCU 110 Temperature Control Unit, both supplied 
by Anton-Paar Ltd. The temperature profiles used are shown in Table 3.1 and Table 3.2. 
Table 3.1: Experimental parameters for the VT-PXRD study or PCM-II with metacetamol hydrate present 
PCM-II + Metacetamol hydrate 
Temperature step Tstart (°C) Tend (°C) Heating Rate (°C min-1) 
1 25.0 25.0 - 
2 25.0 60.0 5 
3 60.0 75.0 2 
4 75.0 84.0 2 
5 84.0 95.0 2 
6 95.0 110.0 2 
7 110.0 123.0 2 
8 123.0 150.0 2 
9 150.0 156.0 1 
10 156.0 175.0 2 
11 175.0 180.0 2 
 
Table 3.2: Experimental parameters for the VT-PXRD of PCM-II 
 PCM-II 
Temperature step Tstart (°C) Tend (°C) Heating Rate (°C min-1) 
1 25.0 25.0 - 
2 25.0 77.5 5 
3 77.5 89.8 2 
4 89.8 98.0 2 
5 98.0 107.3 2 
6 107.3 113.5 2 
7 113.5 120.5 2 
8 120.5 146.3 2 
9 146.3 151.8 2 
10 151.8 159.8 2 
11 159.8 172.4 2 
3.3 Crystallisation with benzoic acid derivatives 
Initial solubility analysis of paracetamol and the 4-substituted halobenzoic acids in 60:40 H2O:IPA 
solvent (Figure 3.10) allowed for design of cooling profiles; the 4-substituted derivatives were 
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chosen as they gave PCM-II most reliably and reproducibly in evaporative studies. 104 Due to the 
fast transformation time from PCM-II to PCM-I in this solvent system, turbidimetric or gravimetric 
solubility analysis could not be performed on PCM-II. As such, the solubility of PCM-II was calculated 
through the use of ratios144, based on the solubility of both PCM-I and PCM-II in water and the 
solubility of PCM-I in 60:40 H2O:IPA. The ratio between the two lines of best fit in H2O was found to 




 = 1.45e−0.0027x 
Substitution of x at different temperatures and addition to the concentration value of PCM-I in 
60:40 H2O:IPA results in the solubility curve shown in Figure 3.10. 
Figure 3.10: Solubility curves for 4-BrBA, 4-ClBA, 4-FBA and both polymorphs of PCM in a 60:40 H2O:IPA solvent system 
Cooling crystallisations were designed to ensure the co-former molecule remains in solution at the 
end of the crystallisation, with the concentrations of co-former molecules chosen to correspond to 
an undersaturated solution at the final temperature of 5 °C (i.e. for 4-FBA no concentrations above 
40 mg/g were used, for 4-BrBA and 4-ClBA no concentrations above 5 mg/g were used). 
Initial crystallisations using a concentration of PCM of 350 mg/g gave a solid product of PCM-I. 
However, a pink hue of the liquor in the vial, and its absence in the blank crystallisation vial, 
prompted this to be decanted and evaporated. Analysis of the evaporated product showed the 
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presence of PCM-II. For subsequent experiments, the concentration of PCM was decreased in order 
to decrease the supersaturation ratio of the system, allowing for more controlled nucleation; the 
concentration of PCM was chosen to ensure the system still remained supersaturated with respect 
to PCM-II in order to try and induce crystallisation of this polymorphic form. 

















1 300 4-ClBA 1.0 800 0.02 1 
2 300 4-ClBA 1.7, 2.3, 4.0 800 0.02 1 
3 250 4-BrBA 0.4, 1.6, 2.4 800 0.02 1 
4 250 4-ClBA 1.2 800 0.02 1 
5 250 4-BrBA 1.2, 2.0, 2.4 400 0.02 1 
6 250 4-ClBA 1.2, 1.6 400 0.02 1 
7 250 4-FBA 4.8 400 0.02 1 
8 250 4-FBA 0.8, 2.0, 2.8 800 0.05 1 
9 250 4-ClBA 0.6 800 0.05 1 
10 250 4-FBA 3.4 400 0.02 1 
Investigations were conducted with all three 4-substituted derivatives in varying concentrations, 
with varying PCM concentrations, stirring speeds and cooling rate, with Table 3.3 highlighting the 
conditions through which PCM-II was produced. The highlighted rows indicate conditions under 
which the production of PCM-II is fully reproducible; these conditions were used to produce enough 
PCM-II for solubility analysis. The production of PCM-II was confirmed through PXRD analysis and 
the absence of any co-former molecule in the solid product through DSC and NMR analysis. 
The poor reproducibility of some of the experiments can be attributed to the small vials in which 
the crystallisations were carried out. In these small volumes, presence of varying amounts of 
impurities, such as dust or surface imperfections, between vials would have a greater effect than in 
a larger bulk solution where on average these would even out.  
In general, it can be seen that those experiments where 4-BrBA and 4-ClBA were used, which display 
considerably lower solubility in comparison to 4-FBA, a higher stirring rate of 800 rpm was needed 
in order to direct the formation of PCM-II. The use of these higher stirring rates can be attributed 
to the fact that these conditions provide greater mass transfer required for these lower 
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concentrations. For cases where this does not hold true (Experiment Set 5 and 6), it can be seen 
that PCM-II production was only achievable at the higher concentrations of co-former molecules, 
where it had been seen at lower concentrations under the same conditions with a faster stirring 
rate. 
The cooling rate used here for the production of PCM-II would not be conducive to transfer into 
continuous crystallisation platforms; to achieve a cooling rate this slow in a continuous 
crystallisation environment would require very long crystallisers consisting of many straights (in the 
case of the COBC) or vessels (in the case of an MSMPR). As such, investigations with faster cooling 
rates of 0.1 °C min-1 and 1 °C min-1 were performed, however all experimental parameters 
investigated with these cooling rates resulted in the production of pure PCM-I. 
3.3.1 Seeding experiments 
Attempted scale-up of the production of PCM-II using halobenzoic acid template molecules has 
been largely unsuccessful. Experiments were performed at both 5 ml and 10 ml scale, however only 
the production of PCM-I was observed under all conditions attempted. It can be postulated that 
this is due to the low solubility of the template molecules combined with the naturally reduced 
mass transfer experienced upon scale-up.  
As such, seeding experiments at the 50 ml scale, in both the absence and presence of template 
molecule, were conducted to investigate another method for large-scale production of PCM-II.  
Table 3.4: Experimental parameters investigated for seeding experiments. For templated experiments within the Table, 

























5 N 0.5 0.1 55 7 Form I 
5 N 0.5 0.1 53 4 Form I 
5 Y 0.5 0.1 48 5 Form I 
10 Y 0.5 0.1 46.5 0 Form I 
5 Y 0.3 0.1 48.5 2 Form I 
5 Y 0.3 0.1 48.0 6 Form I 
5 Y 0.3 0.1 47.8 2 Form I 
5 Y 0.3 0.1 47.9 3 Form I 
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Table 3.4 highlights the experimental parameters investigated for the seeding experiments. The 
two experiments performed in the absence of any templating molecule were unsuccessful, yielding 
only PCM-I and so succeeding experiments were performed with 4-FBA as a template molecule in 
a 1:30 (4-FBA:PCM) ratio; this ratio ensured that no 4-FBA was present in the final solid product. 
Initial experiments with a 5 % seed loading showed obvious seed dissolution followed by visible 
crystallisation in the hold period, indicating the seed was added too early and the supersaturation 
generated by dissolution resulted in crystallisation. PXRD analysis on the filtered solid product 
showed the production of PCM-I. As such, the seed loading was increased to 10 % and the 
temperature of seed addition decreased. However, although no visible seed dissolution was 
observed, this resulted in instantaneous nucleation. It can be suggested that the seed was added 
at the point of highest supersaturation in the system, close to nucleation, resulting in this 
instantaneous nucleation. Again analysis of filtered solid product showed the presence of PCM-I. 
For subsequent experiments, the cooling rate before seed addition was decreased from  
0.5 °C min-1 to 0.3 °C min-1; it was hoped that this slower cooling rate would allow the solution to 
equilibrate more to give more control over the point of nucleation in the system and aid with 
addition of seeds at the correct temperature. However, four experiments with seed addition at 
different temperatures all resulted in the production of pure PCM-I. 
The lack of success in producing PCM-II in attempted scale-up crystallisations with benzoic acid 
derivatives as templating molecules prompted work with some structurally similar template 
molecules. 
3.4 Crystallisation with metacetamol 
Metacetamol is a structural isomer of paracetamol and displays a much higher solubility in a 
60:40 H2O:IPA solvent system than the benzoic acid derivatives; the solubility curves in two 
different solvent systems are shown in Figure 3.11. It was hoped that this solubility increase would 
mean higher concentrations of template molecule could be used, aiding in the scaled-up production 
of PCM-II, but still achieving the desired outcome of no template molecule being present in the final 












As with the halobenzoic acid crystallisations, a concentration of PCM of 250 mg/g was used, and 
concentrations of metacetamol again chosen so that this component was undersaturated with 
respect to the solvent system. Initial experiments at the 1 ml scale allowed for determination of 
which solvents and concentrations of MCM were likely to produce PCM-II and these were used to 
inform future larger scale experiments. These initial experiments investigated three different 
solvent systems (60:40 H2O:IPA, EtOH and IPA) with percentages of MCM between 1 and 25 w/w %. 
PCM-II was produced from both 60:40 H2O:IPA and EtOH, but its appearance was never observed 
in the product from IPA; use of IPA was therefore not investigated further after these experiments. 
A systematic study was conducted at the 10 ml scale to investigate the reproducibility of the 
production of PCM-II in the two selected solvent systems under varying crystallisation conditions. 
Table 3.5 highlights the experimental conditions under which PCM-II has been obtained 
reproducibly. 







60:40 H2O:IPA 0.02 Stepped 10, 25 
EtOH 0.02 Stepped 5, 10, 25 
60:40 H2O:IPA 0.2 Stepped 5, 10, 15, 25 
EtOH 0.2 Stepped 5, 10, 15, 25 
60:40 H2O:IPA 1 Stepped 10, 15, 20, 25 
EtOH 1 Stepped 10, 15, 20, 25 
60:40 H2O:IPA 1 Linear 10, 20, 25 
EtOH 1 Linear 10, 20, 25 
 
The reproducible production of PCM-II was observed through a variety of crystallisation conditions. 
Those crystallisations performed with a cooling rate of 1 °C min-1 are of most interest as this cooling 
Figure 3.11: Solubility curves of metacetamol in (a) 60:40 H2O:IPA and (b) EtOH 
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rate would be more conducive to what would be achievable in a continuous crystalliser. At higher 
percentages of metacetamol, some vials showed the presence of small quantities of an extra 
crystalline form within the PCM-II solid (Figure 3.12); this extra form was confirmed by PXRD to be 
metacetamol hydrate (MCM·H2O), as reported by Pulham et al.184  Despite water being used in one 
of the solvent systems, the hydrate was more prevalent in the ethanol crystallisations. The presence 










The ability to obtain PCM-II through a linear cooling profile is of great interest in terms of its transfer 
to continuous crystallisation platforms. However, as a consequence of not having the periods of 
dwelling to allow the solution to equilibrate, combined with a widening of the metastable zone 
width (MSZW) in the presence of MCM, crystallisation did not occur until lower temperatures. This 
effective crash cooling resulted in the crystallisation of MCM in the solid product (Figure 3.13). It 
can be suggested that the control exerted through the stepped cooling profile is needed to direct 
the formation of MCM·H2O, which is not exerted through a quick linear cooling profile.  As such, for 
scale-up experiments (see Chapter 4), the stepped cooling profile was employed in order to 





Figure 3.12: PXRD analysis confirming the presence of predominately PCM-II, with circled peaks showing the 












Analysis of the yields of the crystallisations showed lower yields from the ethanol solvent system: 
an expected result due the enhanced solubility of PCM in this solvent. The yields from ethanol 
crystallisations were typically around 35 %, with those from 60:40 H2O:IPA ranging between 60 and 
70 % (Full experimental yields are shown in Appendix A3). The lower yields and the higher 
propensity for hydrate formation in an ethanol solvent system meant that investigations into the 
scaling potential of PCM-II production with MCM as a template were conducted in a 60:40 H2O:IPA 
solvent system (see Chapter 4). 
Use of DSC, PXRD, SCXRD and NMR spectroscopy confirm the absence of any MCM·H2O in the solid 
sample. SCXRD analysis was performed to confirm whether any MCM has been included into the 
crystal lattice, a distinct possibility owing to the structural similarity of PCM and MCM. Single 
crystals from crystallisations were analysed by a full structure determination. The refinement 
parameters are good and the crystal structure shows no extra electron density that could 




Completeness (%) 99.8 
GooF 1.068 
R1 (observed) 0.0411 
R1 (all) 0.0547 
wR2 (all) 0.0989 
Figure 3.13: PXRD analysis showing the presence of small quantities of MCM from linear cooling 
experiments (circled in red). The y-axis displays relative intensity in arbitrary units. 
Figure 3.14: Refinement parameters and a molecule of paracetamol showing small thermal ellipsoids at a 
50% probability level 
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Interestingly, evaporative crystallisation of PCM with MCM in a 1:1 ratio in five different solvents 
(ethanol, methanol, IPA, acetonitrile and acetone) yielded a physical mixture of PCM-I and MCM 
(Figure 3.15). It can be suggested that this is the case due to the static nature of an evaporative 
crystallisation vial; cooling crystallisation experiments demonstrated the importance of efficient 











Investigations were also conducted in order to try to ‘reverse’ the templating effect, i.e. template 
metacetamol form II (MCM-II) with paracetamol, as the literature shows that MCM-II has similar 
characteristics to those of PCM-II.184 Due to their similar solubilities in the 60:40 H2O:IPA solvent 
system, the concentration of MCM of 300 mg/g was used with wt.% of PCM between 5 and 25 %. 
The dominant product in all crystallisations was MCM-I. However, at higher percentages of PCM, 
there are peaks evident in the PXRD patterns that correspond to the formation of PCM-II 
(Figure 3.16). Further experiments were performed with an increased MCM concentration of 
400 mg/g, however this yielded the same result as those with the lower MCM concentration, with 





Figure 3.15: PXRD analysis of PCM/MCM evaporative crystallisations showing the formation of a physical 













3.4.1 Metacetamol hydrate (MCM·H2O) 
The appearance of small quantities of metacetamol hydrate (MCM·H2O) in some of the 
crystallisation products prompted further investigations into its presence and properties by using 
analytical techniques. The presence of MCM·H2O within PCM-II samples resulted in a DSC trace as 
shown in Figure 3.17. 
The endothermic peak at 100 °C can be attributed to loss of water; however, the origin of the event 
at 150 °C (endotherm followed directly by exotherm) was unclear.  As such VT-PXRD analysis was 
performed on a sample of pure PCM-II (Figure 3.18) and a sample of PCM-II with metacetamol 
hydrate present (Figure 3.19). 
Figure 3.16: PXRD patterns showing the formation of some PCM-II (peaks in red boxes) within MCM samples. 
The y-axis displays relative intensity in arbitrary units. 





Figure 3.18 clearly shows the phase transition from PCM-II to PCM-I between 121 °C and 146 °C. 
However, the VT-PXRD for PCM-II with some MCM·H2O present is slightly more complicated. At 
room temperature there are two peaks at 2θ = 15.5° and 2θ = 16° (shown inside the purple box in 
Figure 3.19) that correspond to MCM·H2O. Upon heating beyond 60 °C, these peaks are lost and 
there is the appearance of a peak at 2θ = 17° (shown inside the pink box in Figure 3.19); these peaks 
correspond to MCM. Therefore, it can be concluded that this is the dehydration step. Between 
123 °C and 150 °C, the metacetamol melts and there is a partial transformation from PCM-II to 
Figure 3.18: VT-PXRD of a sample of pure PCM-II showing the transition from PCM-II to PCM-I between 
121 °C and 146 °C. The y-axis shows relative intensity in arbitrary units. 
Figure 3.19: VT-PXRD for a PCM-II containing small amounts of MCM·H2O. The y-axis displays relative 
intensity in arbitrary units. 
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PCM-I. Unlike in the sample with no hydrate present, where this transformation is complete, there 
are still a few PCM-II peaks present in the PXRD pattern at 150 °C (shown inside the blue boxes in 
Figure 3.19). It could be suggested that the metacetamol melt acts to stabilise the PCM-II against 
the transformation to PCM-I.  The transformation is only complete when extra energy is supplied 
to the system by further heating; once heated beyond 150 °C the transformation is driven to 
completion and the remaining sample is pure PCM-I, which then melts at ~ 170 °C. 
3.4.2 SEM  
SEM image analysis was undertaken in order to compare the morphologies of the samples of  
PCM-II produced with each individual template molecule; the shape of the crystals could help to 
elucidate a mechanism through which the template molecule acts, that affects the growth of  
PCM-II. Figure 3.20 shows the comparison between the samples of PCM-II produced in the presence 
of 4-FBA and MCM. It can be seen that crystals produced in the presence of 4-FBA are more 
elongated than those produced in the presence of MCM, which display a more block-like 
morphology. Block crystals are more favourable in terms of ease of downstream processing steps185 
and so use of MCM to produce PCM-II is again advantageous; samples of PCM-II produced in the 
absence of any template molecules have been reported to adopt a needle like morphology. The 
varying sizes of the crystals from each sample can be attributed to the use of magnetic bottom 
stirring in the crystallisations and its corresponding grinding motion, leading to fracturing of the 
forming crystals.186-187 
SEM analysis was also used to compare any morphological differences between samples of pure 
PCM-II and samples of PCM-II that contained low levels of MCM·H2O (Figure 3.21). The samples 
analysed were produced from crystallisations on the 100 ml scale (the details of which will be 
outlined in Chapter 4). 
Figure 3.20: SEM images showing the morphology of samples produced in the presence of (a) 4-FBA and (b) 
MCM (both from a 60:40 H2O:IPA solvent system) 
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It can be seen from Figure 3.21 that samples of pure PCM-II adopt a block, prismatic morphology. 
This same morphology is evident in samples that contain MCM·H2O, however on the surface of 
these crystals are smaller crystals. It can be postulated that these crystals are metacetamol hydrate. 
It is reported in literature that metacetamol acts as a ‘docking’ molecule178-179, adsorbing onto the 
growing crystal surface, further supporting the fact that these crystals could be MCM·H2O. A 
technique such as Raman mapping of the surface would be required to confirm this. 
3.5 Crystallisation with other structurally related compounds 
Owing to the success of MCM as a templating molecule for PCM-II production, a variety of other 
structurally similar molecules to PCM were investigated for their templating abilities. Initial work 
was carried out with orthocetamol (OCM) at the 1 ml scale; much of this work was performed by  
L. Wayment (MChem 2015/16) under the direction of the author. Solubility analysis on OCM was 
performed in three solvent systems (Figure 3.22) to allow determination of the concentrations to 
be used for the templating investigations. Initially a slow cooling rate of 0.02 °C min-1 was employed 
with 400 rpm magnetic bottom stirring. Weight percentages of OCM (as a proportion of the weight 







Figure 3.21: SEM images showing the morphology of samples produced for samples of (a) pure PCM-II and 













The use of 60:40 H2O:IPA as solvent combined with both 2 % and 3 % OCM as a template resulted 




Figure 3.23: PXRD analysis showing a mixture of PCM-II and PCM-I being formed with 2 % and 3 % OCM 
(the peaks boxed in red are those that correspond to PCM-I). The y-axis displays relative intensity in 
arbitrary units. 
Figure 3.22: Solubility curves for OCM in (a) 60:40 H2O:IPA, (b) EtOH and (c) IPA solvent systems 
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For succeeding experiments, the stepped cooling profile was truncated at a temperature of 20 °C 
to try to mitigate the formation of PCM-I; if the system was crystallising at a higher temperature 
and being left until 5 °C for filtration, this period of dwelling could result in the solution mediated 
phase transformation being initiated. Weight percentages of OCM of 2 %, 2.4 %, 2.8 % and 3 %, 
each in triplicate, were subjected to a 70-20 °C stepped cool at a rate of 0.02 °C min-1. The three 
vials containing 2.4 % OCM all gave PCM-II, with no trace of PCM-I in the solid product. Despite 
crystallisations being performed on the same scale, the two concentrations of OCM (2 % and 3 %) 
that previously gave PCM-II, albeit with small quantities of PCM-I, reproducibly gave PCM-I in this 
set of experiments. Using such low percentages of OCM on a small scale can result in inaccuracies 
in weighing, combined with difficulties in reproducibility on the small-scale, as explained previously. 
These inaccuracies could account for the difference in results from this set of experiments.  
The slow cooling rate of 0.02 °C min-1 used in these experiments is not conducive to transfer to 
continuous crystallisation platforms and as such investigations with a faster cooling rate of 
0.2 °C min-1 were undertaken. Again, weight percentages of OCM of 2 %, 2.4 %, 2.8 % and 3 %, each 
in triplicate, were subjected to a stepped cooling profile. Here, the use of 2.4 % OCM resulted in a 
mixture of PCM-II and PCM-I, with 2.8 % OCM giving samples of pure PCM-II (Figure 3.24), within 
the limits of detection of PXRD. However, reproducibility of these results has been poor and further 
experiments would be required to fine-tune the conditions suitable for the production of PCM-II 
reproducibly; this will be the subject of future work. 
Attempted scale-up of the templated production of PCM-II using OCM as a template molecule have 
been unsuccessful, encountering the same combined low solubility and poor mass transfer effects 
as was found for the benzoic acid derivatives described above. 
Figure 3.24: PXRD analysis confirming the production of a mixture or PCM-II and PCM-I 
with 2.4 % OCM, but the production of pure PCM-II with 2.8 % OCM. The y-axis displays 
relative intensity in arbitrary units. 
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As such, investigations were conducted with other structurally similar, size-matched components 
to PCM: p-acetanisidide (PACN), 3’-amino-4’-methoxyacetanilide (3A4MA), 4-acetamidobenzoic 
acid (4ABA) and methyl paraben (MP). Much of this work was carried out by S. Wright (MChem 
2016/17) under the supervision of the author. Many of the compounds investigated have been 
shown to affect the morphology of PCM-I in low concentrations, but their use as additives to 
encourage the production of PCM-II is unreported. Due to equipment availability, solubility analysis 
was unable to be performed on these compounds and so concentrations of template molecules 
were chosen on a trial and error basis after initial crude solubility studies. Owing to previous 
problems experienced with transfer from the 1 ml solvent scale to higher volumes in larger vessels, 
all initial crystallisations were carried out at the 3 ml scale. Further, due to time constraints and the 
eventual goal of scaled production, very slow cooling rates were not examined in this work and 
were limited to 1 °C min-1 and 0.1 °C min-1. Initial crystallisations utilised weight percentages (of the 
mass of PCM) of the template molecules between 5 and 25 %. The majority of these crystallisations 
resulted in the production of pure PCM-I, with the exception of MP that showed some PXRD peaks 
characteristic of another crystalline form. These peaks did not correspond to PCM-II or MP and it is 
possible that a new molecular complex may have been formed. As such, evaporative crystallisation 
experiments containing PCM and MP in varying ratios, in different solvent systems were set up and 
the products analysed. However, under the conditions investigated, all crystallisations yielded one 
of the two starting materials. The origin of these extra peaks is subject of future work. 
For succeeding experiments, the concentrations of each of the template molecules were increased, 
examining percentages between 30 and 60 %. Under all conditions examined, the use of PACN,  
4-ABA and MP has resulted in the production of PCM-I with some template molecule in the resulting 
solid product; the presence of these peaks in the PXRD meant the concentrations of these 
components could not be increased any further. However, use of 40 % 3A4MA combined with a 
cooling rate of 1 °C min-1 resulted in the production of PCM-II with some peaks in the PXRD from 








Reproducibility of the production of PCM-II on the 3 ml scale was investigated by examining the 
concentration range between 35 and 45 % of 3A4MA. In order to mitigate the crystallisation of 
3A4MA, initial crystallisations were cooled to 25 °C (instead of 20 °C as in previous crystallisations), 
and were left stirring at this temperature for a period of 2 hours until crystallisation occurred. 
Analysis of the product showed, instead of PCM-II, the production of pure PCM-I in the absence of 
any 3A4MA. It can be suggested that by forcing crystallisation at 25 °C this resulted in a faster 
solution mediated phase transition (SMPT) to PCM-I and PCM-II was unable to be stabilised. As 
such, the same crystallisations were repeated, but instead truncating the cooling profile at a 
temperature of 20 °C. Analysis of the powder produced from these experiments showed the 
production of PCM-II at percentages of 3A4MA of 35 % and 40 % thus supporting the interpretation 
that the SMPT from PCM-II to PCM-I is suppressed at this lower temperature. However, small 
quantities of the template molecule were detectable in the product through PXRD analysis. DSC 
analysis of this sample shows a similar behaviour to that observed from the product containing 
metacetamol hydrate (Figure 3.26). 
 
Figure 3.25: Production of PCM-II in the presence of 3A4MA as a template, with 




VT-PXRD was also performed on the sample at AstraZeneca in Macclesfield in order to elucidate 










The VT-PXRD, shown in Figure 3.27, shows some interesting features. At 25 °C and 60 °C, the 
pattern contains mainly PCM-II, with some peaks corresponding to 3A4MA at ~12°, 17° and 22.5° 
2θ. Upon heating above 60 °C (corresponding the first small endothermic event in the DSC), the 
Figure 3.26: DSC trace of a sample of PCM with some 3A4MA present 
Figure 3.27: VT-PXRD patterns of a sample of PCM-II with small quantities of 3A4MA present. The y-
axis displays relative intensity in arbitrary units. 
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peaks corresponding to 3A4MA disappear, with all patterns from 75 °C to 123 °C showing only the 
presence of PCM-II. Interestingly, the melting point of 3A4MA is not usually observed in DSC until 
120 °C, with no corresponding thermal event seen in Figure 3.27. It could be that a solvated form 
of 3A4MA has been formed in the crystallisations, and upon desolvation at temperatures above 
60 °C the crystal structure collapses and crystallinity is lost, meaning peaks from this compound are 
no longer observed in the PXRD pattern. Between 140 °C and 156 °C a phase transformation from 
PCM-II to PCM-I is seen. However, this is only a partial transformation as peaks from PCM-II are still 
visible in the spectra at 156 °C (boxed in red in Figure 3.27); a behaviour seen where small quantities 
of metacetamol hydrate are present in PCM-II samples. This further suggests that small quantities 
of these structurally similar molecules within PCM-II samples are acting to stabilise the metastable 
PCM-II against the polymorphic transformation. 
Attempts have been made to investigate the scaling potential of the templated production of  
PCM-II with 3A4MA at the 50 ml solvent scale. Utilising the concentrations of 3A4MA used in small-
scale batch crystallisations resulted in the production of PCM-I (Table 3.6, Experiment 1). As such, 
the concentration of 3A4MA was increased (Table 3.6, Experiment 2 and 3) in order to counteract 
the reduced mass transfer seen upon scale-up. However all crystallisation conditions examined 
have resulted in the production of PCM-I with 3A4MA in the solid product. 
Table 3.6: Experiments performed with 3A4MA at the 50 ml scale. A concentration of PCM of 300 mg/g was used 
throughout 
Experiment % 3A4MA Cooling rate ( °C min-1) Solid product 
1 35 1 PCM-I 
2 40 1 PCM-I + 3A4MA 
3 45 1 PCM-I + 3A4MA 
Investigations have also been conducted into the possible templating effect of polymers in the 
production of PCM-II. These experiments were undertaken with two different polymers that 
possess similar functional groups to PCM; polymers are typically used in very low concentrations 
which would be more desirable than the use of, for example, 25 w/w % of the structurally similar 
MCM as a templating molecule in terms of overall product purity. Crystallisations with polyacrylic 
acid (PAA) and polyvinyl alcohol (PVA) at the 3 ml solvent scale, under a variety of crystallisation 
conditions, whereby the concentration of each polymer was varied between 0.25 and 1 w/w % at 
a cooling rate of 1 °C min-1, did not result in the production of PCM-II in any instance, with PCM-I 
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being formed in all crystallisations. Polymers that contained aromatic rings, which would further 
mimic the structure of PCM, were not used due to their poor solubility in the solvents investigated 
in this work. Polymers like this, such as nylon 6, have been shown to produce PCM-II through 
heterogeneous templating (i.e. on surfaces) approaches in literature studies but further work is 
required to establish if they can template in a solution mediated process. 10 
3.6 Mechanistic information 
Upon cooling a saturated solution of PCM, Ostwald’s Law of Stages is obeyed, with the metastable 
PCM-II crystallising first, which then undergoes a solution mediated phase transformation (SMPT) 
to PCM-I. Having this knowledge, it was thought that the template molecule might be acting to 
interfere with this SMPT, either by stabilising the metastable PCM-II or hindering the nucleation or 
growth of PCM-I. To test this hypothesis, PCM-II was slurried in the presence of varying percentages 
of MCM at the temperature at which the SMPT would normally occur (i.e. the point of nucleation 
in the system); from batch crystallisations at the same scale this was found to be 35 °C. A 60:40 
H2O:IPA solvent system was used with 400 rpm magnetic bottom stirring employed for a period of 
24 hours. The resultant solid was filtered and analysed through PXRD (Figure 3.28). 
Analysis of the PXRD patterns shown in Figure 3.28 shows that for percentages of MCM between 
1 % and 20 %, complete conversion to PCM-I is observed over the 24 hour period. However, for 
25 % MCM, the concentration used for the batch production of PCM-II, the PXRD pattern is still 
largely dominated by peaks corresponding to PCM-II, with only partial conversion to PCM-I being 
Figure 3.28: PXRD patterns of the filtered solid at the end of slurrying experiments in the presence of varying 
percentages of MCM. The y-axis displays relative intensity in arbitrary units. 
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observed. This observation shows that at sufficiently high concentrations, MCM is significantly 
retarding the rate of the SMPT. 
Although use of additives is a common concept found in literature, their use has been largely limited 
to the control of morphology105, 188 or their effect on the growth of a stable polymorphic form179, 189, 
with only limited reports on their use in the controlled production of metastable or elusive 
polymorphic forms102, 190 and even fewer on their mechanism of action in this case. Mukura et al 
examined the effect of structurally related impurities on the solution mediated phase 
transformation of an API, monitoring the transformation with PXRD and computationally modelling 
the uptake of the impurities into the API.153 They concluded that the retardation effect of the 
impurities is due to kinetic stabilisation of the metastable polymorph through inhibition of the 
nucleation of the stable polymorph. They also noted that the driving force for the SMPT is the 
solubility difference between the stable and metastable forms and linked this to the effect of the 
impurities on the solubilities of the API. They postulate that the impurities could act to increase the 
solubility of the stable form, hence reducing the solubility difference (i.e. reducing the free energy 
difference) between the two forms and consequently the driving force for the SMPT, hence 
stabilising the metastable polymorph. Work by Qu et al 151 also showed that additives can act to 
increase the solubility of the stable form preferentially over that of the metastable form, enhancing 
the credibility of the above argument. As such, the effect on the solubility of varying percentages 
of MCM on two different concentrations of PCM was investigated (Table 3.7); recorded in Table 3.7 
is the temperature at which the concentration of PCM and the corresponding percentage of MCM 
dissolves when subjected to a standard solubility experiment (outlined in Chapter 2). A higher 

















250 0 38.7 
250 15 49.9 
250 20 45.4 
250 25 44.7 
250 30 45.0 
300 0 44.2 
300 15 52.1 
300 20 51.6 
300 25 49.7 
300 30 56.8 
 
It is clear from Table 3.7 that the presence of MCM actually acts to decrease the solubility of PCM, 
a result that might be expected due to the large quantities of MCM that are being used, a stark 
contrast to the small (<1 %) quantities used in the literature work. Interestingly, at both 
concentrations of PCM, the solubility in the presence of 25 % MCM (the concentration used 
throughout all batch crystallisation experiments) is increased in comparison to other percentages 
of MCM, but still decreased in comparison to the solubility in the absence of MCM. However, the 
decrease in solubility in the presence of MCM poses an interesting question that could elucidate a 
mechanism of action. If the MCM is acting also to decrease the solubility of PCM-II, then the barrier 
to dissolution, with dissolution being the first step in the SMPT, will be greater. This would reduce 
the driving force for the SMPT, hence stabilising the metastable PCM-II. Put another way, if the 
solubility of PCM-II is lowered, then crystallisation may not drop the solution concentration into the 
undersaturated region of the solubility phase diagram, meaning no dissolution of PCM-II can occur. 
If this dissolution does not occur, the SMPT cannot begin.  
The concentrations of the template molecules employed in this work, especially when scaled to 
larger volumes, are relatively large in comparison to traditional additive concentrations, which 
typically employ concentrations below 10 %.22, 189, 191-192 The reason that additives are typically able 
to act at such low concentrations is the fact that the concentration of active growth sites on a 
surface is low and so only small quantities are required to fill these sites. 2 As such, one would expect 
the templating effect to work at much lower concentrations of MCM if it was purely a growth effect. 
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It has been documented that high impurity loadings decrease the nucleation and growth rate 
coefficients for the stable form, increasing the transformation time (i.e. slowing down the SMPT)153, 
which could act as a further explanation as to why the concentrations need to be so high in order 
to direct the production of PCM-II.  Further, in order to elucidate whether the effect was a 
nucleation or growth effect, the crystallisation containing PCM and MCM was seeded with PCM-I. 
At two seed loadings (1 % and 5 %) the product of these crystallisations was PCM-I. This indicates 
that the MCM is acting to affect nucleation rather than growth; if the MCM was purely acting to 
promote growth of PCM-II over PCM-I, there would have been some PCM-II in this solid product. 
In order to hinder the growth of PCM-I, the template molecules approaching the surface of the 
PCM-II crystals must be able to mimic a PCM molecule in terms of the interactions it makes at the 
surface. Using the calculated BFDH morphology from Mercury, the (002) face is the plane to which 
hydrogen bonded layers in PCM-II grow parallel (see above, Figure 3.5). Calculation of this plane in 
the Mercury software shows that the functionality lying on this surface is the carbonyl group of the 
amide (Figure 3.29). As such, to mimic a PCM molecule and continue this hydrogen bonding, the 
template molecule must first and foremost contain a hydrogen bond donor that is likely to be able 
to form a hydrogen bond to this carbonyl.  Looking at the template molecules investigated in this 
work (Figure 3.7), all those templates that have successfully resulted in the production of PCM-II 
satisfy this requirement. This logic can be used to explain why p-acetanisidide does not result in the 
successful production of PCM-II; the ether functionality in place of a hydrogen bond donor means 
this molecule would not continue the hydrogen bonding in PCM-II.  
The next layer of PCM-II molecules, growing parallel to the (002) plane, is formed through N-H···O 
interactions (circled in red in Figure 3.30). Therefore the absence of this moiety in the template 
Figure 3.29: The (002) plane in PCM-II showing the carbonyl group lying on this plane 
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molecule would hinder the continued growth of PCM-II. This reasoning can then be used to explain 
why methyl paraben also does not result in the production of PCM-II. 
However, based on these observations, it would suggest that 4-ABA would be a good molecule to 
direct the formation of PCM-II, differing only from PCM by substitution of the alcohol group for a 
carboxylic acid. It was noticed that at higher concentrations of 4-ABA, the template molecule 
crystallised preferentially over PCM. It may simply be that due to its low solubility and higher 
propensity to crystallise over PCM, 4-ABA is unsuitable as a template molecule; as demonstrated 
above, relatively high quantities of template are needed and if these quantities cannot be 
successfully achieved then the templating ability will be poor. All other templating molecules 
employed in this work have the correct moieties to continue the hydrogen bonding pattern and so 
could promote the growth of PCM-II. The difficulties in the reproducibility and scaling of the 3A4MA 
system could be explained by the added steric bulk from the ether functionality that may hinder 
the continuation of the hydrogen bonding depending at what angle the molecule approaches the 
growing crystal surface. 
Figure 3.30: N-H...O interactions forming the next layer of molecules in PCM-II 
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For MCM, the templating molecule that has been utilised in all further batch scale-up and 
continuous experiments  reported in this work (see Chapters 4 and 5), analysis of the crystal packing 
similarity using the CCDC’s Mercury software enables comparison of the two crystal structures 
(Figure 3.31); this was unable to be performed for the other template molecules due to single 
crystal data not being available or lack of structural similarity in the case of the benzoic acid 
derivatives. 
It can be seen that the packing between the molecules is virtually the same, differing only by the 
torsion of the aromatic ring, supporting MCM’s superior ability as a template molecule. However, 
MCM’s enhanced ability to template PCM-II in comparison to the other templating molecules 
investigated can also be attributed to its enhanced solubility, meaning more of the template 
molecule can be used.  
3.6.1 Stability of samples 
It is well documented that the presence of any of the stable PCM-I within PCM-II samples will seed 
the conversion from PCM-II to PCM-I. The PCM-II samples produced in this work from the MCM and 
4-FBA templated studies are currently stable for a period of 24 months (Figure 3.32), indicating the 
polymorphic purity of the samples produced through this templating method. 
Figure 3.31: Crystal packing similarity of PCM-II (grey) and MCM (green) - hydrogen atoms have been 
removed for clarity 
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Although the PCM-II to PCM-I solid-state polymorphic transformation is well-documented, the 
speed of the transformation and quantification in relation to the percentage of PCM-I within a  
PCM-II sample is previously unreported. As such, doping experiments were performed whereby 
varying percentages (ranging from 1-50 %) of PCM-I were included within PCM-II samples and left 
in a closed vial. Aside from initial stirring with a spatula to distribute the PCM-I evenly throughout 
the sample, the samples were left in a non-agitated environment to ensure any polymorphic 
transformation was only due to the presence of PCM-I in the sample. Analysis of the solid product 
each week allowed for determination of a transformation time. Those samples containing more 
than 5 % PCM-I within were difficult to interpret as it was not possible to distinguish peaks present 
from the PCM-I simply being in the solid or from conversion; the limit of detection of PXRD using 
the instrument available is ~5 % and so the powder pattern recorded at the beginning of the 
stability studies to act as a reference contained peaks from PCM-I. Further, as the PXRD set-up is 
flat plate, preferred orientation effects are often seen and so peak heights cannot be used to help 
in this determination and full quantitative phase analysis was not undertaken. However, the 
analysis of the sample with 1 % form I seed loading provides some useful results (Figure 3.33); after 
a period of a month peaks from PCM-I are present in the PXRD pattern, indicating some conversion 
from PCM-II to PCM-I (1 % is well below the limit of detection of PXRD and so these peaks must, at 
least in part, be from converted PCM-I). 
 
 






The production of metastable paracetamol form II (PCM-II), which displays enhanced physical 
properties of greater compressibility and higher solubility, has been investigated with three p-
substituted halobenzoic acid derivatives and a variety of structurally similar, size-matched 
molecules as template molecules; here a template is defined as a molecule included in the 
crystallisation process that forces the adoption of a particular polymorphic form of a substance 
without itself being present in the final crystal product.  
Based on previous literature evaporative work, initial crystallisations were carried out at the 1 ml 
scale using three p-substituted halobenzoic acid derivatives. Although all yielded PCM-II under 
varying experimental conditions, only the production of PCM-II with 3.5 wt.%  4-fluorobenzoic acid 
(4-FBA) and 0.4, 1.6 and 2 wt.% 4-bromobenzoic acid in a 60:40 H2O:IPA solvent system were fully 
reproducible at this scale. The poor reproducibility of other experiments at this scale can be 
attributed to accuracy in weighing small quantities of template molecule. Attempted scale-up of 
the production of PCM-II using these derivatives were largely unsuccessful, postulated to be due to 
the low solubility combined with the naturally poorer mass transfer experienced at the larger scale. 
As such, work was conducted using a variety of structurally similar molecules. Use of metacetamol 
(MCM) resulted in the reproducible production of PCM-II up to the 20 ml solvent scale (the further 
scaling of this system will be detailed in Chapter 4). Work with MCM showed the production of 
PCM-II at a relatively fast cooling rate (1 °C min-1) in two different solvents (60:40 H2O:IPA and 
Figure 3.33: PXRD patterns over a one month period with a 1 % PCM-I seed loading, 




ethanol) through both a stepped and linear cooling profile; a stark contrast to the work with the 
benzoic acid derivatives that required a slow (0.02 °C min-1), stepped cooling profile which would 
not be conducive to transfer to a continuous crystallisation environment. The use of MCM required 
higher percentages of template to be present, in comparison to the benzoic acid derivatives, with 
percentages as high as 25 % being employed to enable the production of PCM-II. Use of higher 
quantities of MCM resulted in the production of metacetamol hydrate (MCM·H2O) in the solid 
product; however this was eliminated through truncation of the temperature profile at a 
temperature of 20 °C. Trace levels of MCM·H2O resulted in a characteristic DSC pattern, with the 
nature of the thermal events in this pattern being quantified using VT-PXRD, showing dehydration 
followed by possible stabilisation of PCM-II in the melt of MCM. When comparing the crystal 
morphologies of PCM-II produced in the presence of 4-FBA and MCM, those with MCM showed a 
more block-like morphology, desirable in terms of ease of downstream processing; this is another 
reason why the templated production of PCM-II with MCM was explored further. 
Other small scale studies showed the production of PCM-II using the templating molecules 
orthocetamol (OCM) and 3’-amino-4’-methoxyacetanilide (3A4MA). Initial experiments with OCM 
showed the production of a mixture of PCM-II and PCM-I with 2 wt. % and 3 wt. % OCM when 
cooled to a temperature of 5 °C at a rate of 0.02 °C min-1. Investigations in this percentage region 
combined with truncation of the cooling profile at 20 °C resulted in the reproducible production of 
PCM-II with 2.4 % OCM in a 60:40 H2O:IPA solvent system. Due to this cooling rate not being 
conducive to transfer to continuous crystallisation platforms, a faster cooling rate of 0.2 °C min-1 
was investigated, with 2.8 % OCM resulting in the production of PCM-II. However, reproducibility 
at this cooling rate has been poor. Attempted scale-up of this system has been unsuccessful, 
encountering similar problems to the benzoic acid derivatives due to OCM’s low solubility in the 
solvent system used. Initial experiments examining weight percentages of 3A4MA between 1 % and 
25 % resulted in the production of PCM-I. However, upon increasing the percentage of 3A4MA to 
40 %, utilising a stepped cooling profile and cooling rate of 1 °C min-1, PCM-II was formed; however 
some 3A4MA was detected in the solid product. Attempts to mitigate the formation of 3A4MA by 
truncating the cooling profile resulted in the production of PCM-I. However, upon scale-up of this 
system to the 10 ml scale, utilising 35 % 3A4MA, pure PCM-II was produced in the absence of any 
3A4MA.  
Slurrying experiments, whereby PCM-II was stirred for a period of 24 hours with varying 
percentages of MCM at the temperature at which the solution mediated PCM-II to PCM-I phase 
transition usually occurs were used to try and elucidate a mechanism of action of the template 
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molecules. These experiments showed that for percentages of MCM between 1 and 20 %, full 
conversion back to PCM-I was observed. However, for 25 % MCM, only partial conversion to  
PCM-I was observed, with the filtered product PXRD still being largely dominated by peaks from 
PCM-II. As such, it was concluded that the presence of the template molecule was hindering the 
solution mediated phase transformation, stabilising the metastable PCM-II. 
The samples produced through this templated crystallisation method display a stability of 
24 months against the well-documented PCM-II to PCM-I solid state transformation, which is 
accelerated by the presence of even trace quantities of PCM-I in a PCM-II sample. Investigations 
into this transformation time through doping of PCM-II samples with varying percentages of  
PCM-I showed that the presence of 1 % PCM-I or greater started the conversion back to the 
thermodynamically stable PCM-I within a month. The stability of the PCM-II samples produced here 
further highlights the polymorphic purity of the samples produced through this method.  
The transfer of the templated crystallisation of a metastable polymorphic form to a cooling 
crystallisation environment, as demonstrated in this chapter, is a key first step towards the 
continuous crystallisation of these metastable polymorphic forms, which often display enhanced 
physical properties. It represents a breakthrough in the manufacture of these metastable 
polymorphic forms with previously reported methods of obtaining these metastable forms being 
largely limited to small scale discovery environments, with samples displaying poor polymorphic 











4 Scaled batch crystallisation of PCM-II and 
transfer to a MSMPR crystalliser 
 
The work presented in this chapter has been published as part of a Crystal Growth and 
Design special issue of selected papers presented at the 12th International Workshop on 
the Crystal Growth of Organic Materials (CGOM12 Leeds, UK): 
L.R. Agnew, T. McGlone, H.P. Wheatcroft, A. Robertson, A.R. Parsons and C.C. Wilson, 
‘Continuous Crystallization of Paracetamol (Acetaminophen) Form II: Selective Access to 
a Metastable Solid Form’, Cryst. Growth Des., 2017, 17(5), 2418-2427 
Small scale experiments (outlined in Chapter 3) highlighted a system that showed promising results 
in selective formation of a metastable form with scaling potential; the reproducible production of 
paracetamol form II (PCM-II) was achieved with use of the structurally similar metacetamol (MCM) 
as a template molecule. The aim of the further work presented in this Chapter was to attempt to 
scale this system, highlighting optimum conditions for PCM-II production and moving towards 
transfer to a variety of continuous crystallisation platforms. 
4.1 Design of Experiments (DoE) at the 100 ml scale 
4.1.1 Initial investigations into scaling potential in an RBF 
In order to assess the suitability of the PCM/MCM system for a Design of Experiments at the 100 ml 
scale, initial investigations into the scaling potential of the system in a round-bottomed flask (RBF) 
had to be performed. The aim of these crystallisations was to identify conditions under which  
PCM-II could be produced, which could then be optimised and fine-tuned through use of a DoE 
approach, exploring the experimental limits of PCM-II production. Initial scaled-up crystallisations 
in an RBF were conducted using a magnetic bottom stirring rate of 800 rpm; this was increased 
from small scale experiments to take into account the reduced mass transfer that could be 
experienced on scale up.  As observed in Chapter 3, the use of ethanol resulted in more PXRD peaks 
corresponding to the metacetamol hydrate phase and so a solvent system of 60:40 H2O: IPA was 
used throughout all further experiments. Investigations with lower percentages of MCM (10-25 %) 
that resulted in the successful crystallisation of PCM-II at the small scale, employing both a slow 
(0.02 °C min-1) and fast (1 °C min-1) cooling rate resulted in the production of PCM-I at this scale.  As 
such, the use of larger proportions of MCM was investigated (Table 4.1). The working volume of all 
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experiments was 50 ml. RBFs were subjected to the stepped cooling profile detailed in Chapter 3, 
cooling from 70 °C to 20 °C at 1 °C min-1 , unless otherwise stated. 





Temperature of crystallisation (°C) Product 
RBF1 40 20 PCM-II + MCM·H2O 
RBF2 40 Did not crystallise - 
RBF3 35 13 PCM-II + MCM·H2O 
RBF4 30 15 PCM-II + MCM·H2O 
 
The use of magnetic bottom stirring, and the associated reduced mass transfer, required larger 
quantities of MCM to be used in order to direct the formation of PCM-II. Further, the widening of 
the metastable zone width experienced with larger quantities of MCM meant crystallisations had 
to be cooled below 20 °C, resulting in more MCM·H2O in the solid product. As such, all further 
investigations were conducted with overhead stirring. In order to try to aid the crystallisation of 
PCM-II at higher temperatures, which will have the effect of mitigating the formation of MCM·H2O, 
the concentration of PCM was increased to 300 mg/g for subsequent experiments (Table 4.2). 









RBF5 50 25 30 PCM-II + MCM·H2O 
RBF6 50 25 25 PCM-II + MCM·H2O 
RBF7 100 25 30 PCM-II + MCM·H2O 
RBF8 100 25 30 PCM-II 
RBF9 100 25 30 PCM-II 
RBF10 150 25 30 PCM-II + MCM·H2O 
RBF11 150 25 30 PCM-II + MCM·H2O 
 
For all experiments shown in Table 4.2, DSC was required to detect the small quantities of MCM·H2O 
present. This reduction in the quantities of MCM·H2O in the solid products combined with 
inconsistencies at the 100 ml scale prompted a Design of Experiments (DoE) study to be performed, 
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with the aim of fine-tuning the conditions needed to produce pure PCM-II in the absence of any 
MCM·H2O. 
4.1.2 Introduction to DoE 
Traditionally, optimisation of a process is achieved through changing one factor at a time until a 
perceived optimum is found; this approach to experimentation is called one variable at a time 
(OVAT) or the COST approach (illustrated with black dots in Figure 4.1). It can often be an inefficient 
method of experimentation, requiring large numbers of experiments, and could result in missing 
the optimum conditions, especially if two different factors interact and are thus correlated. As such, 
many researchers now employ a Design of Experiments (DoE) approach to experimentation. DoE 
varies all factors simultaneously in a systematic manner to produce a model to describe the 
behaviour of the system with respect to these variables.193-194 From this model, through selection 
of correct factors and meaningful responses, producing a statistically relevant model, can allow for 
prediction of future results from experiments not performed, allowing an optimum to be 
discovered without the need for extensive experimentation (Figure 4.1; red dots). 
There are three scenarios for which DoE is commonly employed: screening, optimisation and 
robustness testing.195 Screening is used to identify important factors and the corresponding ranges 
for which they should be investigated. As the name suggests, optimisation is used to elucidate the 
factors that allow for optimal conditions for production of the desired product. Robustness testing 
analyses how small changes in operating conditions could affect the outcome of the experiment, 
for example if small amounts of an impurity were introduced into a crystallisation process. The DoE 
Figure 4.1: A visual representation of the COST approach (black dots) and the DoE approach (red dots) 
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approach has been used to determine important parameters in graphene synthesis196, in the kinetic 
resolution of oxazinones194 and to aid in the preparation of nano- and micro-particles with a desired 
size distribution. 197 
Consider a system that has k factors each with a high and low value, coded as +1 and -1 respectively. 
Then suppose a full factorial experiment is carried out with n= 2k runs, with each run consisting of 
each factor set at either +1 or -1. The experiments make up a matrix within which all factors are 
varied over the two levels. For example a full factorial design with two factors (x1 and x2) consists 
of four runs with (x1,x2) = (1,1), (1,-1), (-1,1) and (-1,-1).198 Each of the experimental conditions forms 
the corner of a square; similarly a full factorial with three factors would consist of eight 
experiments, with each condition forming the vertices of a cube. 
Upon completion of the runs, data must be analysed in order to see the effect of factors on the 
responses. The data produced is fitted to one of three possible polynomial models: linear, 
interaction or quadratic. The type of model to which the data are fitted will depend upon the 
objective of the DoE. For screening and robustness testing objectives, linear and interaction models 
are commonplace. For an optimisation objective, quadratic models are used as these tend to be 
more flexible to complex response functions. In the present work, a screening objective was used 
and so an interaction model was employed. For the simple two factor full factorial design outlined 
above, the interaction model would take the form of Equation 4.1.  
𝒚 =  𝜷𝟎 + 𝜷𝟏𝒙𝟏 + 𝜷𝟐𝒙𝟐 + 𝜷𝟏𝟐𝒙𝟏𝒙𝟐 + 𝜺   Equation 4.1 
Where y is the response, x1 and x2 are the two factors, the β terms are the model parameters and 
ε is the residual response variation not explained by the model. Partial least squares (PLS) 
regression is then used to fit the data to the model to allow determination of the β terms, 
quantifying the interactions between the factors.   
The aim of the work presented here was to identify conditions under which PCM-II could be formed 
in high polymorphic purity, in the absence of any MCM·H2O impurity. In order to explore a number 
of factors, in a designed and systematic approach, it was decided that a DoE approach was 
appropriate.  
4.1.3 Materials and methods 
Paracetamol (4’-hydroxyacetanilide; PCM) was purchased from Sigma Aldrich Chemie Gmbh 
(Steinheim, Germany). Metacetamol (3’-hydroxyacetanilide; MCM) was purchased from TCI Ltd. All 
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were used without further purification. Laboratory grade solvents purchased from Sigma Aldrich 
were used for all crystallisations. 
4.1.3.1 Overhead stirring experiments in the Polar Bear Plus 
Initial experiments utilising overhead stirring were conducted using the Polar Bear Plus crystalliser 
with an overhead motor and shaft (Figure 4.2). Investigations were carried out at both the 50 ml 
and 100 ml scale using a 100 ml and 250 ml round bottomed flask (RBF), respectively; the different 
RBF sizes were used to ensure effective mixing was experienced at the different scales. All initial 
experiments at this scale were performed using the stepped cooling profile shown to allow 
reproducible production of PCM-II on the small scale (Chapter 3). 
4.1.3.2 Design of Experiments for optimisation of PCM-II production 
The MODDE 11 Pro software was used to design a full factorial DoE with five factors: stirring rate, 
concentration of PCM, wt.% MCM, stirring time at the final temperature and final temperature. A 
full factorial design with five factors results in 32 experiments; three control experiments are also 
performed at the same ‘mid-point’ conditions to determine the reproducibility of the model, 
resulting in a total of 35 experiments. All the factors selected appeared to have an effect on the 
polymorphic form produced in initial experiments at the same scale. Appropriate high and low 
values for each of the factors were chosen; this resulted in varying the stirring rate between 
200 rpm and 400 rpm, the concentration of PCM between 250 mg/g and 300 mg/g, the wt.% of 
MCM between 25 % and 30 %, the stirring time at the final temperature between 30 mins and 
120 mins and the final temperature between 15 °C and 20 °C. Two responses, polymorphic form 
Figure 4.2: Polar Bear Crystalliser with overhead motor and shaft to provide 
overhead stirring to the system 
112 
 
and yield, were selected for the DoE. The MODDE software requires the responses to have a 
quantitative value. As such for the polymorphic form response, numerical values were assigned to 
each of the possible polymorphic form outcomes, with a 0 representing PCM-I, 1 representing  
PCM-II and 2 representing a mixture of PCM-II with some MCM/MCM·H2O impurity present. 
Table 4.3 highlights the experimental parameters investigated in this DoE, alongside the responses 
measured. All experiments were performed at the 100 ml scale in a 250 ml RBF. Temperature 
control was provided by the Polar Bear Plus crystalliser and overhead stirring from an overhead 
motor and shaft (Figure 4.2). A stepped cooling profile with one hour dwell periods, as used in small 











































N1 18 200 250 25 30 15 2 30 
N2 31 400 250 25 30 15 2 43 
N3 27 200 300 25 30 15 2 59 
N4 4 400 300 25 30 15 1 57 
N5 29 200 250 30 30 15 2 35 
N6 1 400 250 30 30 15 2 36 
N7 17 200 300 30 30 15 2 35 
N8 32 400 300 30 30 15 2 48 
N9 28 200 250 25 120 15 2 51 
N10 2 400 250 25 120 15 2 56 
N11 33 200 300 25 120 15 2 60 
N12 23 400 300 25 120 15 2 65 
N13 12 200 250 30 120 15 2 64 
N14 26 400 250 30 120 15 2 46 
N15 6 200 300 30 120 15 2 -1 
N16 22 400 300 30 120 15 2 55 
N17 19 200 250 25 30 20 2 29 
N18 34 400 250 25 30 20 1 37 
N19 5 200 300 25 30 20 2 30 
N20 16 400 300 25 30 20 2 44 
N21 8 200 250 30 30 20 2 37 
N22 24 400 250 30 30 20 2 27 
N23 15 200 300 30 30 20 2 35 
                                                          






















N24 10 400 300 30 30 20 1 46 
N25 21 200 250 25 120 20 2 40 
N26 25 400 250 25 120 20 1 39 
N27 7 200 300 25 120 20 2 51 
N28 13 400 300 25 120 20 2 41 
N29 3 200 250 30 120 20 2 33 
N30 11 400 250 30 120 20 2 48 
N31 20 200 300 30 120 20 2 40 
N32 9 400 300 30 120 20 1 46 
N33 14 300 275 27.5 75 17.5 2 51 
N34 30 300 275 27.5 75 17.5 2 49 











4.1.4 Results and discussion 
PXRD analysis (Figure 4.3) shows that PCM-II was formed under all experimental conditions 
investigated in the DoE (polymorphic outcomes 1 and 2 in Table 4.3). Only one experiment showed 
the production of MCM·H2O in the solid product at high enough levels to be detected by PXRD (N3; 
peaks corresponding to MCM·H2O shown in the red box in Figure 4.3). In order to determine 
whether trace quantities of MCM·H2O were present in the solid product, differential scanning 
calorimetry (DSC) analysis was performed on each of the samples after being left to dry in air 
overnight; this was to ensure any of the peaks attributed to solvent were from the internal crystal 
structure rather than any solvent left on the surface of the crystals. As shown in Chapter 3, the 
presence of a melt/recrystallisation event in the DSC before the final melt can be attributed to the 
presence of MCM or MCM·H2O. Only five experiments result in the production of pure PCM-II, with 
experiment N4 resulting in the highest yield; as such a concentration of PCM of 300 mg/g coupled 




Figure 4.3: PXRD analysis on all 35 DoE experiments, y-axis shows intensity 









Application of partial least squares regression to the data produced from these experiments gave 
the DoE summary of fit plot shown in Figure 4.5. 
There are four indicators used to produce the summary of fit plot: R2, Q2, model validity and 
reproducibility. R2 represents how well the model produced fits the data; the value of R2 needs to 
exceed 50 % to be informative, with a value over 75 % indicating a good model. Q2 gives an 
indicator as to how well the model predicts new data; an important parameter to consider if the 
purpose of the DoE is to allow prediction of future results. A useful model should have a high value 
of Q2, with a low Q2 resulting from either poor reproducibility or poor model validity. Good model 
validity has a value above 0.25, indicating there is no lack of fit of the model and the associated 
model error is within experimental error. The reproducibility represents the variation of the 
response under the same experimental parameters (pure error), compared to the total variation of 
the response over all experiments. 199 
As can be seen from Figure 4.5, the summary of fit plot for the yield response shows good 
reproducibility (93 %), a good R2 value (indicating a good model) and reasonable model validity. 
The value of Q2 is, however, low, likely due to the large number of factors investigated in the 
experiments. The low Q2 value prompted analysis of the factors using the variable importance plot 
(VIP) (Figure 4.6). Although the polymorphic form response has an excellent reproducibility, all 
other indicators show a poor model in terms of validity and ability to predict new data. This is likely 
due to having to represent polymorphic form, a qualitative response, as a quantitative value. The 
formulation of a DoE involves setting each of the responses at one of three levels: a minimum, an 
optimum and a maximum. This works well with responses that yield a numerical value, however in 
Figure 4.5: Summary of fit plot for the both the polymorphic form and yield response 
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the case of the polymorphic form response, numbers had to be assigned to each of the possible 
polymorphic form outcomes, with a level of 1 representing the optimal result of pure PCM-II, and 
2 representing a mixture. As such there were no responses at values in between 1 and 2. Therefore, 
the formation of a histogram to determine the distribution of responses, which should display a 
normal distribution (i.e. rising and falling each side of a maximum in the traditional bell curve), only 
represents the two values of 1 and 2, skewing the distribution, resulting in a poor model. 
Furthermore, as there is perfect reproducibility for the polymorphic form response, the pure error 
will be zero. The reason for low model validity is due to the model error being significantly larger 
than the pure error, resulting in a lack of fit.  
The VIP plot (Figure 4.6) summarises the importance of the terms in the model and the interaction 
between individual factors. They are normalised such that a VIP of 1.0 corresponds to average 
importance. It is common practice to keep anything with a VIP>0.8, removing all factors that have 
a value lower than this. However, the MCM factor was retained, as removal of this factor would 
result in removal of the correlation PCM*MCM which can be seen to have an importance >0.8. 
Removal of the other factors with VIP < 0.8 resulted in the summary of fit plots shown in Figure 4.7. 
Figure 4.6: Variable Importance plot (VIP) highlighting the importance of factors and their interactions 
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As can be seen from Figure 4.7, removal of these interactions from the model increases the value 
of Q2 for both of the responses. The inherent problem of qualitative values being represented 
quantitatively has not been altered through removal of the interactions, and so the model validity 
for the polymorphic form response remains missing.  It was this refined model that was used to 
examine the coefficient plots for the two responses, allowing quantification of how changing 
different factors impacts the responses (Figure 4.8). 
The coefficient plot displays the regression coefficients with confidence intervals. The coefficients 
are scaled by the MODDE software in order to allow for direct comparison between all factors. The 
size of the coefficient represents the change in the response when a factor varies from 0 to 1, in 
coded units, while the other factors are kept at their averages. The coefficient is considered as 
significant (i.e. different from the noise), when the error bar does not cross the horizontal zero axis.  
Figure 4.8: Coefficient plots for both the responses, quantifying the effect of each of the factors on each of the 
responses 
Figure 4.7: Summary of fit plots after removal of factors with an importance of <0.8 
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For the coeffcient plot for the yield response, it can be seen that increasing the concentration of 
PCM and the time at the final temperature results in an increase in the yield, with time having the 
greatest effect. This is what would be expected: increasing the time allows for more time for growth 
of crystals and increasing the concentration of PCM will cause the system to nucleate at an earlier 
temperature (as it is more saturated) and so has more time for growth to occur. It is interesting to 
note that the concentration of MCM with respect to paracetamol is not seen as significant. Initial 
experiments (outlined in Section 4.1.1) suggested that increasing the concentration of MCM results 
in a widening of the metastable zone; this widening would result in crystallisation at lower 
temperatures, giving less time for growth in the system and hence reducing the yield of 
crystallisation. It can be suggested that within the ranges explored in this DoE, this interaction was 
not as obvious and so was not considered important.  
The results for the polymorphic form coefficient plot are slightly more difficult to interpret, due to 
the software requiring quantitative values. Therefore, any negative effect on polymorphic form on 
the coefficient plot actually corresponds to an increased propensity for forming PCM-II in the 
absence of MCM·H2O. The only factor found to have a significant effect on polymorphic form is the 
stirring speed; increasing the stirring speed increases the propensity for the formation of pure  
PCM-II. In terms of the polymorphic purity of the samples produced, stability analysis under 
standard room temperature conditions has been investigated, through analysis of the PXRD 
patterns of the samples every three months. The PXRD patterns after a period of 15 months 
(Figure 4.9) show all samples still to be PCM-II, indicating the polymorphic purity of the samples 
produced; the presence of any PCM-I in these samples, as shown in Chapter 3, would seed the 












Figure 4.9: PXRD patterns showing the DoE samples after a period of 15 




A full factorial design with five factors Design of Experiments (DoE) investigation has been 
conducted in order to find the optimal conditions for the production of PCM-II in the absence of 
metacetamol hydrate (MCM·H2O). The concentration of PCM, the wt. % of MCM, the final 
temperature of the cooling profile, the stirring rate and the stirring dwell time at the final 
temperature were investigated to observe their effect on two outcomes, polymorphic form and 
yield of crystallisation.  
All experimental parameters investigated resulted in the production of PCM-II, the desirable 
polymorphic form. However, only five experimental conditions resulted in the production of  
PCM-II in the absence of any MCM·H2O, at levels detectable through DSC analysis. As such, for all 
future experiments a concentration of PCM of 300 mg/g and 25 % MCM was used as these showed 
the production of pure PCM-II in the highest yield. The samples produced from all DoE experiments 
are currently stable for a period of 15 months, indicating the polymorphic purity of the PCM-II 
samples produced. 
Inputting the responses to the MODDE software resulted in the production of a model which 
allowed for the effects of factors and interactions between factors to be examined. The yield 
response showed good model statistics, with the four indicators of R2, Q2, model validity and 
reproducibility indicating a reliable model. It was shown that a higher concentration of PCM and a 
longer dwell time at the final temperature of the cooling profile resulted in increased yields. The 
former would allow crystallisation earlier, resulting in a longer crystallisation time, allowing more 
time for growth and hence an increased yield. The latter would allow for increased time for growth, 
again resulting in an increased yield. However, due to an inherent problem with representing a 
qualitative response quantitatively, the polymorphic form response resulted in poor model 
statistics. However, general trends could be identified that showed that the stirring rate was an 
important factor, with a faster stirring rate showing a higher propensity for the production of pure 







4.2 Scaled crystallisation in the OptiMax 
4.2.1 Introduction and aims 
The ability to scale systems beyond discovery scale is crucial if a manufacturing method within an 
industrial setting is to be established. However, with the reduction in mixing efficiency upon scale-
up comes the possibility of supersaturation build-up in certain areas of the crystalliser, resulting in 
potentially different particle attributes and impurity rejection. 200-201 As such, much industrial and 
academic interest has been dedicated towards developing scalable crystallisation processes.  
As many currently operational continuous crystallisers operate on the principle of cooling 
crystallisation, a large scale cooling crystallisation route to the target PCM-II first had to be 
developed, which will be the subject of this section. This work was performed in collaboration with 
Dr Thomas McGlone at the CMAC National Facility housed within the Technology and Innovation 
Centre at the University of Strathclyde. 
4.2.2 Experimental 
Initial cooling crystallisations were carried out at the 100 ml scale using the Mettler Toledo EasyMax 
(Figure 4.10), in order to check the transferability between the Polar Bear Plus and this platform, 
which both operate at the same working volume. One important consideration in this initial 
transferability investigation was to ensure that the results seen in the laboratory in Bath were not 
due to accidental seeding of the vessels. These crystallisations also allowed for optimisation of the 










Figure 4.10: The Mettler Toledo EasyMax 
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Scaled-up batch experiments were conducted using the Mettler Toledo OptiMax (Figure 4.11). 
Crystallisations were monitored with Raman PhAT and FBRM probes. For all experiments, a Mettler 
Toledo FBRM probe (G400 series) was used with iC FBRM V4.3 incorporated in the iControl V5.2 
software. Each measurement was collected with a 2 s scan speed and a 15 s sampling interval. 
A Kaiser RXN2 Raman spectrometer with PhAT probe was used to monitor the polymorphic form 
produced throughout the process non-invasively. The PhAT probe had the laser beam optically 
expanded to give a 3 mm spot size, with a focal length of 12.5 mm. The beam was directed at the 
process through the top of the vessel. The laser wavelength of 785 nm was produced by an Invictus 
diode laser operated at 350 mW at the source, with a CCD detector cooled to −40 °C by a Peltier 
cooling system. In advance of any measurements a verification (which measures relative peak 
intensity and peak position against known peaks from a cyclohexane standard) using the external 
sample compartment accessory for the instrument was performed. Raman spectra were recorded 
using iC Raman V4.1 software, also incorporated in the iControl software. Each Raman spectrum 
was recorded with two scans and a 30 s integration time resulting in one spectrum every 2 minutes.  
A PCM concentration of 300 mg/g coupled with 25 wt.% MCM was used throughout all 
crystallisations. The temperature was lowered from 70 °C to 20 °C through the stepped cooling 
profile outlined in Chapter 3 at a cooling rate of 1 °C min-1, with an overhead stirring rate of 
400 rpm. 
Figure 4.11: Mettler Toledo OptiMax with inline process monitoring using a Raman PhAT 
probe and FBRM probe
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4.2.2.1 Characterisation techniques 
PXRD patterns were collected on a Bruker AXS D8-Advance transmission diffractometer equipped 
with θ/θ geometry, primary monochromatic radiation (Cu Kα1, λ = 1.54056 Å), a Vantec 1-D position 
sensitive detector (PSD), and an automated multi-position x-y sample stage. Samples were 
oscillated ±0.5 mm in the x-y plane at a speed of 0.3 mm s-1 throughout data collection, to maximize 
particle sampling and minimize preferred orientation effects. 
Offline Raman spectra were collected at the University of Bath using a Renishaw InVia confocal 
Raman microscope. A red laser of wavelength 785 nm (Renishaw, diode laser, 370 mW at source) 
was used for all spectra, operated with a 50x lens and a spot diameter of ~1.9 µm. 
4.2.3 Raman spectra for the polymorphs of paracetamol 
To highlight the differences in Raman spectra between the two polymorphic forms of paracetamol, 
offline Raman spectra were collected for both polymorphic forms of PCM and for metacetamol 
(MCM) (Figure 4.12). The two PCM spectra are very closely related, with Table 4.4 highlighting the 
differences in each spectral region. The assignment of these Raman bands, combined with analysis 
of the crystal structures of the PCM polymorphs, shows that the bands where differences between 
the polymorphs are observed relate to Raman modes that would be different between the 
polymorphic forms; either through differences in hydrogen bonding, torsion angles or packing 
interactions. For example, the C-C-N-C torsion angle in paracetamol form I is ~22 ° and in form II is 
~17 °; this difference could be responsible for the slight shift in peaks in the Raman spectra.  The 
previous analysis by Szelagiewicz et al 202 did not account for the differences in spectra above 
1260 cm-1; in this region, the main difference is the splitting of the peak at 1624 cm-1 in PCM-II; in 
PCM-I there is no such splitting, with the peak only displaying a slight shoulder. This peak 
corresponds to the carbonyl stretch and the difference can be attributed to the slight difference in 
hydrogen bond lengths, and hence strengths, in the polymorphs. Despite its structural similarity to 
paracetamol, the Raman spectra for metacetamol shows easily discernible differences, with the 




Table 4.4: Characteristic Raman bands differentiating PCM-I and PCM-II (adapted from Szelagiewicz et al.202 ) 
Raman shift (cm-1) Form II (cm-1) Form I (cm-1) Functional group 
1200-1260 1242 and 1218-1219 1254-1258 and 1233-1238 Amide 
855-865 860 857-859 C-C ring stretch 
790-810 797-798 795-798 C-N-C ring stretch 
450-470 451-452 460-466 O-H vibration 
200-220 200-201 207-215 C-C stretch (chain) 
 
4.2.4 Results and discussion 
An initial cooling crystallisation performed in the EasyMax showed the production of PCM-II to be 
transferable from the Polar Bear set-up at the same 100 ml scale, verifying the results obtained 
from the DoE. However, PXRD analysis indicated that there were still trace levels of MCM·H2O in 
the solid product. It is likely that this is due to the different mixing conditions experienced in the 
EasyMax in comparison to the RBF due to different vessel shape and use of a different impeller. 
Owing to time constraints, further work was not conducted at this scale in order to optimise the 
system and focus was directed towards trying to scale the system further, utilising the OptiMax. 
Initial experiments in the OptiMax were conducted using a working volume of 500 ml. The 
positioning of the Raman PhAT probe at the top of the vessel, through one of the holes in the lid, 
meant that this lower working volume resulted in a distance from probe to solution longer than any 
focal length obtainable with the varying spot sizes, meaning the spectra obtained from the Raman 
Figure 4.12: Offline reference spectra for PCM-I, PCM-II and MCM; the y axis shows intensity in arbitrary units 
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probe were poor and largely dominated by fluorescence. As such, further experiments utilised a 
larger working volume of 800 ml. 
Determination of the polymorph specific bands shown in Table 4.4  allowed for a peak in the Raman 
spectrum corresponding to PCM-II (1624 cm1) and one corresponding to PCM-I (1236 cm1) to be 
tracked throughout the crystallisation, to allow rapid elucidation of the polymorphic form being 
produced. At the point of nucleation in the system (characterised by the sharp increase in total 
FBRM counts in Figure 4.13), the peak characteristic of PCM-II increases and that of PCM-I drops 
off and remains level for the remainder of the crystallisation. The peak for PCM-I does not drop to 
a zero value as the probe still detects paracetamol dissolved in solution, with the signal for PCM-I 
and dissolved PCM being indistinguishable. The total FBRM counts remain roughly constant 
towards the end of the experiment, indicating steady state has been achieved.   
Figure 4.14 shows the change in the spectra produced from the inline Raman probe over the course 
of the crystallisation. The dominant production of PCM-II at the end of the crystallisation (300 mins) 
is confirmed by the characteristic splitting of the peak at 1624 cm-1, circled in red in Figure 4.14. 
Table 4.5 also highlights the regions of difference specified in Table 4.4, again confirming the 
presence of PCM-II in all cases. However, the presence of extra peaks, circled blue in Figure 4.14, 
indicate the presence of another crystalline phase in the solid. Additional PXRD analysis 
(Figure 4.15) shows this to be metacetamol hydrate; this could not be shown by Raman data as 
phase pure samples of MCM·H2O were unable to be obtained. This scaled-up batch crystallisation 
route allowed for the production of 120 g of PCM-II in a single process run with no evidence of the 
Figure 4.13: Trend output from 800 ml crystallisations in the OptiMax showing the temperature profile employed 
(blue), total FBRM counts (green), PCM-I Raman at 1236 cm-1 (orange) and PCM-II Raman at 1624 cm-1 (pink) 
129 
 
presence of PCM-I. This high degree of scalability offers confirmation of the robustness of the 






















Figure 4.14: Raman spectra collected throughout the course of the crystallisation from the inline PhAT 
probe (0 mins - suspension, 20 mins - after dissolution of all solid, 300 mins - suspension of final product at 
end of crystallisation). The y-axis shows intensity in arbitrary units 
Figure 4.15: PXRD patterns confirming the presence of PCM-II in the OptiMax experiment, with small 
quantities of MCM·H2O present; the y-axis shows intensity in arbitrary units 
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Table 4.5: Each of the spectral regions where differences between PCM-I and PCM-II are visible, showing the shape of 
the patterns from final product (green) to match PCM-II (orange) and not PCM-I (blue) in all regions 














A scalable batch crystallisation route to PCM-II has been developed, allowing production of 120 g 
of PCM-II in a single process run. However, the solid produced on all scales investigated contains 
small quantities of metacetamol hydrate impurity, present at levels high enough to be detected 
through PXRD analysis. It can be suggested that the presence of this MCM·H2O impurity is due to 
sub-optimal mixing conditions experienced upon scale to larger vessels, with mixing shown to be 
an important factor in the production of pure PCM-II in the Design of Experiments outlined in 
Section 4.1. The work was carried out at the University of Strathclyde and due to the time 
constraints of the visit, optimisation of the large scale batch crystallisation of PCM-II has not been 
achieved and would be the subject of any future work on this system. However, this work does 
present the design and implementation one of the only reported large scale productions of a 
metastable polymorphic form of an API. 
4.3 Continuous crystallisation in a MSMPR 
4.3.1 Introduction and aims 
The drive towards continuous crystallisation processes is becoming more prevalent in an industrial 
setting. Although much academic research attention has been directed towards developing the 
huge potential offered by the use of tubular flow crystallisers, owing to their superior heat and mass 
transfer, to date the industrial application of continuous crystallisation procedures has been 
focussed on mixed suspension mixed product removal (MSMPR) crystallisers. A batch crystalliser 
can be modified to a single stage MSMPR by allowing continuous input and removal of 
solution/slurries, maintaining a constant working volume within the vessel. MSMPR’s are the most 
commonly employed method of continuous crystallisation owing to their applicability to most 
systems and ability to achieve the long residence times that are needed to crystallise compounds 
displaying slow nucleation or growth kinetics; this is in contrast to plug flow reactors that require 
fast kinetics to allow growth in the relatively short residence times characteristic of such  
reactors.52, 203 MSMPR systems operate at steady state rather than equilibrium and so residual 
supersaturation may be left in the mother liquor, resulting in yield reductions; however, this can be 
combatted through operation in recycle mode.204 
The use of MSMPR systems is not limited to single stage vessels, with many employing multi-stage 
MSMPRs in a cascade.53, 205 It is often the case that the first stage acts a nucleator vessel, producing 
nuclei of the desired product, with the second stage acting as a growth vessel to allow yield to be 
maximised.74  Transfer between vessels can be made through peristaltic pumps, which can result in 
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damage to particles, or as demonstrated more recently, through vacuum  
transfer.53, 190 The use of MSMPRs for the continuous crystallisation of a variety of compounds has 
been demonstrated including paracetamol form I55, albuterol sulfate56, cyclosporine53 and 
preferential crystallisation of the enantiomers of threonine.57 The continuous crystallisation of 
metastable α-glutamic acid has been reported in an MSMPR206, the only other reported example of 
the continuous crystallisation of a metastable organic solid; the continuous crystallisation of 
inorganic solids has been reported widely in the literature. 207-210 
Unlike traditional operation of MSMPRs, characterised by the continual addition and removal of 
suspensions, there has been recent work directed towards the use of periodic mixed suspension, 
mixed product removal (PMSMPR) crystallisers.54, 211 As the name suggests, these systems allow for 
the periodic addition and removal of suspensions at a high flow rate over short periods of time.211 
Having periods of dwelling within each vessel allows access to longer residence times and can help 
with obtaining steady state more rapidly. The use of a PMSMPR crystalliser has been demonstrated 
for paracetamol form I54 and for obtaining control over the stable form of a polymorphic  
co-crystal. 211 
The aim of the work presented in this section is to transfer the templated crystallisation of PCM-II 
seen in a batch crystallisation environment to an MSMPR continuous crystallisation platform. 
Through operation of an MSMPR in periodic mode this system should better mimic the stepped 
cooling profile used in batch cooling crystallisation experiments (Chapter 3) than tubular flow 
crystallisers (outlined below in Chapter 5).  
4.3.2 Experimental 
4.3.2.1 Continuous crystallisation experiments 
Continuous crystallisation experiments in an MSMPR system were carried out at the AstraZeneca 
site in Macclesfield; a two-stage MSMPR working in recycle mode was used throughout all 
experiments. The set-up consisted of a 500 ml jacketed feed/dissolver vessel and two 140 ml 
jacketed MSMPR vessels (Figure 4.16 and Figure 4.17), each operated at a working volume of 80 ml. 
To avoid crystal breakage on transfer between vessels, a vacuum transfer system was used to 
transfer solids from MSMPR 1 to MSMPR 2 and from MSMPR 2 back to the feed/dissolver vessel. A 
Masterflex peristaltic pump, equipped with Masterflex tubing was used to transfer the clear 










A dip tube was positioned in MSMPR 1 and MSMPR 2 to allow transfer of a calibrated volume (8 ml) 
between these two vessels and MSMPR 2 and the feed vessel, respectively.  As the MSMPR was 
operated in periodic mode, this transfer was done through manual opening and closing of valves at 
set time intervals; if the system was to be operated in non-periodic mode, the valves would remain 
constantly open for the duration of the experiment. The time between transfers was dictated 
through the residence time within each vessel, with calculations being done based on ten transfers 
between the two vessels per residence time (RT). 
Temperature control was provided by three JULABO heater/chiller units operated on control of 
thermocouple temperature rather than chiller internal temperature. The transfer tube from 
MSMPR 2 to the feed vessel was fitted with a three-way valve to allow sampling with an inline 
filtration unit. Filter papers in this filtration unit were changed every residence time to allow for a 
sample from each residence time to be taken. 
Figure 4.16: Schematic of the MSMPR set-up used 




Table 4.6 and Table 4.7 highlight the start-up calculations and operational parameters for each of 
the two residence times (30 minutes and 45 minutes) explored in this work. In all experiments a 
concentration of PCM of 300 mg/g with 25 wt.% MCM were dissolved in 410 ml of 60:40 (v/v) 
H2O:IPA at a temperature of 60 °C with an overhead stirring rate of 250 rpm. Once dissolved, clear 
solution was pumped through the peristaltic pump at a specified flow rate to MSMPR 1, until a 
volume of 80 ml in MSMPR 1 was reached. At this point, valve V2 was opened and then closed to 
transfer 8 ml of solution/slurry to MSMPR 2. The two vessels were left stirring with an overhead 
stirring rate of 350 rpm for 4.5 minutes or 3 minutes (for a 45 minute and 30 minute residence time 
respectively). Valve V2 was then opened and closed to transfer 8 ml of solution to MSMPR 2. This 
process was repeated until the volume in MSMPR 2 reached 80 ml. At this point, both valve V2 (to 
transfer solution from MSMPR 1 to MSMPR 2) and valve V1 (to transfer solution from MSMPR 2 to 
the feed vessel) are opened simultaneously. As both vessels have now reached the desired 
operating volume, this simultaneous opening of V2 and V1 is done each time for the remainder of 
the experiment. Sampling of solution was done through opening of valve V1 at time points not 
corresponding to the opening of the valves for transfer of solution. At the end of the experiment, 
the contents of MSMPR 1 and MSMPR 2 were removed and filtered to isolate the solid for analysis. 
4.3.2.2 Characterisation techniques 
PXRD patterns and DSC traces were collected at AstraZeneca. The PXRD samples were mounted on 
silicon wafer mounts and analysed using a Bruker D4 X-ray diffractometer (Cu-Kα radiation,  
λ = 1.5418 Å) equipped with a LYNXEYE detector. Each sample was exposed for 0.32 s per 0.02° 2θ 
increment (continuous scan mode) over the range 2° to 40° in θ-θ mode. The X-ray generator was 
operated at 40 kV and 40 mA. DSC studies were carried out using a Thermal Advantage Q2000 from 
TA Instruments. Up to 3 mg of material was contained in an aluminium pan, fitted with a lid, and 
heated over the temperature range 25−200 °C at a constant heating rate of 5 °C min−1. Data were 
collected using the software Advantage for Qseries (Ver. 5.40 software © 2001−2011 TA 
Instruments-Waters LLC). Imaging was performed on a Hitachi TM-1000 scanning electron 
microscope (SEM) operating with an accelerating voltage of 15 kV. Samples were mounted on an 
aluminium stub with carbon tab and gold coated in a Quorum Q150R sputterer to a target thickness 




Table 4.6: Operating parameters and start-up calculations for experiments operated with a 45 minute residence time 





















Feed 500 200 250 1.8 140.6 - - - - 
MSMPR1 160 80 80 1.8 45.0 80.0 45.0 4.5 10 
MSMPR2 160 80 80 1.8 45.0 80.0 90.0 4.5 10 
Table 4.7: Operating parameters and start-up calculations for experiments operated with a 30 minute residence time 












to pump (ml) 






Feed 500 200 250 2.7 93.8 - - - - 
MSMPR1 160 80 80 2.7 30 80.0 30.0 3.0 10 
MSMPR2 160 80 80 2.7 30 80.0 60.0 3.0 10 
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4.3.3 Results and discussion 













AZ1 45 60 25 20 
PCM-II + PCM-I + 
MCM·H2O 
1.63 
AZ2 45 60 30 25 PCM-II  1.03 
AZ3 45 60 30 25 PCM-II 1.03 
AZ4 30 60 30 25 PCM-II 1.03 
 
Table 4.8 highlights the experimental parameters investigated in the MSMPR continuous 
crystallisation experiments; note the supersaturation ratio is calculated at the point of nucleation, 
relative to PCM-II. As the effect of using this set-up on the metastable zone width (MSZW) of the 
crystallisation was not known, the temperature of the final MSMPR in experiment AZ1 was set at 
20 °C, which considering batch crystallisation experiments nucleate at 30 °C, should allow for 
crystallisation in the system. Crystallisation in the system was observed initially in MSMPR 2 after 
the third transfer in RT2 (i.e. after 59 minutes), with a dense slurry being observed in MSMPR 2 by 
the end of RT3. The high solid loadings produced in this experiment resulted in settling of solid in 
the vacuum transfer lines (Figure 4.18); although in this experiment this did not result in blockage, 
over extended operation times this settling could become detrimental to the crystallisation process 
either through blockage of transfer lines or of possible conversion to the stable PCM-I and 
subsequent seeding. 
Solid from each of the residence times along with the solid from both MSMPR vessels at the end of 
the crystallisation were analysed by PXRD (Figure 4.19), DSC (Figure 4.20) and SEM (Figure 4.21). 
 
 











Figure 4.21: SEM images for the samples from experiment AZ1 (RT2 was not 
analysed due to the small amount of solid available). 
Figure 4.20: DSC analysis on the samples taken from experiment AZ1; the y axis shows heat flow in mW. 
Figure 4.19: PXRD analysis of RT2 and RT3 of experiment AZ1 showing the production of predominately PCM-II with 
some PCM-I present (peaks corresponding to PCM-I boxed in red). The y-axis shows intensity in arbitrary units. 
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PXRD analysis confirms the production of predominately PCM-II, however there are peaks 
corresponding to another crystalline form. These are not from MCM·H2O, as would be expected, 
but correspond to the presence of PCM-I. Interestingly, looking at the SEM images, all residence 
times display large block like crystals that can be attributed to PCM-II. On the surface of these 
crystals are finer, needle crystals. It can be suggested that these needle crystals can be attributed 
to PCM-I; in contrast, SEM from batch crystallisation experiments show metacetamol hydrate to 
adopt a block morphology on the surface of PCM-II crystals (Chapter 3). Literature work has always 
suggested PCM-I adopts a hexagonal block-like morphology, with PCM-II adopting a needle-like 
morphology.24, 180 Block-like morphologies are likely to have more desirable flow properties than 
needles and perform better in downstream processing steps such as filtration and charging in the 
drug product process, so this alteration in morphology of PCM-II offers an additional advantage to 
the templating approach adopted in this work. It can be suggested that this nucleation of PCM-I is 
due to crystallisation at a higher supersaturation ratio, which would result in less controlled 
nucleation. Further, as crystallisation was initially observed in MSMPR 2 when the volume was low, 
the different mixing dynamics at the volume may have induced nucleation of PCM-I. The DSC 
analysis does show small quantities of MCM·H2O to be present in earlier residence times, through 
the presence of a thermal event at 145 °C. 
As such, for future experiments (AZ2-4), the temperature of MSMPR 2 was increased to 25 °C and 
correspondingly the temperature of MSMPR 1 to 30 °C, reducing the supersaturation ratio at the 
point of nucleation, hence providing greater control over crystallisation. Experiment AZ2 and AZ3 
were executed with the same experimental parameters, however experiment AZ3 was run for a 
longer period of time (c.a. 5 hours) to see whether the polymorphic form outcome could be 
retained over longer operation times. In both cases, crystallisation was observed whilst still filling 
MSMPR 2, in RT1. It can be suggested that crystallisation was observed earlier due to a reduction 
in cooling rate, narrowing the MSZ, as a result of increasing the temperatures of the two MSMPR 
vessels. Upon discharging remaining solid from the two MSMPR vessels, encrustation on the vessel 







Offline characterisation of the solid produced from each residence time and the discharged solid 
from each of the two MSMPR vessels shows the production of PCM-II (PXRD; Figure 4.23) in the 
absence of any metacetamol hydrate (DSC; Figure 4.24). This MSMPR run has thus been successful 






Figure 4.22: Encrustation on the walls of MSMPR 2 in experiments AZ2 and AZ3. 
Figure 4.23: PXRD patterns showing the production of PCM-II in Experiment AZ3. The y-axis shows 










Due to time constraints, for the SEM analysis, images were only taken of the samples from each of 
the MSMPR vessels at the end of the experiment. These images (Figure 4.25) show the production 
of large diamond-shaped crystals of PCM-II. Since all analytical methods indicate the absence of any 
MCM·H2O, the smaller crystals present in the SEM images can be attributed to either crystal 
breakage or to crystals that have not had as much time for growth; the latter explanation is more 







The final experiment, AZ4, investigated a reduction in the residence time within the crystalliser to 
observe whether the polymorphic form outcome could be retained. Reducing the residence time, 
whilst maintaining the correct polymorphic form, would be beneficial as it would allow for shorter 
operation times and hence higher throughput, increasing plant productivity. After 30 minutes of 
operation, the solution in MSMPR 1 appeared turbid, indicating the onset of nucleation, with 
crystallisation following shortly. Crystallisation in MSMPR 2 was observed at the end of RT2. This 
difference in point of crystallisation can be attributed to the faster pumping rate of solution into 
Figure 4.24: DSC traces for experiment AZ3, showing the absence of any MCM.H2O. The y-axis shows heat flow in mW. 
Figure 4.25: SEM analysis of samples from each of the MSMPR vessels in Experiment AZ3 
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the MSMPRs associated with a shorter residence time, which could alter the kinetics of the 
crystallisation process. Blockage of the inline filtration unit (Figure 4.26) meant that a sample for 








PXRD (Figure 4.27) and DSC analysis (Figure 4.28) shows the production of PCM-II in the absence of 
any MCM·H2O. SEM analysis (Figure 4.29) again shows the production of large diamond shaped 




Figure 4.26: Blockage of the inline filtration unit in experiment AZ4 










The samples produced in experiments AZ2-4 display a high degree of polymorphic purity, with the 
samples stable as PCM-II for a period of a year at the time of writing (Figure 4.30), with no peaks 
indicating conversion back to the thermodynamically stable PCM-I. Using knowledge from the 
doping experiments outlined in Chapter 3, which showed that the presence of 1 wt.% or greater of 
PCM-I in a PCM-II sample would catalyse the process of conversion back to PCM-I within one month, 





Figure 4.29: SEM analysis of samples from each of the MSMPR vessels in Experiment AZ4 
Figure 4.28: DSC traces for experiment AZ4, indicating the absence of any MCM·H2O. The 
y-axis shows heat flow in mW 
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Similar stability analysis was performed on the samples from Experiment AZ1, where some samples 
showed the presence of PCM-I initially at the point of crystallisation. The 12 month stability analysis 
shows peaks corresponding the presence of PCM-I appearing in all samples (boxed in red in 
Figure 4.31); these peaks were not present in initial samples for RT4, MSMPR 1 and MSMPR2, 
confirming the peaks are due to the solid-solid PCM-II to PCM-I transformation. 
Literature has suggested that MSMPR systems tend to be useful for systems that display slower 
nucleation and growth kinetics; the presence of MCM in the crystallisation process widens the 
metastable zone width and increases the induction time to nucleation, resulting in slow nucleation 
kinetics, making the MSMPR crystalliser suitable for this system. Further, the Design of Experiments 
Figure 4.30: 12 month stability PXRD patterns for samples produced in experiments AZ2, AZ3 and AZ4; the y-
axis displays relative intensity in arbitrary units 
Figure 4.31: 12 month stability PXRD patterns for samples produced from AZ1 with peaks corresponding to 
PCM-I boxed in red; the y-axis displays intensity in arbitrary units 
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outlined in Section 4.1 indicated the importance of stirring time at final temperature for increased 
yields of crystallisation. Operation of an MSMPR system in periodic mode would allow for these 
enhanced yields to be obtained, a contrast to flow crystallisers where growth time is limited by the 
residence time within the crystalliser due to the continuous flow of solution. 
4.3.4 Conclusions 
A two-stage periodic MSMPR operated in recycle mode, utilising vacuum transfer between the 
vessels, has allowed for the production of samples of PCM-II with high chemical and polymorphic 
purity. This crystallisation platform eliminates the metacetamol hydrate impurity that has been 
problematic in batch crystallisation environments and produces samples of PCM-II that display 
good stability with respect to the solid state transformation to the thermodynamically stable  
PCM-I. PCM-II has been successfully crystallised in three operational runs, with an initial experiment 
producing samples of PCM-II with trace quantities of PCM-I. This PCM-I was eliminated from 
succeeding experiments through alteration of the temperature profile, allowing more controlled 
crystallisation at a lower supersaturation ratio. The experiments investigated two different 
residence times and were operated for a maximum of c.a. 5 hours whilst retaining the polymorphic 
form outcome. These experiments represent the first reported continuous crystallisation of a 
metastable polymorphic form of an API. 
Use of this MSMPR system in periodic mode better mimics the stepped cooling profile used in batch 
crystallisation experiments, giving more control over the crystallisation. The MSMPR set-up 
employed here is thus well suited for the crystallisation of PCM-II in the presence of MCM as it 
allows for the longer residence times required to crystallise systems which display slow nucleation 
kinetics.  
4.4 Chapter Conclusions 
A Design of Experiments (DoE) approach has been used in order to investigate the effect of five 
factors on the polymorphic form and yield outcomes in the batch crystallisation of PCM-II in the 
presence of MCM as a templating molecule at the 100 ml scale. These experiments showed that 
the time at the final temperature and concentration of PCM were important factors in the yield 
outcome; increasing the time and increasing the concentration of PCM resulted in the highest yields 
due to an increased time for growth. Due to the inherent problem of representing a qualitative 
polymorphic form outcome as a quantitative response, the model produced for this response 
displayed poor statistics. However, general trends could be identified and it was found that the 
stirring rate was the most important factor in the polymorphic form outcome, with a higher stirring 
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rate resulting in a higher propensity to form PCM-II in the absence of any MCM·H2O impurity. This 
DoE investigation allowed for the optimal concentration of PCM and percentage of MCM for future 
experiments to be determined, as well as allowing for an explanation for some observations seen 
both in this Chapter and in Chapter 5 below. 
Once the optimal concentration of PCM and MCM had been determined, work at the CMAC 
National Facility at the University of Strathclyde looked at scaling the production of PCM-II through 
this templated crystallisation. Initial investigations with the EasyMax, which operates at the same 
working volume as the DoE work performed at Bath, showed the production of PCM-II to be rapidly 
transferable between the two different platforms. Scaled-up experiments were conducted using 
the OptiMax operating at a working volume of 800 ml, with the crystallisation monitored through 
inline process analytical technologies: a Raman PhAT probe to monitor the polymorphic form and 
an FBRM probe to help track nucleation events. Tracking of a peak in the Raman unique to PCM-II 
showed the nucleation of this form at the point of nucleation of the system, characterised by an 
increase in FBRM counts. Raman data at the end of the crystallisation from the PhAT probe, 
combined with PXRD analysis, showed the production of PCM-II with some MCM·H2O impurity 
present. It can be suggested that MCM·H2O was present in large enough quantities to be detectable 
through PXRD due to less efficient mixing at the larger volume required at this larger scale; at an 
industrial scale this could be combatted through the use of multiple impellors along the shaft. 
A two-stage MSMPR crystalliser, at AstraZeneca in Macclesfield, allowed for investigations into the 
continuous crystallisation potential of the templated production of PCM-II with MCM as a template 
molecule. The crystalliser was operated periodically in recycle mode, with an in-line filtration unit 
to provide sampling of the crystallisation, with vacuum transfer used to transfer solution/slurry 
between the vessels.  Initial crystallisations whereby the temperature of MSMPR 1 and MSMPR 2 
were set at 25 °C and 20 °C, respectively, resulted in the production of PCM-II with small quantities 
of PCM-I present. A further three experiments were performed with the temperatures of MSMPR 1 
and MSMPR 2 at 30 °C and 25 °C respectively, investigating a residence time within each MSMPR 
of 45 minutes and 30 minutes. Both residence times resulted in the crystallisation of PCM-II with a 
high level of both polymorphic and chemical purity. Samples produced displayed good stability with 
respect to the solid state transformation to PCM-I, indicating a polymorphically pure sample. PXRD 
and DSC analysis did not detect any MCM·H2O in any of the solid products from these three 
crystallisation experiments. Experiments were run for a maximum of five hours, with retention of 
the production of phase pure PCM-II throughout all residence times. Morphology analysis of the 
samples produced via SEM images show the production of a diamond-shaped, block morphology 
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for the samples of PCM-II; this would be favourable in terms of ease of filtration and downstream 
processability, an added benefit of this templated crystallisation method. These experiments 
represent the first reported successful continuous crystallisation of a metastable polymorphic form 
of an API, showing that the scalable production of these forms that display enhanced physical 
























5 Continuous flow crystallisation of PCM-II 
Some of the work presented in this chapter has been published as part of a Crystal 
Growth and Design special issue of selected papers presented at the 12th International 
Workshop on the Crystal Growth of Organic Materials (CGOM12 Leeds, UK): 
L.R. Agnew, T. McGlone, H.P. Wheatcroft, A. Robertson, A.R. Parsons and C.C. Wilson, 
‘Continuous Crystallization of Paracetamol (Acetaminophen) Form II: Selective Access to 
a Metastable Solid Form’, Cryst. Growth Des., 2017, 17(5), 2418-2427 
Although much industrial application of continuous crystallisation has been focussed on MSMPR 
crystallisers (as outlined in Chapter 4), owing to the ease of adapting existing batch crystallisation 
vessels, much academic interest in the area of continuous crystallisation has been dedicated 
towards the use of tubular flow crystallisers. These are of particular interest owing to their superior 
heat and mass transfer properties and may therefore offer significant opportunities for scalable 
continuous manufacturing processes based on crystallisation of molecular  
systems. 49, 51, 58, 65-66 
Flow chemistry for synthetic purposes has become more prevalent over the past few  
decades212-213, reflecting interest in the opportunities offered by available and emerging 
technologies in this area. However, it is only within recent years that continuous flow crystallisation 
has attracted increased interest, with centres such as the EPSRC CMAC Future Manufacturing Hub 
and the joint MIT-Novartis Center for Continuous Manufacturing pioneering the way towards 
establishing the technical and scientific background required for the adoption of these 
manufacturing methods. The work in this Chapter will look at transferring the templated 
crystallisation of PCM-II described in Chapters 3 and 4 into two continuous flow crystallisation 
platforms. 
5.1  Continuous crystallisation in the COBC 
5.1.1   Introduction and Aims 
The continuous oscillatory baffled crystalliser (COBC) (Figure 5.1), originally developed by NiTech 
Solutions214, is a tubular crystalliser consisting of a series of jacketed straights and unjacketed 
bends, contained within which are periodically spaced baffles, intended to generate favourable 
mixing conditions (Figure 5.1, left). The platform utilises the method of cooling crystallisation in 
order to generate supersaturation in the system, with the temperatures of each of the straights 
controlled through a series of circulators. 
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The peristaltic pump imparts net flow to the system; as the solution flows through the baffle 
constrictions, eddies are generated in the direction of flow (Figure 5.2, upstroke). Combining this 
net flow from the peristaltic pump and the oscillatory motion generated from the bellows results 
in the generation of these eddies in the direction opposite to the flow also (Figure 5.2, downstroke). 
Thus, eddies are generated on each side of the baffle constrictions. These eddies are responsible 
for the mixing observed within the COBC; each baffle spacing can be considered as a micro batch 
reactor. The small volumes of fluid within each micro batch reactor combined with the turbulence 
of mixing, resulting in greater homogeneity, gives the COBC its superior mass transfer 
characteristics compared with conventional batch crystallisers.  
As the mixing is governed by oscillation and not net flow, plug flow conditions are achieved even at 
low flow rates that are usually more conducive to laminar flow. The plug flow conditions ensure 
that all particles in the crystalliser experience the same environment in terms of temperature, 
mixing and residence time. The differences between plug flow and laminar flow are illustrated in 
Figure 5.3, with the arrows representing the velocity of a particle.  
 
Figure 5.2: The generation of eddies within the baffles in a COBC 211 
Figure 5.1: The compact 4-straight COBC set-up at the University of Bath (left) 
with the baffle geometry highlighted (right) 
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Flow within the COBC is governed by three main equations which give rise to dimensionless 
constants used to describe flow conditions: the oscillatory Reynolds numbers (Reo), the net flow 
Reynolds number (Ren), and the Strouhal number (St). 












Where f = frequency of oscillation (Hz), ρ = density (kg m-3), d = tubing internal diameter (m),  
χo = centre to peak amplitude (m), µ = viscosity (kg m-1 s-1), u = mean velocity (m s-1). 
The ratio of the oscillatory Reynolds number to the net flow Reynolds number gives the velocity 
ratio, ϕ. 




General guidelines and limits exist for these quantities in order to direct operation under plug flow 
including Reo ≥ 100, St ≤0.5 and Ren ≥ 50. The velocity ratio should always exceed 1 (i.e. the 
oscillation velocity should be greater than the net flow velocity), with values between 2 and 10 
advised for operation under plug flow conditions.58 
The aim of this work was to transfer the templated crystallisation of PCM-II in the presence of MCM 
to a COBC set-up, optimising the conditions for its formation to obtain polymorphically and 
chemically pure product.  
 
Figure 5.3: Plug and laminar flow through a pipe 
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5.1.2 Experimental 
Continuous crystallisation experiments were performed in a 15 mm internal diameter (DN15) COBC 
mounted in a vertical geometry (Figure 5.1). The feed vessel for the experiments was an unjacketed 
5 L RBF fitted with an overhead stirrer, with heating provided by a hotplate via a DrySyn® former.  
For all experiments, a concentration of PCM of 300 mg/g and a 60:40 H2O:IPA solvent system were 
used. Full experimental details are given in Table 5.2. Dissolved feed solution was transferred from 
the feed vessel to the main crystalliser via a Watson Marlow 520S peristaltic pump. The peristaltic 
pump used was calibrated with a variety of oscillation conditions in order to reproducibly obtain a 
flow rate of 50 ml min-1. Optimal oscillation conditions were chosen based on previous work in the 
group with succinic acid (Dr A Klapwijk, 2016 PhD Thesis215), with which the author assisted, and on 
advice from the CMAC National Facility. The main COBC set-up consisted of varying numbers of 
jacketed straight sections (ranging from 4 to 12) and non-jacketed bends; the temperature of the 
jackets was controlled through four Grant R3 TX150 circulator systems filled with water. Three 
thermocouples were used to monitor the temperature of the reaction mixture throughout the 
crystallisation. In all crystallisations there was a good agreement between the jacket and solution 
temperature.  
 
Before priming of the system, all jackets were set to their crystallisation temperature and allowed 
to equilibrate whilst the feed solution was dissolving. All air bubbles were removed from the system 
by initial priming with water. The system was then primed with the crystallisation solvent (60:40 
H2O:IPA) set at a temperature of 55 °C (the temperature of the feed solution). The inlet tube was 
then transferred to the heated feed vessel; temporary pausing of the oscillation and flow allowed 
for minimisation of any further air ingress into the system. Oscillation in the system was controlled 
through a bellows set up (note: due to pressure build up the bellows were operated only partially 
full). 
 
Solids were collected through a tube connected to an outlet piece and separated immediately from 
solution through vacuum filtration. Solids were collected for each residence time (RT).  In this work 
a distinction between residence time and solid residence time is made. Residence time is defined 
as the period of time spent within the crystalliser. The first residence time of all COBC experiments 
consists of replacing the priming solvent that is already in the crystalliser with saturated solution. 
Unless the system displays very fast nucleation kinetics, very little crystallisation would be seen in 
this first residence time. Solid residence time is calculated based on the residence time in which 
solid is first observed i.e. in most cases COBC RT2 = solid RT1.   
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5.1.2.1 Characterisation techniques 
PXRD and DSC analysis were performed on all samples to determine the solid form produced and, 
based on key outcomes indicated from batch and MSMPR investigations presented in Chapters 3 
and 4, to detect any trace quantities of MCM·H2O.  
Quantitative NMR analysis was performed with the Bruker Avance II+ 500 MHz spectrometer with 
BBFO probe at 298 K. Samples were dissolved in D2O and spectra were referenced to the residual 
solvent peak (δ = 4.79 ppm). 1H NMR of PCM and MCM were performed to act as reference samples 
and highlight differences in the spectra (Table 5.1). The differences in the two spectra are seen in 
the aromatic region, owing to the differing substitution positions in the two isomers.  
Table 5.1: Chemical shift information for the NMR spectra of PCM and MCM 
PCM MCM 
δ (ppm) Splitting Integral δ (ppm) Splitting Integral 
Methyl protons 
2.14 Singlet 3 2.16 Singlet 3 
Aromatic protons 
6.91 Doublet 2 6.75 Doublet 1 
7.25 Doublet 2 6.96 Doublet 1 
 
7.02 Singlet 1 
7.29 Doublet of doublets 1 
 
T1 values were calculated and the highest value was the singlet in MCM at 7.02 ppm (with a coupling 
constant 2 Hz), T1 = 9 seconds. The differences between quantitative 1H NMR and standard 1H NMR 
are the number of scans (to achieve sufficient signal-to-noise ratios to be able to integrate the MCM 
peaks with confidence) and the delay between scans, which should be at least five times the longest 
T1. All quantitative 1H NMR experiments were run with 200 scans each and a delay of 50 seconds. 
A peak corresponding to MCM (δ = 7.02 ppm) was integrated to allow quantification of the 


















Reo Ren St Feed T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
4-straight set-up 
COBC 1 0 2 25 
1538 46 0.09 
50 12.23 55 35 25 20 15 - - - - - - - - 
COBC 2 0 2 25 50 12.23 45 30 27 25 22 - - - - - - - - 
COBC 3 25 2 25 50 12.23 60 35 30 25 20† - - - - - - - - 
COBC 4 25 2 25 50 12.23 55 30 20 15 13 - - - - - - - - 
COBC 5 25 2 25 50 12.23 55 30 20 15 15 - - - - - - - - 
8-straight set-up 
COBC 6 25 2 25 
1538 46 0.09 
50 21.84 55 30 30 20 20 15 15 15 15 - - - - 
COBC 7 25 2 25 50 21.84 55 30 30 20 20 15 15 15 20 - - - - 
COBC 8 25 2 25 50 21.84 55 30 30 20 20 20 20 20 20 - - - - 
COBC 9 18 2 25 50 21.84 55 30 30 20 20 20 20 20 20 - - - - 
COBC 10 18 2 25 50 21.84 55 30 30 25 25 25 25 25 25‡ - - - - 
COBC 11 18 2 25 50 21.84 55 30 30 23 23 23 23 23 23 - - - - 
                                                          
† Temperature of T4 reduced to 15 °C to induce crystallisation 

















Reo Ren St Feed T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
12-straight set-up 
COBC 12 18 2 25 1538 46 0.09 50 33.20 55 30 30 25 25 25 25 25 25 25 25 25 25 














5.1.3 Results and Discussion 
5.1.3.1 Experiments with a four-straight COBC set-up 
COBC 1 and COBC 2: Experiments with no MCM 
Experiments COBC 1 and COBC 2 were performed in the absence of any MCM, acting as control 
crystallisations for future experiments. Conditions for COBC 1 were chosen based on batch 
crystallisation experiments, with temperatures chosen to ensure crystallisation would be observed 
in the system. After 14 minutes (i.e. within the first solid RT) crystallisation was observed in the 
third and fourth straight. By the end of the first solid residence time, encrustation was observed on 
baffle edges and walls (Figure 5.4). 
PXRD analysis of the harvested solid confirmed the presence of PCM-I, as would be expected in 
absence of any templating molecule. One further experiment (COBC 2) was performed in attempts 
to reduce the encrustation observed through increasing the temperature of the straights. 
Encrustation was reduced with this approach, but not eliminated completely. As the focus of this 
work was to try and obtain PCM-II through a templated crystallisation in the COBC, all future work 
in this area was directed towards this aim. 
COBC 3 and 4: Initial investigations with a four-straight set-up 
Crystallisation of PCM-II in the absence of MCM during batch cooling crystallisation experiments 
was observed at a temperature of 25 °C, as such the final straight temperature in experiment 
COBC 3 was set to 20 °C; a slightly reduced temperature to account for the relatively quick 
residence times experienced in the COBC, which could result in a longer induction time for 
nucleation. At the end of solid RT1, crystals were observed in the filter paper but not within the 
main crystalliser, indicating crystallisation occurred on the filter paper. As such, during the same 
experiment, the temperature of the final straight was reduced to 15 °C. This resulted in visible 
crystals in the exit piece of the crystalliser (Figure 5.5). 
 
Figure 5.4: Encrustation on the baffle walls in Experiment COBC 1 
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These crystals were collected on a second filter paper and subjected to PXRD analysis (Figure 5.6). 
Crystallisation was also observed in the Buchner flask; this is likely due to sudden crystallisation 
upon contact with the flask and saturated solution from RT1. This solid was separated from the 
mother liquor and analysed through PXRD (Figure 5.6). 
PXRD analysis confirms the production of PCM-II, and the absence of PCM-I, in all three samples 
analysed. However, crystallisation yield was very poor and could not be measured. As such, for 
experiment COBC 4, the temperature of the final straight was reduced to 13 °C in order to induce 
crystallisation within the system. Crystallisation was observed in straight 4 in RT1, with crystals 
observed in straight 3, midway through RT2, indicating possible back-mixing within the system. The 
crystallisation was run for four residence times (c.a. 1 hour of operation), with solid from each 
residence time analysed through PXRD (Figure 5.7). The mass of solid produced in each residence 
time was recorded and yields of crystallisation calculated (Table 5.3). The yields of crystallisation 
are calculated based on the concentration of PCM in a known residence volume (residence volume 
is the volume of solution within the crystalliser in one residence time); for a concentration of 
300 mg/g of PCM in 612 ml, a theoretical 100 % yield would be 183.6 g. The yields of crystallisation 
Figure 5.5: Crystallisation in the exit piece in experiment COBC 3 
Figure 5.6: PXRD analysis of the samples for experiment COBC 3; the y-axis shows relative 
intensity in arbitrary units 
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can be seen to be low in comparison to the batch crystallisation of PCM-II (ca 50 %), likely due to 
the long induction time needed to crystallise PCM-II in the presence of MCM not being amenable 
to the short residence times seen in this system. 
Table 5.3: Solid yields for experiment COBC 4 
Residence time Mass solid (g) Yield (%) 
RT1 20.7486 11 
RT2 67.8748 37 
RT3 61.0844 33 
RT4 24.9980 14 
 
PXRD analysis confirms the presence of PCM-II, however some peaks corresponding to MCM·H2O 
(the main peaks from which are boxed in red in Figure 5.7) are also observed, confirming the 
presence of some MCM·H2O in the solid product. This is likely due to the low temperatures needed 
to induce crystallisation in this compact four-straight set-up.  
COBC 5: T1 = 30 °C, T2 = 20 °C, T3 = 15 °C, T4 = 15 °C 
In order to mitigate the formation of MCM·H2O in the final solid product (as seen in COBC 4), the 
temperature of the final straight was increased (from 13 °C to 15 °C) with the rationale that 
crystallisation at a higher temperature would stop the crystallisation of this unwanted impurity. 
However, as demonstrated in experiment COBC 3, having one straight at 15 °C resulted in a very 
poor solid yield. As such, the final two straights in this experiment were each set at 15 °C; the 
Figure 5.7: PXRD patterns from experiment COBC 4, showing the production of PCM-II 
with some peaks from MCM.H2O present (boxed in red). The y-axis displays relative 
intensity in arbitrary units 
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rationale being that having a longer period of time at this temperature may allow for more 
crystallisation. 
Little crystallisation was observed in RT1 (reflected in the low solid yield in Table 5.4), with 
crystallisation in the exit piece observed within RT2 (Figure 5.8). Crystals were only observed by eye 
in the final straight in RT3. It could be that the increase in temperature from the jacketed straights 
to the unjacketed exit piece provided the energy to overcome the barrier to nucleation, which 
would explain why solid was only observed in the exit piece initially. 
Solids from each residence time were collected on separate filter papers and the weights of solid 
with corresponding yield calculated (Table 5.4). Solid yields can be seen to be lower in this 
experiment than from COBC 4, the higher temperature of the final straight resulting in less solid 
crystallising from solution.  
Table 5.4: Crystallisation yields from Experiment COBC 5 
Residence time Mass of solid (g) Yield (%) 
RT1 2.56 1.4 
RT2 26.65 14.5 
RT3 34.87 19.0 
RT4 22.28 12.1 
 
PXRD analysis (Figure 5.9) of the solid from each of the residence times indicates the formation of 
PCM-II, in the absence of PCM-I, in all residence times, with increasing amounts of MCM·H2O in 
later residence times. 
Figure 5.8: Crystallisation in the exit piece in Experiment COBC 5 
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5.1.3.2 Experiments with an eight-straight COBC set-up 
It was concluded from the experiments with the compact four-straight COBC set-up that 
crystallisation needed to take place at a higher temperature in order to eliminate the MCM·H2O 
from the final solid product.  The four-straight COBC set-up (total length - 3.58 m) did not provide 
a sufficiently long enough residence time at a higher temperature to induce crystallisation in the 
system. As such, the length of the COBC was doubled to an eight-straight set-up (total length - 
6.38 m) for the next set of experiments whilst the net flow rate was maintained at the previous 
value, doubling the residence time within the crystalliser.  
COBC 6  
Initial experiments with this eight-straight set-up utilised a similar cooling profile to that of 
Experiment COBC 5, with the number of straights for each temperature doubled (Figure 5.10). 
Figure 5.9: PXRD patterns for Experiment COBC 5 showing the production of 
predominately PCM-II, with some peaks (boxed in red) from MCM.H2O. The y-axis 
displays relative intensity in arbitrary units 







Crystals were observed in the filter at the end of the solid RT1; however it was not until solid RT2 
that crystals were visible in the final two straights of the COBC.  During solid RT2 and solid RT3 the 
amount of crystallisation was observed to increase. The experiment was run until the feed volume 
expired (at a time of 1hr 22 mins; after three solid residence times). As with previous experiments, 
samples were collected for each residence time to allow yield calculations (Table 5.5) and for 
analysis of solid form produced (Figure 5.11). 
Table 5.5: Solid yields in Experiment COBC 6 
Residence time Mass of solid (g) Yield (%) 
Solid RT1 5.24 1.6 
Solid RT2 8.87 2.7 
Solid RT3 98.27 30.0 
 
Again, the long induction time to nucleation in this system is reflected in the poor solid yields for 
RT1 and RT2. PXRD analysis (Figure 5.11) shows the production of PCM-II, however there are peaks 
corresponding to MCM·H2O present in the samples extracted from all residence times. It is likely 
that, due to the fact the system is crystallising at a temperature of 15 °C, this results in the 
crystallisation of MCM·H2O, as was observed in the Design of Experiments outlined in Chapter 4.  
COBC 7 
The observation of crystallisation in the exit piece in Experiment COBC 5 was explained through 
possible nucleation due to an increase in temperature providing the energy to overcome the barrier 
to nucleation. Combining this knowledge with the observation in multiple experiments that 
Figure 5.11: PXRD patterns for Experiment COBC 6 showing the production of PCM-II 




crystallisation at 15 °C resulted in the production of some MCM·H2O in the solid product, an 
experiment was carried out whereby the final straight was heated to a higher temperature 
(Figure 5.12). It was thought that if nucleation was induced at 20 °C instead of 15 °C, PCM-II may be 
able to be crystallised in the absence of MCM·H2O. 
Within solid RT1, small amounts of crystallisation were observed in straight 8. By the beginning of 
solid RT2, crystals were appearing in straight 7, with a significantly higher slurry density visible in 
straight 8. Problems with filtration of the slurry were observed in this experiment due to 
crystallisation in the Buchner funnel as the remaining saturated solution was filtered from solid. 
This crystallisation indicates that the conditions within the COBC using this temperature regime do 
not lead to complete desupersaturation of the solution. The experiment was run for 1 hr 44 mins 
(4.84 residence times), at which point crystallisation was visible in straights 4 and 5, possibly due to 
back mixing of crystals from later straights. Solid was collected for each solid residence time to 
allow determination of yields (Table 5.6) and analysis of the solid form produced (Figure 5.13).  
Table 5.6: Crystallisation yields for Experiment COBC 7 
Residence time Mass of solid (g) Yield (%) 
Solid RT1 1.23 0.4 
Solid RT2 43.64 13.3 
Solid RT3 88.08 26.9 
The crystallisation yields reflect the observation that crystallisation was seen at an earlier time point 
during the crystallisation in comparison to previous experiments; however the yield for solid RT3 is 
less than that observed for the same residence time in Experiment COBC 6. Heating of the final 
straight clearly helped to induce nucleation in the system as the yield for RT2 for experiment COBC 7 
is greater than in COBC 6, indicating earlier nucleation in the system. However, although nucleation 







was induced into the system earlier, the yields of crystallisation for later residence times were 
reduced for COBC 7 in comparison to COBC 6 as the temperature of crystallisation was higher. The 
DoE outlined in Chapter 4 clearly shows how cooling to a temperature of 15 °C compared to 20 °C 
increases the yield of crystallisation. 
Analysis of the PXRD patterns (Figure 5.13) shows the production of PCM-II in all residence times, 
with some MCM·H2O detectable in RT2 and RT3. Combining this data with observations from the 
experiment it can be concluded that in solid RT1, where no MCM·H2O was detectable in the solid 
through PXRD analysis, crystallisation occurred only in the final straight set at a temperature of 
20 °C. As such, it can be postulated that through facilitating crystallisation at 20 °C, MCM·H2O can 
be eliminated from the crystallisation product. This is supported by observations from solid RT2 and 
solid RT3 where some MCM·H2O was detectable in the solid through PXRD analysis; these samples 
result from crystallisation observed in straights set at a temperature of 15 °C. 
COBC 8 
As previous experiments have suggested a temperature of 20 °C is needed to induce crystallisation 
of PCM-II in the absence of any MCM·H2O, the next set of experiments investigated the effect of 





Figure 5.13: PXRD patterns showing the production of PCM-II with some MCM.H2O 









After 30 minutes of operation (i.e. midway through solid RT1) a few crystals were observed in the 
filter paper and in the final straight. By 62 minutes (towards the end of solid RT2), more crystals 
were observed in straight 8 and a few in straight 7; however it was noted that the suspension was 
much less dense than observed in previous experiments. This reduction in observed solid yield is 
supported by the calculated yields from filter paper masses (Table 5.7) and can be explained 
through the system having an increased induction time to nucleation at higher temperatures. As 
with Experiment COBC 7, problems with filtration due to crystallisation in the funnel were observed, 
indicating incomplete desupersaturation of the system within the COBC.  
Table 5.7: Solid yields in Experiment COBC 8 
Residence time Mass of solid (g) Yield (%) 
RT1 1.63 0.5 
RT2 1.23 0.4 
RT3 69.25 21.1 
 
Although solid yields were poor, PXRD analysis (Figure 5.15) does not indicate the presence of any 
MCM·H2O in the solid harvested from each of the three solid residence times. As such, DSC analysis 
was performed to detect any trace levels of MCM·H2O in the solids; these DSC scans did in fact 
indicate the presence of MCM·H2O in all residence times, characterised by the melt/re-
crystallisation event at 150 °C (Figure 5.16). 









Having the final six straights at 20 °C resulted in the crystallisation of trace amounts of MCM·H2O 
and previous experiments had also resulted in low solid yields. It was therefore possible that 
increasing the temperature of these final straights further would result in very little crystallisation 
but would favour inducing nucleation of PCM-II in the system without nucleating MCM·H2O. 
Therefore, the concentration of MCM used was decreased from 25 % to 18 %. In batch 
crystallisation experiments, the presence of MCM was seen to widen the metastable zone (MSZ), 
resulting in a delayed onset of nucleation.   Therefore, by decreasing the concentration of MCM, 
the MSZ may be narrowed slightly, resulting in crystallisation at a higher temperature and hence 
eliminating the crystallisation of MCM·H2O. Experiment COBC 9 used the same temperature profile 
as COBC 8 to allow direct comparison between the two experiments. 
Figure 5.16: DSC analysis showing the presence of some MCM·H2O in all three residence 
times in Experiment COBC 8 (exothermic up) 
Figure 5.15: PXRD analysis showing the production of PCM-II in Experiment COBC 8; the 
y-axis displays relative intensity in arbitrary units 
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Crystallisation in the final straight was observed in RT1, after a period of 25 minutes, earlier than 
has been seen in previous experiments. This indicates that reducing the concentration of MCM has 
the desired effect of reducing the induction time to nucleation. However, this resulted in high solid 
loadings in the crystalliser (Figure 5.17), leading to eventual blockage of the unjacketed bends and 
poor suspension of solid. 
Problems with filtration meant that accurate solid yields of crystallisation could not be determined 
for this experiment. However, samples were collected to allow for PXRD analysis; the outcomes for 
two separate samples are given for RT2 as the filtration problems resulted in filter papers being 
changed multiple times throughout the course of the experiment. The PXRD analysis (Figure 5.18) 
shows the production of PCM-II with some MCM·H2O present in small quantities. There are two 
possible reasons for this MCM·H2O being present at sufficiently high levels to be detected by PXRD. 
First, the high solid loadings in the crystalliser could have affected the mixing conditions; the DoE 
outlined in Chapter 4 highlighted the importance of mixing for the elimination of MCM·H2O. 
Secondly, the filtration problems experienced in this experiment were due to crystallisation in the 
filter funnel; it is plausible that the MCM·H2O detected in the PXRD is crystallising in the filter. 
Implementation of an inline Raman PhAT probe would allow for elucidation of whether this is the 
case. 




Owing to the presence of MCM·H2O in the solid for each of the residence times in COBC 9, in 
COBC 10 the effect of increasing the temperature of the final six straights from 20 °C to 25 °C was 
investigated with the aim of eliminating this impurity from the crystallisation in the COBC. The 
concentration of MCM remained at 18 %. By the end of solid RT1, very little crystallisation was 
observed, with only a few crystals in the filter and exit piece. As such, the temperatures of the final 
four straights (T4 – T8) were reduced to 23 °C to induce more crystallisation in the system. This step 
was successful in promoting further crystallisation; however this experiment experienced 
detrimental filtration problems due to crystallisation occurring in the filter as a result of the low 
solid yields produced within the main crystalliser, indicating incomplete desupersaturation of the 
system. Because of this, samples were not collected based on residence times, but instead were 
defined by the volume filtered before blockage in the filtration occurred. Six samples were collected 
throughout the course of the experiment, every 5 minutes for the last 30 minutes of the 
experiment, which was only able to be run for 1 hour due to these filtration issues. All six samples 
were subject to PXRD analysis (Figure 5.19). 
 
 
Figure 5.18: PXRD patterns confirming the production of PCM-II with trace MCM.H2O 





PXRD analysis (Figure 5.19) indicates that the production of PCM-II has been achieved in the 
absence of any MCM·H2O. As such, DSC analysis was performed on the samples to determine 
whether MCM·H2O was present in quantities not detectable through PXRD; due to the low mass of 
solid produced for Samples 1 and 2 only samples 3-6 were analysed through DSC (Figure 5.20). 
 
DSC analysis shows the production of pure PCM-II in the absence of MCM·H2O in Samples 3 and 4. 
However, the presence of MCM·H2O is seen to increase with time, with Samples 4 and 5 displaying 
the characteristic melt/recrystallisation event at around 145-150 °C of MCM.H2O (see Chapter 3). 
However, it could be that the MCM·H2O is crystallising in the filter; due to the filtration problems 
experienced in this experiment, saturated mother liquor remained on top of the filter cake for 
Figure 5.19: PXRD analysis of each of the six samples taken during the course of 
Experiment COBC 10; the y-axis displays relative intensity in arbitrary units 
Figure 5.20: DSC analysis for samples 3-6 in Experiment COBC 10 (exothermic up) 
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extended periods of time which could result in further crystallisation of either PCM-II or MCM·H2O. 
As such, results from this experiment should be treated with caution, with the experiment being 
repeated in Experiment COBC 11. 
COBC 11 
Owing to the fact that in Experiment COBC 10, the temperature of the final four straights had to be 
reduced to 23 °C in order to induce any significant crystallisation in the system, for COBC 11 the 
final six straights were set at a temperature of 23 °C.  
This temperature profile resulted in a successful experiment in terms of onset of nucleation; 
crystallisation was observed shortly into solid RT1 (at a time of 24 minutes) in straight 6. Nucleation 
in earlier straights is beneficial as it allows more time for growth, increasing yield, and more 
complete desupersaturation of the system. The crystallisation was run for three solid residence 
times (total operating time of 90 minutes) without any blockages or difficulties with filtration. 
Samples were collected for each residence time and solid yields calculated (Table 5.8). 
Table 5.8: Solid yields for Experiment COBC 11 
Residence time Mass of solid (g) Yield (%) 
Solid RT1 42.19 12.9 
Solid RT2 43.38 13.2 
Solid RT3 55.73 17.0 
Despite being more successful than the previous experiment, solid yields are still poor. It is likely 
that the eight-straight set up employed in this experiment does not allow for a long enough 
residence time within the crystalliser to allow for full desupersaturation of the solution, resulting in 
lower yields. However, the yields can be seen to be relatively consistent over the three solid 
residence times indicating the system is close to achieving operation at steady state; a parameter 
that is crucial for obtaining consistent particle property attributes. PXRD analysis was performed on 
each of the samples to determine the solid form of the product. This analysis confirms the 
production of PCM-II, however there are two peaks from MCM·H2O in each of the three residence 







5.1.3.3 Experiments with a 12-straight COBC set-up 
It was concluded from experiments using an eight-straight set-up that the residence time within 
the crystalliser was not long enough to induce nucleation at a temperature that eliminated 
MCM·H2O from the solid product, whilst giving reasonable yields. As such, the COBC was further 
increased in length to a 12-straight set-up (9.7 m). Two experiments were performed using this set-













Figure 5.21: PXRD analysis for the solid produced in Experiment COBC 11 confirming the 
production of PCM-II with some peaks from MCM.H2O (boxed in red). The y-axis 
displays relative intensity in arbitrary units 










COBC 12 utilised the same net flow rate and oscillation conditions as all previous experiments 
performed. After a period of 49 minutes (half way through solid RT1) crystallisation was observed 
in the final two straights. At the end of solid RT1, crystals were visible in straights 9 and 10. However, 
the experiment was hampered by significant suspension problems in the final four straights and 
detrimental filtration problems. The suspension problems were likely due to oscillation dampening, 
suggesting different oscillation conditions or methods (e.g. a piston set-up rather than bellows) 
would be required in order to suspend the particles in this longer set-up. As the temperature of 
crystallisation was set to 25 °C in order to induce crystallisation in the absence of MCM·H2O, it is 
likely that the addition of four extra straights was not enough to sufficiently desupersaturate the 
solution to prevent the filtration problems.  
Due to the filtration problems, solids were not collected based on residence time but as in COBC 10 
were defined on the volume filtered before the funnel became blocked. Four samples were taken 
throughout the 1 hr 25 minute operation (every 10 minutes from 50 minutes into the crystallisation) 






Figure 5.24: DSC analysis on the samples taken from Experiment COBC 12 
Figure 5.23: PXRD analysis for the samples taken during experiment COBC 12; the y-axis displays relative 
intensity in arbitrary units 
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PXRD analysis (Figure 5.23) confirms the presence of PCM-II, with no MCM·H2O present at levels 
detectable through PXRD. As such DSC analysis was used to confirm whether any MCM·H2O was 
present at levels below the detection limit of PXRD. This analysis (Figure 5.24) seemed to indicate 
the absence of any MCM·H2O; however there is a small event around 150 °C that could correspond 
to the presence of this form. As such, quantitative NMR analysis was performed on each of the 
samples in order to quantify the levels of any MCM·H2O that may be present in the sample. A peak 
at δ = 7.02 ppm corresponding to MCM (Table 5.1) was used to elucidate the percentage of  
MCM·H2O in the samples. The presence of MCM·H2O was detected in all samples at levels between 
2 % and 3.5 % w/w (Table 5.9). 
Table 5.9: Percentages of MCM·H2O in PCM-II samples from quantitative NMR analysis 






It is likely that the poor mixing experienced in the final four straights is responsible for the small 
quantities of MCM.H2O detected in the final solid product, an observation supported by the DoE 
highlighted in Chapter 4. The poor filtration seen in this experiment could also be responsible for 
the presence of this impurity, which could have crystallised whilst saturated mother liquor sat on 
top of the filter cake.  
COBC 13 
In order to aid in the suspension of particles in later straights, the oscillation conditions were 
changed by increasing the frequency of oscillation; the amplitude could not be increased further 
due to limitations with the bellows construction. The temperature profile remained the same as 
that used in Experiment COBC 12. Crystallisation in the end piece and on the filter paper was 
observed at the beginning of solid RT1. Again, the experiment was hampered by poor filtration and 
poor suspension of particles, resulting in premature termination of the experiment after a period 
of 1 hour. Four samples were taken throughout the operating time, with each sample subjected to 
PXRD and DSC analysis to confirm the solid form produced in the experiment. 
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PXRD analysis (Figure 5.25) confirms the production of PCM-II in all samples taken. It also indicates 
the absence of any MCM·H2O at levels detectable through PXRD analysis. As such, DSC analysis was 
performed in order to indicate whether trace levels of MCM·H2O were present in the samples 
(Figure 5.26). The DSC of Samples 1 and 2 show a small thermal event at 150 °C (boxed in red in 
Figure 5.26), which corresponds to the presence of MCM·H2O. The DSC traces of Samples 3 and 4 
appear to only show one thermal event, the final melt at 170 °C. As MCM·H2O was detected in the 
first two samples, quantitative NMR analysis was performed on Samples 3 and 4 in order to detect 
any trace MCM·H2O in the solid samples (Table 5.10), the presence of which was confirmed in small 
quantities, at similar wt.% levels as found in COBC 12. 
 
 
Figure 5.25: PXRD analysis of the samples taken in Experiment COBC 13; the y-axis 
displays relative intensity in arbitrary units 
Figure 5.26: DSC analysis of the samples taken in Experiment COBC 13 
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Table 5.10: Quantitative NMR analysis on samples from COBC 13 





In conclusion, metastable paracetamol form II (PCM-II) has been successfully crystallised in a 
reconfigurable COBC set-up. This represents the first example of a metastable polymorphic form of 
an API produced in a COBC. 
Initial crystallisations in a compact four-straight set-up resulted in the first successful continuous 
crystallisation of PCM-II (these experiments preceded the MSMPR runs detailed in Chapter 4); 
however MCM·H2O was present in the solid samples at high enough levels to be detectable by PXRD 
analysis (i.e. at least 5 % w/w). In order to induce crystallisation in the system, the temperature of 
the final straight was set to 13 °C. It can be postulated that the crystallisation of MCM·H2O is seen 
by forcing the system to crystallise at 13 °C; the batch Design of Experiments investigation outlined 
in Chapter 4 supports this observation, showing the prevalence of MCM·H2O at lower temperatures 
of crystallisation. The same result was observed when the final two straights were set at a 
temperature of 15 °C. It was concluded that the residence time within this compact set-up was not 
sufficient to induce crystallisation at temperatures that would result in elimination of the MCM·H2O 
impurity. The flow rate could not be decreased any further as this would not be sufficient to 
suspend and pump particles within the crystalliser. 
As such, the length of the COBC was increased to an eight-straight set-up, increasing the residence 
time within the system. Increasing the time at which the crystallising solution is held at a higher 
temperature should allow crystallisation of PCM-II at this temperature, in the absence of any 
MCM·H2O impurity. Initial investigations with this eight-straight set-up utilised a 25 wt. % 
concentration of MCM.  A variety of temperature regimes were employed in attempts to eliminate 
the hydrate impurity from the final solid product. Setting the final six straights to a temperature of 
20 °C produced the most successful crystallisation, resulting in levels of MCM·H2O only detectable 
through additional DSC analysis (i.e. not present at levels detectable through PXRD). However, solid 
yields of crystallisation were poor, possibly due to a widening of the metastable zone (MSZ) in the 
presence of MCM. Therefore, the concentration of MCM was reduced to 18 wt. % for all 
subsequent experiments. The cooling profile remained the same, with the final six straights set at 
20 °C. This reduction in MCM concentration had the desired effect of decreasing the MSZ, inducing 
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crystallisation earlier in the system. However, this decrease in MSZ resulted in higher solid loadings 
within the crystalliser, resulting in eventual blockage of the unjacketed bends. Furthermore, the 
final PCM-II solid still contained trace levels of MCM·H2O. As such, the temperatures of the final six 
straights were increased to 25 °C in the aim of inducing crystallisation in the absence of any hydrate 
impurity. No crystallisation was observed within the COBC in this temperature regime and the 
experiment was hampered by blocking of the filter funnel; it was thought that this blocking was due 
to incomplete desupersaturation of the solution within the main crystalliser. Therefore, to induce 
crystallisation and obtain more complete desupersaturation of the system, the temperatures of the 
final six straights were reduced to 23 °C. Although this resulted in crystallisation, blockage of the 
filter was still observed and the PCM-II solid still contained some MCM·H2O. As such, it was 
concluded that a still longer set-up was needed in order to desupersaturate the system fully and 
induce crystallisation at a higher temperature to eliminate MCM·H2O from the PCM-II solid product. 
Two further experiments were conducted using a 12-straight COBC set-up, equating to a residence 
time within the crystalliser of ca. 30 minutes. Setting the final 10 straights at 25 °C resulted in 
crystallisation of PCM-II in the apparent absence of any MCM·H2O. However, quantitative NMR 
analysis shows its presence at levels between 2 and 3.5 %. Suspension of particles in the final four 
straights was poor due to oscillation dampening. Increasing the frequency of oscillation had little 
effect on suspension. Experiments were again hampered by poor filtration due to crystallisation in 
the filter funnel. Any future experiments could look into operating in recycle mode, taking small 
samples for each residence time and transferring the tube back into the feed vessel in order to 
mitigate problems with filtration and allow for longer operation times. 
Future work on this system would look to investigate longer COBC set-ups in order to increase the 
residence time within the crystalliser. This increase in residence time would allow for more 
complete desupersaturation of the system, mitigating the problems seen here with filtration. 
However, it has been noted in literature that COBC set-ups may not be the most suitable for systems 
that display slow nucleation and growth kinetics, like the PCM/MCM system explored in this work. 
Despite all samples still containing trace quantities of MCM·H2O it is very likely that through 
increasing the length of the COBC, phase pure samples of PCM-II could be produced. Furthermore, 
the process understanding gained from these experiments allowed for rapid transferability to the 
MSMPR platform described above in Chapter 4.  
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5.2 Continuous crystallisation in the KRAIC 
5.2.1  Introduction and Aims 
The COBC continuous crystallisation platform described above works on high-throughput volumes 
(typically L/h). Previously reported work for smaller volumes has focussed on micro-reactors (µL/h), 
which display small internal diameters prone to blocking with particles any larger than nanometre 
in size.216-218 With a rise in concepts such as ‘dial-a-particle’ and the drive towards distributed 
manufacturing concepts, implying smaller manufacturing sites at point of use, the need for niche 
reactors that allow for crystallisation of particles with desirable physical properties in smaller 
volumes at the lab scale (mesoscale) is highly desirable. These lab scale reactors are also crucial in 
scaling up processes from discovery scale and moving towards larger manufacturing scales.219 
Furthermore, use of such mesoscale reactors allows for development of crystallisation processes 
using lower quantities of material; this is a key challenge in the pharmaceutical industry where 
process development has to occur with small quantities of material, especially in the early stages 
of development.  
Mesoscale crystallisers are generally of tubular geometry utilising either static mixers or operating 
with segmented flow. 67, 220-221 Much previous work in this area has focussed on gas  
segmentation222-225, however this results in solution wetting the walls of the crystalliser and 
formation of discrete air slugs (Figure 5.27). As the solution comes into contact with the walls, this 
can lead to problems with encrustation, which can result in eventual blockage of the crystalliser. By 
contrast, use of two immiscible liquids, whereby the carrier fluid preferentially wets the walls the 
crystalliser, resulting in the formation of discrete slugs of solution (Figure 5.27), would minimise 
contact between the solution and crystalliser walls, theoretically reducing encrustation in the 
system. The main barrier to implementation of liquid/liquid segmentation into mesoscale reactors 





The mixing in each slug is provided by the characteristic recirculating motion (Figure 5.28); the 
edges of the slugs act as stagnation points which cause reversal of the direction of flow.226 The two 
distinct edges of the slugs both providing this flow reversal result in the recirculating motions. 
The kinetically regulated automated input crystalliser (KRAIC; Figure 5.29) is a continuous 
crystallisation platform designed by Dr Karen Robertson (Wilson group PDRA). It is an open tubular 
crystalliser that operates on the principle of segmented flow. Owing to the inherent problems of 
encrustation experienced with air segmentation, due to solution touching the walls of the 
crystalliser, the KRAIC utilises an immiscible carrier fluid, a perfluropolyether polymer (Galden 
SV110). The carrier fluid is chosen as it is highly inert and preferentially coats the walls of the 









Figure 5.27: Schematic representing the differences between air and liquid segmentation 
Figure 5.28: Recirculating motion within slugs which provide mixing to the 
system 
Figure 5.29: The KRAIC segmented flow crystalliser as set-up at the University of Bath 
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Feed solution is pumped via a gear pump to the mixer piece, where it is combined with carrier fluid 
and/or air, giving resultant segmented flow. From here, the solution desupersaturates with a 
gradually decreasing temperature gradient over three temperature controlled coils, resulting in 
crystallisation. Crystals are separated from solution and carrier fluid at the outlet. 
The feed vessel is heated via a DrySyn® former with magnetic bottom stirring to aid dissolution of 
material. Jacketed tubing, equipped with flexible tubing jackets, transfers solution from the feed 
vessel to a mixer piece which is submerged in a heated water bath to mitigate encrustation of the 
mixer piece (Figure 5.30). 
The three coils of the KRAIC are constructed of a single piece of fluorinated ethylene propylene 
(FEP) tubing, 15 m in length with an internal diameter of 3.2 mm. Coil 1 is contained within a glass 
dish, placed on a hotplate. Graphite powder provides a medium for heat transfer to allow efficient 
heating of the coil. Coils 2 and 3 are pressed against DrySyn® formers with air surrounding them, to 
allow a progressively reducing temperature gradient to be established. In its current set-up, the 
KRAIC does not allow for cooling of coils below ambient temperatures. As such, for systems which 
require cooling below ambient temperatures to induce nucleation, a cold tube can be introduced 
into the set-up; the portion of FEP tubing between the mixer piece and coil 1 is contained within 
larger diameter (9.5 mm ID, 12.7 mm ED) silicone tubing which is dynamically temperature 












A specialised end piece has been developed to aid in both the propulsion of crystals into the filter 
and allow for separation and recycling of the carrier fluid (Figure 5.32). As the slugs of solution reach 
the end of the crystalliser, a neutral solvent is pumped in; here a neutral solvent is defined as a 
miscible solvent that will neither induce further crystallisation nor result in dissolution of existing 
particles. The purpose of the neutral solvent is to mitigate any possible fouling issues by increasing 
the velocity of the solution, propelling crystals out of the tubing into the filter. After neutral solvent 
is added, the contents pass through the carrier fluid recovery section (inset Figure 5.32). A series of 
holes in the tubing allow for selective removal of the carrier fluid that preferentially wets the 
crystalliser walls and not the slurry. In the event solvent also migrates through these holes, the 
tubing end is placed into a separating funnel which will allow separation of the two immiscible fluids 
based on density. After separation of the carrier fluid, the remaining slurry is propelled from the 
crystalliser, aided by the downward slope of the mouth of the end piece. Here, crystals are 
immediately separated from mother liquor through vacuum filtration. 
Figure 5.32: Novel end piece to allow separation of carrier fluid from solution flow 
Figure 5.31: The cold tube attached to the KRAIC to allow cooling below ambient temperatures 
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5.2.2  Experimental 
A concentration of PCM of 300 mg/g with the corresponding percentage of MCM (Table 5.11) were 
dissolved in 1 L of 60:40 H2O:IPA in a 5 L feed vessel, with magnetic bottom stirring to aid 
dissolution. 2 L of pure 60:40 H2O:IPA was heated to the same temperature as the feed solution. 
The temperatures of the transfer tube, mixer bath, cold tube and coils were set at this point to 
allow equilibration before the beginning of the experiment.  
Once at temperature, the pure solvent feed was used to prime the system for a period of 1-2 hours. 
It is during the priming step that flow rates of the feed, air and carrier fluid and mixer piece 
orientation are adjusted in order to obtain regular segmentation throughout the crystalliser. By 
priming with the same solvent as the crystallisation solvent, the solution slug properties are unlikely 
to deviate significantly through introduction of solution into the crystalliser.  
Once primed, the transfer tube is moved from the pure solvent feed to the solution feed. The air 
bubble generated from this transfer is used to help determine the residence time in the crystalliser; 
here the residence time is measured from when the air bubble exits the mixer piece to when it exits 
the crystalliser i.e. the time spent by particles under segmented flow. Full details of all experimental 
parameters for each of the KRAIC experiments are given in Table 5.11. 
The neutral solvent pumped in to the end piece was 60:40 H2O:IPA at room temperature; cooling 



















Flow rate (ml min-1) 
Residence 
Time 

















KRAIC 1 25 300 Y X 2.1 2.1 2.1 30 mins 55 55 55 15 30 20 20 
KRAIC 2A 25 300 Y K 2.1 2.1 2.1 30 mins 55 40 35 10 20 20 20 
KRAIC 2B 25 300 Y K 2.1 2.1 2.1 30 mins 55 55 40 13 20 20 20 
KRAIC 3 18 300 N Y 4.6 4.1 - 20 mins 55 55 40 - ICE 30 20 
KRAIC 4 25 300 Y Y 4.6 6.3 - 
12 mins 
43 secs 
55 55 40 8 20§ 20 20 
KRAIC 5 0 250 Y X 3  2.1 0.2 
18 mins 
10 secs 





                                                          
§ Ice placed inside coil 1 after 28 minutes to help induce crystallisation 
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5.2.3  Results and discussion 
KRAIC 1 
Initial experiments incorporating MCM as a template molecule utilised a cross mixer piece 
(Figure 5.33) to give tri-segmented flow within the main crystalliser coils. Due to residence time 
restrictions, stemming from pump operational limits and tubing length, and the widening of MSZ 
for the PCM/MCM system, it was deemed necessary to induce nucleation by use of a cold tube. A 
0.50 m cold tube was incorporated into the set-up as detailed in section 5.2.1. It was anticipated 
that induction of nucleation in the cold tube could result in high solid loadings which could result in 
blockage of the crystalliser. As such, initial investigations adopted heating of the first coil to a 
temperature of 30 °C in order to mitigate this potential problem. However under the conditions 
investigated in this experiment, no crystallisation was observed, with inconsistent slug sizes seen 
throughout; regular slug sizes are crucial for consistent particle attributes, ensuring all particles 
experience the same conditions in terms of mixing and residence time within the crystalliser. The 
temperature of both the cold tube and the mixer bath were decreased to 5 °C and 35 °C 
respectively; however after a period of 2.5 hours, crystallisation was still not evident in the system 
and the experiment was halted. 
As with the COBC, the KRAIC is a flow crystalliser and so the residence time is dictated by the length 
of the tubing and the net flow rate. The temperature control and profile obtained in the KRAIC is a 
function of tubing length and as this is fixed at a constant length the crystallisation cannot be run 
for longer periods of time as can be done for batch crystallisations. It can be suggested that the cold 
tube was not of sufficient length/ low enough temperature to induce crystallisation in the system. 
This combined with the short residence time (30 minutes) provided by the three coils were not 
sufficient to allow crystallisation in the system. 
Figure 5.33: The cross mixer piece alignment used in KRAIC 1 
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KRAIC 2A and KRAIC 2B 
In order to address the issues with inconsistent segmentation observed in the crystalliser during 
experiment KRAIC 1, in experiment KRAIC 2A the mixer piece was changed to a K-mixer 
(Figure 5.34). Based on experiments presented above of inducing crystallisation in the COBC 
platform, the length of the cold tube was also increased to the same length as one COBC straight 
(0.75 m) in order to provide a greater residence time at the lower temperature, with the aim of 
inducing nucleation in the system. The temperatures of the jacketed tube linking feed to mixer 
piece, the mixer water bath and the first coil were also reduced, as detailed in Table 5.11. 
After 5 minutes, crystals were observed in the cold tube (Figure 5.35), prompting the temperature 
of the cold tube to be increased to 13 °C after 11 minutes to mitigate the formation of blockages. 
At 21 minutes, there were signs of crystallisation in the mixer piece and so the temperature of the 
water bath and the jacketed tube before were increased without any stopping of flow. Due to the 
change in conditions within a run, the subheading KRAIC 2B is henceforth used for the experiment 
after these changes were implemented. 
Figure 5. 34: The K-mixer piece alignment used in KRAIC 3A and 3B 
Figure 5.35: Crystallisation in the cold tube in Experiment KRAIC 2A 
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After the change of conditions, Experiment KRAIC 2B was run for a further 40 minutes, after which 
time the experiment had to be stopped in order to clear blockages caused by very high solid 
loadings throughout all three coils (Figure 5.36). It was observed that the joints connecting the cold 
tube to the main body of crystalliser tubing acted as another site of nucleation and sedimentation, 



















Figure 5.36: High solid loadings in the three coils in Experiment KRAIC 2B (images taken at 12 mins for coil 1 
and 38 mins for coils 2 and 3) 
Figure 5.37: PXRD patterns for Experiment KRAIC 2A and KRAIC 2B; the y-axis displays 
relative intensity in arbitrary units 
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KRAIC 2A corresponds to the point of the crystallisation where encrustation was observed in the 
mixer piece, likely nucleating in the jacketed tube between the feed vessel and mixer, with PXRD 
analysis showing the production of PCM-I. Batch crystallisation experiments showed PCM-I 
crystallises at roughly 45 °C and so it can be suggested that the period of time the solution spent at 
this temperature resulted in the nucleation of this polymorphic form. Due to the fact that the 
crystallisation was not stopped between Experiment 2A and 2B, the PCM-I already produced was 
still present in the coils of the KRAIC and so some PCM-I was still present in the PXRD pattern for 
KRAIC 2B. However, once conditions were altered and crystallisation was controlled such that 
nucleation occurred within the main coils, PCM-II began to crystallise. As such, the PXRD pattern 
for KRAIC 2B shows a mixture of PCM-I and PCM-II. Due to the mixture of the two polymorphic 
forms and the focus of the work being on obtaining the metastable PCM-II, yields for this 
experiment were not calculated. 
KRAIC 3 
Owing to the observation that the joints between the cold tube and the mixer piece/main coil 
tubing acted as sites of nucleation for the crystallisation observed in Experiment KRAIC 2A and 2B, 
Experiment KRAIC 3 investigated removal of the cold tube and replacement with a bag of 
ice/water/salt inside coil 1. Coil 2 was slightly heated to 30 °C to mitigate significant blockages. 
Furthermore, a reduction in the number of available gear pumps meant that only two inputs into 
the mixer piece were possible; owing to the problems that can be experienced with air 
segmentation, the two flows used were solution and carrier fluid. As such, the mixer piece 
orientation was changed to a Y-mixer (Figure 5.38). 
After the first residence time (20 minutes), no crystals were observed and so another bag of ice was 
placed in coil 2 to encourage nucleation. The residence time for this experiment is significantly less 
than those in previous experiments due to the increased flow rates needed to obtain even 
segmentation with the Y-mixer piece. This decreased residence time could explain why 
Figure 5.38: The Y-mixer piece utilised in Experiments KRAIC 4 and KRAIC 5 
184 
 
crystallisation was not observed within the main body of the crystalliser. Although no crystals were 
observed in the slugs of solution, small crystals were captured on the filter paper. It can be 
suggested that due to the shortening of residence time within the crystalliser, the solution did not 
have enough time to fully desupersaturate so crystallisation occurred on the filter paper. That 
notwithstanding, analysis of these crystals showed the production of PCM-II in the absence of any 
PCM-I (Figure 5.39). Owing to the very low solid yields produced in this experiment, experimental 
yields could not be accurately determined. 
Despite best attempts to ensure that the bags of ice placed inside the coils resulted in effective 
cooling of all parts of the coil, the heat transfer could not be as effective as when the entire coil is 
surrounded by a cold tube. Further, over time the ice would melt, effectively increasing the 
temperature. As such, it can be surmised that, the temperature of the coil combined with the time 
spent at this temperature is not sufficient to induce nucleation in a system that displays slow 
nucleation kinetics such as the one investigated here; it is concluded that in order to induce 
consistent nucleation in the system, a cold tube is needed. 
KRAIC 4 
For Experiment KRAIC 4, a zero-volume union was used in order to connect the cold tube (1.14 m 
in length) to the main coil tubing, ensuring the join was not a possible site of nucleation. As far as 
possible the experimental parameters employed for Experiment KRAIC 2B (which resulted in the 
formation of PCM-II) were retained in KRAIC 4, with the exception of the mixer piece which 
remained as a Y-mixer (Figure 5.38), as deployed in Experiment KRAIC 3, and the flow rates (these 
were increased from Experiment 2B in order to obtain even segmentation with the Y-mixer piece). 
However, to keep parameters consistent with Experiment KRAIC 2B, tri-segmented flow was 
Figure 5.39: PXRD patterns showing the production of PCM-II in Experiment KRAIC 3; 
the y-axis displays relative intensity in arbitrary units 
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achieved by delivering both air and carrier fluid from the same pump (set to 4.1 ml min-1) via a valve 
upstream from the pump. The valve enabled a controlled proportion of air to carrier fluid to be 
achieved, here set at 50 % (a 1:1 v/v ratio). The temperature of the cold tube (reduced from 8 °C to 
5 °C after 18 minutes), coil 1 (through addition of ice after 28 minutes) and mixer water bath 
(reduced from 40 °C to 35 °C after 60 minutes) were all reduced throughout the experiment to 
induce nucleation in the system. After one hour of operation, small crystals were observed in slugs 
approaching the exit piece, however were not visible in the filter paper. As such, the filter paper 
was changed to a paper that had a smaller (from 11 µm to 25 nm) pore size in order to collect these 
crystals. Samples collected were analysed by PXRD (Figure 5.40). 
PXRD analysis (Figure 5.40) of samples from these filter papers shows the production of a mix of 
PCM-I and PCM-II in RT2, with pure PCM-II being produced in RT3. However, solid yields were 
extremely low and whilst sufficient for PXRD analysis, insufficient solid product was obtained for 
reliable yield calculations. Further optimisation of this crystallisation process would be required in 
order to produce PCM-II in higher yields. A longer residence time in the system would be required 
in order to allow crystallisation of a system which displays slow nucleation kinetics due to a wide 
metastable zone width such as the one studied in this work.  
KRAIC 5 
Experiment KRAIC 5 was run as a control experiment and investigated the crystallisation of PCM in 
the KRAIC in the absence of any template molecule. A lower concentration of PCM (250 mg/g) was 
used in comparison to the experiments with MCM present; in the absence of MCM a concentration 
of 300 mg/g would result in very high solid loadings which would block the small bore tubing of the 
Figure 5.40: PXRD analysis for Experiment KRAIC 4 – those peaks corresponding to PCM-I in 
RT2 are boxed in red. The y-axis displays relative intensity in arbitrary units. 
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KRAIC. To ensure consistency between this experiment and those containing MCM, a cold tube of 
length 1.14 m was incorporated into the set-up. 
Crystallisation was observed by the end of the second coil in RT1. There were problems with 
blocking of the carrier fluid recovery holes at the point of filtration, however these were alleviated 
easily. After an hour of operation, the experiment was halted due to blockage within the coils. 
Analysis of the solid form of the crystals produced through PXRD confirms the presence of PCM-I, 
with yields of crystallisation shown in Table 5.12. 
Table 5.12: Yields from experiment KRAIC 5 
Residence Time Mass product (g) Yield (%) 
RT1 0.2760 2.04 
RT2 0.8524 5.68 
RT3 0.4259 3.96 
5.2.4  Conclusions 
The templated crystallisation of metastable PCM-II in the KRAIC has been observed, however 
further optimisation of the conditions is required in order to produce this metastable polymorphic 
form in appreciable yields. Segmented flow with an immiscible carrier fluid and air was used 
throughout the experiments. 
The KRAIC design had to be adapted to incorporate a cold tube into the platform in order to induce 
any crystallisation in the system, as the current design does not facilitate controlled dynamic 
cooling of the three coils below ambient temperatures. Ice can be added to the inside of the coils; 
however this does not allow accurate and controllable temperature control to be achieved. The 
temperatures of each of the sections required initial optimisation after crystallisation was observed 
upstream of the mixer piece at a temperature which has been shown to be conducive to the 
crystallisation of PCM-I (see Chapters 3 and 4). Upon controlling the point of nucleation to occur 
within the cold tube, the target metastable PCM-II form was observed in the solid product. 
However, joints between the cold tube and main crystalliser tubing acted as sites of further 
nucleation resulting in high solid loadings which lead to eventual blockage of the small bore 
diameter tubing.  
Repetition of experiments with the modified set temperatures of the mixer bath and cold tube (to 
ensure the stable PCM-I did not crystallise) resulted in crystallisation of small quantities of PCM-II. 
The crystals produced in this experiment were so small that a smaller pore size filter paper was 
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needed in order to harvest them for analysis. PXRD confirmed the presence of a mixture of PCM-II 
and PCM-I in the second residence time, with the product in the third residence time shown to be 
PCM-II. The mixing experienced within the KRAIC platform is significantly gentler than that observed 
in other systems (COBC, MSMPR, batch environments) and so it can be postulated that this relative 
decrease in mixing intensity could be responsible for the small quantities of PCM-I observed in the 
PCM-II solid.  Furthermore, nucleation is being induced at a low temperature, due to limited time 
within the cold tube, and so this could be causing nucleation of the more stable polymorph. As such, 
future experiments should investigate increasing the length of this cold tube further to allow for 
both more nucleation and nucleation at a higher temperature that could mitigate the production 
of the stable PCM-I. A longer residence time within the main body of the crystalliser would also be 
desirable in order to increase the residence time within the system; however with the current 
experimental set-up this is not possible due to experimental limits of tubing length and net flow 
rate. 
As the KRAIC operates at much lower volumes than the two continuous crystallisation platforms 
previously already explored in this work, it may be that use of this platform would be beneficial for 
those systems outlined in Chapter 3 that could not be scaled beyond the 1 ml volume. 
5.3 Chapter conclusions 
This chapter has demonstrated the use of two tubular continuous flow crystallisation platforms in 
the templated crystallisation of metastable PCM-II using MCM as a templating molecule. The KRAIC 
works on much lower working volumes (mL/h vs L/h) and smaller internal diameters (3.2 mm vs 
15 mm) in comparison to the COBC. The mixing in the KRAIC is provided by bolus flow and is gentler 
than the eddies generated through oscillatory motion in the COBC. 
PCM-II was formed in all instances in the COBC; however elimination of the metacetamol hydrate 
impurity proved problematic, with trace quantities present in all samples.  In the case of the KRAIC, 
crystallisation had to be induced through a cold tube, resulting in the crystallisation of PCM-II with 
small quantities of PCM-I in the solid product, as detected through PXRD. Further, the gentle mixing 
in the KRAIC may not be sufficient for the elimination of PCM-I from PCM-II samples; small scale 
experiments performed in Chapter 3 highlighted the importance of mass transfer and mixing in the 
formation of PCM-II in smaller volumes. The elimination of PCM-I from the solid product is a key 
challenge to stop the conversion from PCM-II to PCM-I (see Chapter 3). As such, for the production 
of PCM-II, the COBC would be preferred between the two tubular crystallisers investigated. 
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However, it was noted that both crystallisers did not provide sufficient residence time to allow for 
substantial growth of product. With systems such as this, that display slow nucleation kinetics, flow 
systems would not be as desirable as, for example, crystallisation in a periodic MSMPR (PMSMPR) 
system. These PMSMPR systems allow for periods of dwelling during the crystallisation, increasing 

























6 Hosting of reactive pharmaceuticals 
The research presented in Chapters 3-5 focussed on controlling the polymorphic solid form of 
molecules, in particular APIs, with paracetamol used as an exemplar in a range of investigations. 
One of the major drivers in such control is to produce solid forms with favourable physical 
properties. The work presented in this Chapter looks at using hosting in order to control the 
production of more stable solid forms of pharmaceutical molecules that can be classed as reactive 
in terms of, for example, thermal or hydrolytic stability. The principles used in designing such host-
guest complexes are related to those used in selecting co-molecules, templates and additives – 
notably the choice of GRAS hosts and the aim of enhancing one of more key physical properties of 
the solid state system that will enhance the efficacy of the active ingredient.  
6.1 Introduction and Aims 
Cyclodextrins (CDs) have been chosen as the host materials for the stabilising of reactive target 
molecules, owing to their lack of toxicity and feasibility for use in drug preparations; they are GRAS 
molecules.227 Cyclodextrins are organic molecules comprised of varying numbers of glucose units 
joined together in a ring through α-1,4 glycosidic bonds. There are three native cyclodextrins 
(Figure 6.1); alpha (α-CD), beta (β-CD) and gamma (γ-CD) comprised of 6, 7 and 8 glucose units 
respectively.  
The cyclodextrins consist of a hydrophobic interior cavity and hydrophilic exterior surface, and in 
their parent state contain water molecules loosely bound inside the cavity (Figure 6.2). Inclusion of 
guests within cyclodextrins is driven by an enthalpic and entropic gain from the release of water 
molecules from the cavity upon inclusion. The formation of a variety of intermolecular interactions 
and the release of conformational strain can also be considered driving forces for the inclusion of 
molecules inside the CD cavity.228 An included compound is bound through a hydrophobic 
Figure 6.1: Structural diagrams of the three native cyclodextrins 
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interaction between the interior cavity and a hydrophobic guest molecule, however binding 
through hydrogen bonds from the secondary hydroxyl groups of the cyclodextrin is also possible; 
the included compound must be of comparable size to the cavity for inclusion to occur. The 
complexation process is reversible; the CD with included guest molecule is in dynamic equilibrium 
with the uncomplexed molecules as no covalent bonds are formed upon complexation. It has been 
shown that complexation of a cyclodextrin with another molecule increases the stability of 
cyclodextrins. 229-230 
Cyclodextrins, both native and derivatised, have been used extensively within the pharmaceutical 
sector to improve the aqueous solubility of a variety of poorly soluble drugs; furthermore, 
derivatised CDs are often used to increase the solubility of the parent CD.231-234 Much less research 
has been reported on the use of cyclodextrins to host reactive pharmaceuticals235, where reactivity 
encompasses both pharmaceuticals which are unstable at high temperatures or humidities and 
those that display a short half-life in the body. 
Two guest pharmaceutical molecules (APIs) have been the focus of this work: the antibiotic 
thiamphenicol (THM) and the antioxidant α-lipoic acid (ALA) (Figure 6.3). Thiamphenicol displays 
poor hydrolytic stability across the amide bond236-237, while ALA displays poor thermal stability due 












Literature has shown that incorporation of ALA into β-CD confers increased thermal stability of the 
ALA. 235 The aim of the work presented here on ALA would be to transfer this literature reported 
host/guest system, with proven stabilisation of the ALA, initially into cooling crystallisation 
environments. If this is successful, transfer into continuous crystallisation platforms will be 
targeted. Utilising the premise of hosting within cyclodextrins, attempts at incorporating 
thiamphenicol into a similar hosting system will be explored; hosting of this API in CDs is previously 
unreported. As water molecules are excluded from the hydrophobic cavity upon inclusion of a guest 
molecule, hosting of a hydrolytically unstable guest molecule inside this cavity could help to 
increase its stability against hydrolysis.  
Transfer of these host/guest systems to cooling and continuous crystallisation environments for 
large scale production is unreported with current methods of production using the method of 
saturated aqueous solution.238-240 
6.2 Experimental 
6.2.1 Evaporative crystallisations 
Evaporative crystallisation experiments were conducted as a screening method in order to obtain 
suitable single crystals of CD-thiamphenicol host-guest complexes for SCXRD. Equimolar amounts 
of thiamphenicol (10 mg) and each of the three parent cyclodextrins (27.3 mg α-CD, 31.8 mg β-CD 
and 36.3 mg γ-CD) were dissolved in minimal volumes of water in a 7 ml vial, with each 
crystallisation performed in triplicate. Water was chosen as an initial solvent as there is a risk of 
preferential inclusion of other solvents into the CD cavity over the guest molecule; in their native 
form as supplied, CDs contain water bound inside the cavity. For each of the crystallisations with 
each of the three CDs, the vials were fitted with a pierced lid and placed on temperature controlled 
hotplates at 25 °C, 40 °C and 50 °C to allow slow evaporation of the solvent.  
Figure 6.3: The chemical structures of thiamphenicol and α-lipoic acid, with the bonds that are the 
source of molecular instability highlighted 
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6.2.2 Cooling crystallisations 
Cooling crystallisations for both hosting systems at a variety of scales were conducted using the 
Polar Bear Plus Crystalliser. Ratios of the two components were determined based on the binding 
ratio highlighted from generation of Job plots (see below). Crystallisations were carried out in 20 ml 
glass vials, with varying solvent amounts, with magnetic bottom stirring. Full details will be 
highlighted in sections 6.3.1.3 and 6.3.2.2.  
6.2.3 NMR analysis 
6.2.3.1 Job plots 
In order to determine the stoichiometry of the binding between the host and guest, the method of 
continuous variation to generate Job plots was used. 241 Instead of varying the concentration of one 
component at a time, the method of continuous variation holds the total concentration of host and 
guest constant (in this case at 4 mM) and varies the relative proportions of the host and guest 
(illustrated in Figure 6.4).242 
NMR analysis was used in order to track shifts in certain proton peaks upon changing the ratio of 
host to guest. Reference samples of the host and guest molecules were taken and the peaks for 
each of the protons identified. A combination of standard 1H NMR (Figure 6.9) and correlation 
spectroscopy (COSY)(Figure 6.5) was required to assign all peaks for the cyclodextrin molecule. 
Thiamphenicol 1H NMR (D2O, 500 MHz, 298 K) δ (ppm): 3.13 (s, 3H, CH3), 3.60 (m, 1H, CH), 3.76 (m, 
2H, CH2), 4.12 (m, 1H, CH), 5.08 (s, 1H, CHCl2), 7.57 (d, 2H, ArH), 7.83 (d, 2H, ArH) 
γ-CD 1H NMR (D2O, 500 MHz, 298 K) δ (ppm): 3.47 (t, 8H, H4), 3.54 (dd, 8H, H2),  
3.755 (s, 24H, H5+H6), 3.82 (t, 8H, H3), 5.00 (d, 8H, H1) 
 
 
Figure 6.4: Illustration of the method of continuous variation, used to generate data for the Job’s plot 
approach to determine host-guest stoichiometry 
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Protons thought to be involved in interactions between the host and guest molecules upon 
inclusion were identified. For each of the two guests these were chosen based on those proton 
signals that were still easily identifiable upon inclusion into the cyclodextrin host and are labelled 
in Figure 6.3. For the cyclodextrin molecule, protons were chosen based on those which 
stereochemistry would indicate would point in towards the interior of the cavity and so would be 







Figure 6.6: A single glucose unit showing the proton labelling scheme 
Figure 6.6: A single glucose unit showing the proton labelling scheme 
Figure 6.5: COSY NMR spectrum for γ-CD 
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A 4 mM solution of each of the molar fractions outlined in Figure 6.4 was made up in D2O and 
subjected to 1H NMR analysis using a Bruker Avance II+ 500 MHz spectrometer at 298 K. Data were 
processed using ACD Labs NMR processor which allowed the chemical shifts of appropriate protons 
to be tracked upon changing solution composition (Table 6.1- Table 6.4). 
Table 6.1: Proton shifts in thiamphenicol upon inclusion into γ-CD 
 










THM γ-CD ppm δH δH x [THM] ppm δH δH x [THM] 
1 0 4.0 7.822 0.0000 0.000 6.105 0.000 0.000 
0.9 0.1 3.6 7.815 0.0070 -0.0252 6.095 0.010 -0.0360 
0.8 0.2 3.2 7.8105 0.0115 -0.0368 6.089 0.016 -0.0512 
0.7 0.3 2.8 7.8052 0.0168 -0.0470 6.085 0.020 -0.0560 
0.6 0.4 2.4 7.8057 0.0163 -0.0391 6.086 0.019 -0.0456 
0.5 0.5 2.0 7.8070 0.0150 -0.0300 6.085 0.020 -0.0400 
0.4 0.6 1.6 7.8040 0.0180 -0.0288 6.080 0.025 -0.0400 
0.3 0.7 1.2 7.8025 0.0195 -0.0234 6.075 0.030 -0.0360 
0.2 0.8 0.8 7.8025 0.0195 -0.0156 6.073 0.032 -0.0256 
0.1 0.9 0.4 7.7958 0.0262 -0.0105 6.068 0.037 -0.0148 





γ-CD THM ppm δH δH x [γ-CD] ppm δH δH x [γ-CD] 
1 0 4.0 3.8170 0.0000 0.0000 3.7350 0.0000 0.0000 
0.9 0.1 3.6 3.8096 0.0074 0.0266 3.7250 0.0100 0.0360 
0.8 0.2 3.2 3.8081 0.0089 0.0285 3.7200 0.0150 0.0480 
0.7 0.3 2.8 3.8046 0.0124 0.0347 3.7152 0.0198 0.0554 
0.6 0.4 2.4 3.8036 0.0134 0.0322 3.7135 0.0215 0.0516 
0.5 0.5 2.0 3.8047 0.0123 0.0246 3.7125 0.0225 0.0450 
0.4 0.6 1.6 3.8015 0.0155 0.0248 3.7080 0.0270 0.0432 
0.3 0.7 1.2 3.7988 0.0182 0.0218 3.7010 0.0340 0.0408 
0.2 0.8 0.8 3.7950 0.0220 0.0176 3.6950 0.0400 0.0320 
0.1 0.9 0.4 3.7950 0.0220 0.0088 3.6900 0.0450 0.0180 
0 1 0.0 - - - - - - 
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Table 6.3: Proton shifts in ALA upon inclusion into β-CD 
 
Table 6.4: Proton shifts β-CD upon inclusion of ALA into the cavity 
 
6.2.3.2 Diffusion 1H NMR 
In order to investigate whether the two components remain complexed in solution, diffusion 1H 
NMR (DOSY) experiments were performed. Hosting complexes were dissolved in D2O and spectra 
obtained at 298 K on a Bruker AV 400 spectrometer operating at 400.13 MHz. 
6.2.3.3 Solid State CPMAS NMR 
Solid state NMR was performed at AstraZeneca in Macclesfield. 13C {1H} cross-polarisation magic 
angle spinning (CPMAS) NMR spectra were recorded on a Bruker Avance III 500WB spectrometer. 





ALA β-CD ppm δH δH x [ALA] ppm δH δH x [ALA] 
1 0 4.0 1.64 0.00 0.000 3.590 0.000 0.0000 
0.9 0.1 3.6 1.63 0.01 -0.036 3.580 0.010 -0.0360 
0.8 0.2 3.2 1.62 0.02 -0.064 3.565 0.025 -0.8000 
0.7 0.3 2.8 1.615 0.025 -0.070 3.560 0.030 -0.0840 
0.6 0.4 2.4 1.61 0.03 -0.072 3.555 0.035 -0.0840 
0.5 0.5 2.0 1.6 0.04 -0.080 3.545 0.045 -0.0900 
0.4 0.6 1.6 1.6 0.04 -0.064 3.540 0.050 -0.0800 
0.3 0.7 1.2 1.6 0.04 -0.048 3.532 0.058 -0.0696 
0.2 0.8 0.8 1.59 0.05 -0.040 3.522 0.068 -0.0544 
0.1 0.9 0.4 1.59 0.05 -0.020 3.519 0.071 -0.0284 





β-CD ALA ppm δH δH x [β-CD] ppm δH δH x [β-CD] 
1 0 4.0 3.84 0.00 0.000 3.730 0.000 0.000 
0.9 0.1 3.6 3.83 0.01 0.036 3.720 0.010 0.036 
0.8 0.2 3.2 3.82 0.02 0.064 3.705 0.025 0.080 
0.7 0.3 2.8 3.81 0.03 0.084 3.690 0.040 0.112 
0.6 0.4 2.4 3.80 0.04 0.096 3.675 0.055 0.132 
0.5 0.5 2.0 3.79 0.05 0.100 3.660 0.070 0.140 
0.4 0.6 1.6 3.79 0.05 0.080 3.655 0.075 0.120 
0.3 0.7 1.2 3.79 0.05 0.060 3.655 0.075 0.090 
0.2 0.8 0.8 3.79 0.05 0.040 3.650 0.080 0.064 
0.1 0.9 0.4 3.79 0.05 0.020 3.650 0.080 0.032 
0 1 0.0 - - - - - - 
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12 kHz.  The spectra were recorded at 125 MHz for 13C, i.e. a 500 MHz spectrometer. The contact 
time was 2 ms with a recycle delay of 5 seconds. Both spectra are externally referenced to the peak 
due to the carbonyl carbon of glycine at 176.03 ppm. The spectrum of the complex was recorded 
for a longer period of time in order to improve the signal-to-noise for the minor peaks. 
6.2.4 Single crystal X-ray diffraction 
Single crystal X-ray diffraction data for the molecular complex of thiamphenicol and γ-CD was 
collected on an Agilent Technologies Supernova diffractometer, using Cu radiation (λ = 1.5406 Å) at 
150 K. The sample temperature was controlled using an Oxford Diffraction Cryojet apparatus and 
the data processed using CrysAlisPro version 1.171.36.21. Data were solved by direct methods using 
SHELXD-2013 and a full least squares refinement of the resulting structure was carried out using 
SHELXL-2013.  
6.3 Results and discussion 
6.3.1 The molecular complex of thiamphenicol and γ-cyclodextrin 
6.3.1.1 Single crystal X-ray diffraction 
Single crystal screening of samples produced from evaporative crystallisation experiments whereby 
attempts were made to host thiamphenicol inside the three native cyclodextrins confirmed the 
formation of a molecular inclusion complex. The molecular complex crystallises in the tetragonal 
space group P4212 with two glucose units of three separate cyclodextrin units in the asymmetric 
unit (Z =6, Z’= 3/4). 
Figure 6.7: The packing in the molecular inclusion complex of thiamphenicol and γ-CD as 
viewed along the crystallographic c axis (hydrogen atoms were unable to be assigned) 
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The packing within the crystal structure (Figure 6.7) shows the γ-CD molecules to form distinct 
channels, with electron density visible inside the channels. As would be expected, the water 
molecules that reside inside γ-CD without a guest molecule present have been displaced to 
locations outside the CD molecules. However, due to the four-fold symmetry of the cyclodextrin 
molecules, resolution of the thiamphenicol molecule inside the channel is difficult. As such, to 
confirm inclusion other evidence was sought and further studies conducted. Initial confirmation of 
inclusion of a non-aqueous guest molecule into the cyclodextrin is obtained through crystal 
structure comparison. In their native form, the cyclodextrin molecules in γ-CD do not form distinct 
channels, rather the molecules are staggered (Figure 6.8). Upon inclusion of a non-aqueous guest 
this structure is changed to a channel structure, as observed in this case, suggesting molecular guest 
inclusion.243 
However, to confirm fully inclusion of the thiamphenicol molecule into the γ-CD pores, the 
molecular complex was subjected to full NMR analysis.  
6.3.1.2 NMR analysis 
NMR analysis was performed on single crystals screened to have the same unit cell parameters as 
the inclusion complex for which full single crystal data had been collected, to ensure the sample 
analysed by NMR was an inclusion complex and not a mixture of the two starting materials.  
 
 
Figure 6.8: Staggered arrangement of γ–CD molecules in native γ-CD as viewed 





Figure 6.9: 1H NMR spectra of each of the two starting materials and the inclusion complex 
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The NMR spectrum can be seen to be an amalgamation of the two individual components; the 
region between 3.4 and 3.9 ppm was horizontally expanded to allow resolution of overlapped peaks 
(Figure 6.10), thus illustrating the good agreement of the complex with the individual γ-CD and 
thiamphenicol spectra. 
Molecular inclusion complex of γ-CD and THM (D2O, 500 MHz, 298 K) δ (ppm): 3.21 (s, 3H, CH3 
THM), 3.56 (t, 8H, H4 γ-CD), 3.63 (dd, 8H, H2 γ-CD), 3.69 (t, 1H, CH THM), 3.86 (m, 36H, H3, H5, H6 
γ-CD), 4.21 (m, 1H, CH THM), 5.08 (s, 8H, H1 γ-CD), 5.18 (s, 1H, CHCl2 THM),  
7.66 (d, 2H, ArH, THM), 7.91 (d, 2H, ArH, THM) 
As noted above, in order to investigate the stoichiometry of the inclusion complex, Job’s method 
of continuous variation was employed. Plotting of the values in Table 6.1 and Table 6.2, results in 








Figure 6.10: Horizontal expansion of the region between 3.4 and 3.9 ppm to 













The point at which the maximum in the curve is observed indicates the host: guest stoichiometry. 
The maxima in Figure 6.11 occur at a mole fraction of γ-CD of 0.7 for the γ-CD protons and 0.3 for 
the thiamphenicol protons, this indicates the two compounds bind in a 2:1 γ-CD: thiamphenicol 
ratio. 242 This ratio provides further indication that this system could be successful at stabilising the 
hydrolytically unstable thiamphenicol molecule; by incorporating inside two neighbouring CD 
molecules, all parts of the relatively long chain of the API will be encapsulated in a water excluded 
cavity. Knowledge of this binding ratio is also crucial for the transfer of this hosting system into 
cooling crystallisation environments (Section 6.3.1.4) by allowing solubility and stoichiometry to be 
controlled.  
DOSY 1H NMR spectroscopy (Figure 6.12) was also performed to verify if the components remain 
associated with one another in the solution state; this would be of relevance to the delivery of CD 
hosted thiamphenicol in aqueous environments such as the body. It can be seen that the 
thiamphenicol is diffusing at a speed of approximately 4.5 x 10-10 m2s-1, whereas the larger γ-CD is 
diffusing at a slower speed of 2.5 x 10-10 m2s-1. As these diffusion speeds are not comparable, it can 
be concluded that the thiamphenicol and γ-CD exist in equilibrium in the solution state. This is of 
particular interest when the stability of the complex in an aqueous environment is considered 
(Section 6.3.1.3) and when thinking about potential uses as a form of drug delivery. 




6.3.1.3 Stability analysis 
A variety of different methods were considered in order to show whether by incorporating 
thiamphenicol inside γ-CD, the hydrolytic stability of the former is increased. In solution, the two 
compounds exist in equilibrium, meaning the thiamphenicol molecule is not always associated with 
a cyclodextrin molecule. As such, all solution based methods for both testing and analysis had to be 
discounted for the purposes of this work. As a method to test hydrolytic stability this eliminates 
slurrying techniques; owing to its higher aqueous solubility, γ-CD would preferentially dissolve in 
this case, leaving the thiamphenicol molecule exposed to the aqueous environment. In terms of 
analysis of the samples, methods such as HPLC and solution NMR also had to be eliminated from 
consideration. 
As such, preparation and analysis using solid state methods was required. In attempts to induce 
hydrolysis in a solid state environment, samples were placed in a humid environment: a tub of salt 
with some water to add moisture was placed inside an oven set at 100 °C, with the samples placed 
within a small glass vial embedded into the salt. Samples of the complex and of thiamphenicol alone 
(to act as a control sample) were placed in these conditions for a period of one month. Analysis of 
the samples was undertaken using solid state 13C NMR (SSNMR); PXRD was deemed inappropriate 
as the pattern is swamped by peaks from the cyclodextrin molecule and PXRD patterns of inclusion 
complexes of CDs are similar irrespective of the guest molecule included within the cavity. Thus, 
possible small changes in the thiamphenicol structure would not be visible through analysis with 
PXRD.  
Figure 6.12: DOSY NMR spectra of the thiamphenicol: γ-CD inclusion complex 
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A SSNMR spectrum of the complex before being placed in humid conditions was taken in order to 
allow comparison to be made (Figure 6.13). 
Inclusion complex of thiamphenicol and γ-cyclodextrin 13C SSNMR (125 MHz, 298 K) δ (ppm):  
44.4 (C16 THM), 61.0 (C6 γ-CD), 73.4 (C2, C3, C5 γ-CD C14, C15 THM), 82.5 (C4 γ-CD, C7, C8, C9, C10. 











Figure 6.14: SSNMR spectrum of the complex after being subjected to stressed (humidity) conditions 
(the peak broadening compared with that in Figure 6.13 indicates the sample has turned amorphous) 
Figure 6.13: SSNMR of the inclusion complex before being placed in humid conditions 
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Figure 6.14 shows the SSNMR spectrum of the molecular inclusion complex of γ-CD and 
thiamphenicol after being subjected to humidity conditions (90% RH, 100 °C) for a month. The 
broad nature of the peaks suggests the stressed conditions have resulted in the sample turning 
amorphous. However, all peaks positions remain the same, and despite loss of definition, it can be 
suggested that the complex remains intact upon exposure to humid conditions for a one month 
period. However, due to the peak broadening, it is not possible to track the small shifts that would 
be expected in the carbonyl peak at 165.3 ppm in the case where hydrolysis of the amide to a 
carboxylic acid group had taken place. As such, another method of monitoring potential solid-state 
hydrolysis in these samples is required; however, due to the time constraints of this project, this 
could not be performed and would be the subject of any further work on the system. Possible 
experiments could include using another salt such as potassium sulfate that would provide high 
humidity conditions at lower temperatures, aiding the sample to retain its crystallinity. The 
potential validity of this approach is supported by the observation that the sample of thiamphenicol 
placed in the same conditions melted over the exposure time.  
The indication from SSNMR that the samples, while potentially retaining the integrity of the 
thiamphenicol within the complex, turned amorphous upon being treated under stressed 
conditions, prompted investigations into the relative thermal stability of the molecular inclusion 
complex in comparison to the two starting materials. DSC was used in order to evaluate the melting 
temperature of each of the three materials (Figure 6.15). 
 
Thiamphenicol melts at a temperature of 165.6 °C, characterised by the sharp endothermic event 
in Figure 6.15. There is a broad endothermic event in the region 90-120 °C in the DSC traces for 
Figure 6.15: DSC analysis of thiamphenicol, γ-CD and the molecular inclusion complex of 
thiamphenicol and γ-CD (exothermic up) 
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both γ-CD and the inclusion complex. Since both CD and the complex have lattice water, and since 
the broad nature of the peak suggests it is not a melt event, thermogravimetric analysis (TGA) 
(Figure 6.16) was performed in order to elucidate the origin of this event. In its native state, γ-
cyclodextrin contains water molecules, bound both inside the cavity and hydrogen bonded to 
external hydroxyl groups. The TGA trace (Figure 6.16) shows a percentage mass loss of 7.6 % 
between 30 °C and 130 °C. According to the crystallographic information for γ-CD, it contains 14 
water molecules in its native state, eight of which are bound within the cavity and six are bound 
externally, as would be seen in a conventional hydrated crystal structure. Those bound around the 
external perimeter of the CD molecule will be easier to release than those bound inside the cavity. 
As such, it is suggested that the 7.6 % mass loss observed in the TGA corresponds to those six water 
molecules bound around the edge of the cyclodextrin molecule (the theoretical % mass loss for 
these is 8.3 %). In the inclusion complex, the crystal structure confirms water to be present only 
around the edges of the cyclodextrin molecule, as thiamphenicol has displaced that which was in 
the cavity. Therefore, in the DSC of the complex, it would be expected that this water would also 
be lost over a similar temperature range as that in γ-CD. Although TGA was unable to be performed 
on the complex, it is reasonable to conclude that the endothermic event in the DSC of both γ-CD 
and the inclusion complex of γ-CD and thiamphenicol can be attributed to the loss of water bound 
around the edges of the cyclodextrin molecules. 
The larger mass loss of 70 % at ~300 °C can be attributed to the thermal degradation of the glucose 
units in γ-CD, into carbon and water vapour. Taking into account the removal of six water molecules 
from the thermal event at lower temperatures, the chemical formula remaining in γ-CD is 
C48H80O40·8H2O. Decomposition into carbon and water would result in the release of 48 water 
molecules, equivalent to a mass loss of 67 %. The DSC of γ-CD (Figure 6.15) shows an endothermic 
Figure 6.16: TGA analysis of γ-CD 
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event at the same temperature as this large mass loss in the TGA, further supporting this 
interpretation. 
Crucially, the melt of the inclusion complex, characterised by a sharper endothermic event than the 
loss of water, can be seen to be at a temperature of 239.04 °C, 73.62 °C higher than the melt of 
pure thiamphenicol. This suggests that through complexation with γ-CD, the thermal stability of 
thiamphenicol has been substantially increased. This has importance when considering the high 
temperatures that could be encountered during processing of drug products. After the melt of the 
complex, there is a sharp exothermic event and upon removal of the pan from the DSC, the pan had 
‘jumped’ off its stand. It is documented that at high temperatures glucose, which is the primary 
building block of γ-CD, undergoes caramelisation before decomposing into carbon and water which 
could provide an explanation for this exothermic event.244  
6.3.1.4 Transfer to cooling crystallisation 
Utilising the knowledge that the host-guest complex formed has a 2:1 γ-CD: thiamphenicol binding 
ratio, as obtained from the Job plot (Figure 6.11), it was possible to design initial cooling 
crystallisations at the 1.5 ml scale. As there was no prior knowledge of the solubility of system, 
varying concentrations of thiamphenicol (the API) ranging between 3 mg/ml and 17 mg/ml and the 
corresponding molar ratios of γ-cyclodextrin (24 mg/ml – 120 mg/ml) were weighed into 1.5 ml 
vials and 1.5 ml of water added. Water was chosen as a solvent to ensure no preferential inclusion 
of solvent over thiamphenicol inside the cyclodextrin cavity. The concentrations of thiamphenicol 
were chosen based on those utilised in the previous evaporative crystallisation experiments that 
were dissolved in a similar volume of solvent. 
Vials were subjected to cooling from 50 °C to 5 °C at a rate of 0.1 °C min-1 with a magnetic bottom 
stirring speed of 300 rpm. Only those vials containing higher concentrations of the two components 
resulted in crystallisation, however not enough solid was produced to allow PXRD analysis of the 
solid form produced or accurate determination of crystallisation yields. This prompted experiments 
with higher concentrations of thiamphenicol (27 mg/ml – 40 mg/ml) and γ-CD (170 mg/ml – 
270 mg/ml), still in a 1:2 (THM: γ-CD) ratio. All concentrations explored resulted in crystallisation of 
the molecular inclusion complex, as confirmed through PXRD and through comparison of PXRD 
patterns obtained from the samples generated from cooling with those from ground-up single 
crystals obtained from evaporative crystallisations (Figure 6.17). Some of the peaks in the PXRD 
display differing intensities (most obviously the peak at 35 ° 2θ), which can be attributed to 
preferred orientation effects; grinding of single crystals from evaporative crystallisations compared 
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to a fine powder as the product of a cooling crystallisation could result in preferential alignment of 
some lattice planes over others, giving rise to these effects. 
As a proof of concept 2:1, 1:1 and 1:3 (THM: γ-CD) molar ratios of thiamphenicol: γ-CD were also 
investigated in the cooling crystallisation environment. Both the 2:1 and 1:1 molar ratios resulted 
in the crystallisation of thiamphenicol on its own, with the more soluble γ-CD remaining in solution. 
The 1:3 molar ratio resulted in the crystallisation of the molecular inclusion complex of 
thiamphenicol and γ-CD, however excess γ-CD was detectable by PXRD, through a small but 
characteristic peak at 5° 2θ (Figure 6.18). 
Attempts were made to scale the system beyond the 1.5 ml scale, first utilising a working volume 
of 5 ml. The higher concentrations explored in the 1.5 ml scale experiments (THM between 
27 mg/ml and 40 mg/ml and γ-CD between 170 mg/ml and 270 mg/ml) were used at the 5 ml scale. 
Figure 6.18: PXRD pattern of the crystallisation product using a 1:3 THM: γ-CD ratio, showing 
excess γ-CD boxed in red 




Again vials were subjected to a 50-5 °C cooling regime at 0.1 °C min-1 with 300 rpm magnetic 
bottom stirring. Solids produced in the experiment were harvested through vacuum filtration and 
dry solid analysed by PXRD. It was observed that the solid was viscous and had ‘sticky’ properties. 
This property decreased with increasing concentration of the two components.  
The PXRD patterns from the harvested solid (Figure 6.19) show a good match with the PXRD pattern 
obtained from single crystals of the complex. However, the peaks, particularly those at higher 2θ 
values, show some broadening in comparison to the evaporative pattern. This suggests some 
amorphous character in the solid, further supported by the observation of ‘sticky’ solid. It can be 
suggested that the grinding action of the magnetic stirrer could be contributing to this. As such, 
experiments utilising overhead stirring would be beneficial to see if the overall crystallinity of the 
product can be improved; however due to time restraints, this work was unable to be completed 
during this project.  
Further, only one cooling rate was explored in this work (0.1 °C min-1), which would not be 
conducive to transfer into continuous crystallisation environments. As such, future work should 
look into investigating faster cooling rates that would be more amenable to transfer to continuous 
crystallisation platforms. However, it is important to note that initial transfer to a cooling 
crystallisation environment, as achieved successfully in the present work, is a crucial first step 




Figure 6.19: PXRD pattern showing the production of the molecular inclusion complex at 
the 5 ml scale 
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6.3.2 The molecular complex of α-lipoic acid and β-cyclodextrin 
The molecular inclusion complex of α-lipoic acid (ALA) and β-cyclodextrin (β-CD) (CSD ref: HAXJIB, 
Figure 6.20), has been shown to improve the thermal stability of ALA, and its structure has been 
determined from PXRD data. This shows binding in a 1:1 molar ratio. 235 
6.3.2.1 NMR analysis 
In order to confirm complexation in a 1:1 ratio, Job’s method of continuous variation was used. 
Plotting of the data displayed in Table 6.3 and Table 6.4 resulted in the Job plot shown in 
Figure 6.21. The peak at a mole fraction of β-CD of 0.5 indicates binding in a 1:1 ratio. 
Figure 6.20: The crystal structure of the inclusion complex of ALA and β-
CD, as viewed down the crystallographic c axis 
Figure 6.21: Job plots for the inclusion complex of ALA and β-CD 
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6.3.2.2 Transfer to cooling crystallisation 
The ALA-β-CD complex reported in the literature was formed from a 60:40 MeOH: H2O mixture. 
This acted as an initial starting point for the transfer of synthesis of the inclusion complex to a 
cooling crystallisation environment. Crude solubility measurements were performed in this solvent 
system, which showed 30 mg of ALA to dissolve in 1 ml of solvent. As such, varying concentrations 
of ALA (5, 10, 15 and 20 mg/ml) with the corresponding 1:1 molar ratio of β-CD 
(27.5, 55, 82.5 and 110 mg/ml) were weighed into 1.5 ml vials and 1.5 ml of 60:40 MeOH: H2O 
added. To allow complete dissolution of the higher concentrations, vials had to be heated to 70 °C. 
Vials were then cooled from 70 °C to 5 °C at 0.1 °C min-1, with a magnetic bottom stirring speed of 
400 rpm. Solid was harvested via vacuum filtration and analysed with PXRD. 
PXRD patterns (Figure 6.22) show peaks characteristic of the complex as predicted from single 
crystal data. However, the high, curved background suggests amorphous characteristics. It is 
possible that the need to heat the solutions to 70 °C, for dissolution of higher concentrations, 
caused the ALA to melt (Tm = 60 °C), could be responsible for some of the amorphous characteristics 
seen here.  As such, for future experiments, concentrations were reduced to allow dissolution at a 
temperature of 55 °C. All crystallisations presented hereafter were subjected to a 55 °C to 5 °C cool, 
with further experimental details given in Table 6.5.  
 
 
Figure 6.22: PXRD analysis from initial cooling crystallisation experiments showing comparison to the 
PXRD pattern predicted from single crystal data for the inclusion complex; although peaks from the 
complex are present the pattern displays amorphous characteristics 
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Table 6.5: Experimental information for cooling crystallisations of ALA and β-CD (throughout all experiments a 
concentration of ALA of 6.7 mg/ml and β-CD 36.7 mg/ml and a stirring rate of 400 rpm was used) 
Experiment 
set 




































Experiment Set 1 
Experiment Set 1 investigated varying ratios of methanol and water on the crystallisation outcome. 
The percentage of methanol in a water/methanol mix was varied between 0 % (100 % water) to 
100 %. Crystallisation was observed in all eight vials, with solids analysed through PXRD. 
PXRD analysis (Figure 6.23) shows that those vials containing higher percentages of water resulted 
in the crystallisation of complex. However, upon increasing the concentration of methanol, the 
selective crystallisation of β-CD is observed. This can be explained by considering the high water 
solubility of β-CD; upon increasing the proportion of methanol (in which β-CD is insoluble), the  
β-CD becomes less soluble and starts to crystallise alongside the inclusion complex. The PXRD 
patterns produced still contain some broad peaks, but are more crystalline than those in previous 
Figure 6.23: PXRD analysis showing the presence of complex in those vials containing higher 
percentages of water and β-CD in those vials containing higher percentages of MeOH 
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experiments (shown by lack of the amorphous hump that was prominent in the samples cooled 
from 70 °C (Figure 6.22)). 
Experiment Set 2 
Experiment Set 2 utilised the observations from Experiment Set 1 and only considered those 
crystallisations containing higher percentages of water. Two vials of each of the 100:0, 90:10 and 
80:20 (H2O: MeOH) solvent ratios were cooled from 55 °C to 5 °C. The scaling potential of the 
system was investigated by increasing the working volume to 12 ml. Crystallisation was observed 
in all vials with the solid harvested and analysed by PXRD. The PXRD patterns for the solid products 
of the 100:0 and 90:10 (H2O: MeOH) were noisy and showed poor crystallinity. However, those 
produced from the 80:20 (H2O: MeOH) show a higher degree of crystallinity, with peak positions 
matching those of the calculated pattern for the molecular inclusion complex, while still showing 
evidence of amorphous component (Figure 6.24). 
Experiment Set 3 
Experiment Set 3 investigated a change in the alcohol solvent present in the solvent mixture. 
Methanol is an ICH Class 2 solvent and would not be recommended for industrial large scale 
applications owing to its toxicity. As such ICH Class 3 alcohol solvents, namely ethanol (EtOH) and 
isopropanol (IPA), were investigated. Based on observations from Experiment Set 1 and Experiment 
Set 2, which showed that higher water: alcohol ratios resulted in the formation of the molecular 
inclusion complex, only 80:20, 90:10 and 100:0 (water: alcohol) ratios were investigated. The 
cooling profile (55 °C to 5 °C at 0.5 °C min-1) remained the same as Experiment Set 2 to allow direct 
comparison between the results. Crystallisation of the target ALA-β-CD complex was observed in 
Figure 6.24: PXRD pattern confirming production of the molecular inclusion complex of 
ALA and β-CD at the 12 ml scale 
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all solvent compositions, however those containing an 80:20 water: alcohol ratio produced more 








Experiment Set 4  
Although crystallinity is improved through incorporation of small amounts of alcohol in the solvent 
mix, some peaks are still broad. As such, Experiment Set 4 investigated the effect of a slower cooling 
rate on the crystallisation outcome. By employing a slower cooling rate (0.05 °C min-1), the 
crystallisation could be under thermodynamic rather than kinetic control, giving greater control 
over the particle attributes; this is the same reason that slow evaporation is usually the method of 
choice to obtain large single crystals suitable for X-ray diffraction. All other experimental 
parameters remained the same as Experiment Set 3, only investigating those solvent compositions 
containing higher proportions of water. Harvested solid analysed via PXRD confirms the presence 
of the molecular inclusion complex, again with the samples from the 80:20 water: alcohol mixtures 
producing samples with the highest crystallinity (Figure 6.26). 
Figure 6.25: PXRD patterns for Experiment Set 3, showing the production of the 
molecular inclusion complex 




Interestingly, the samples produced using small quantities of EtOH and IPA display higher 
crystallinity than those produced in other experimental sets using methanol. It can be suggested 
that the complex displays a slightly lower solubility in these two solvent mixes; the lower solubility 
would ensure crystallisation in a more controlled manner rather than having to induce 
crystallisation quickly through cooling to low temperatures. The latter would give less control over 
the crystallisation, resulting in a less crystalline product.  
Experiment Set 5 and 6 
Although samples produced in Experiment Set 4 showed a good degree of crystallinity, a cooling 
rate of 0.05 °C min-1 would not be amenable to transfer to a continuous crystallisation environment, 
which would be the eventual aim of the work presented here. As such, a faster cooling rate was 
investigated. A cooling rate of 0.5 °C min-1 investigated in Experiment Sets 1-3 still resulted in 
formation of the target complex, but with PXRD showing some amorphous characteristics; as such, 
a cooling rate of 0.1 °C min-1 was investigated. Although not conducive to continuous crystallisation 
platforms, this cooling rate would result in a batch crystallisation of ca 8 hours. Although shorter 
experiment times are desirable in terms of maximising throughput in limited and expensive plant 
times, if a large scale batch crystallisation route to this hosting complex could be established, this 
could serve as a method for seed generation for more efficient continuous crystallisation processes. 
Again, only 80:20 and 90:10 (water: alcohol) solvent mixtures were investigated. Each vial was 
subjected to a 55 °C to 5 °C cool at a rate of 0.1 °C min-1. Experiments were performed at the 6 ml 
and 12 ml volume scale. Solid from each vial was harvested and analysed through PXRD 
(Figure 6.27). 
Figure 6.27: PXRD patterns showing the production of the inclusion complex at both the 
6 ml and 12 ml scale 
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At both scales, all solvent compositions resulted in the formation of the molecular inclusion 
complex of ALA and β-CD, as confirmed through comparison with the calculated pattern from single 
crystal data. The samples produced display a good degree of crystallinity, showing sharp, well 
defined peaks. Scaling beyond the 12 ml scale would be desirable, in particular investigations with 
overhead stirring, and could be the subject of any future work on the system. 
6.4 Conclusions 
Two systems, in which a reactive pharmaceutical compound has been hosted within a benign 
molecule with a view of increasing the stability of the pharmaceutical, have been studied in the 
work presented in this chapter. In work presented in the literature, α-lipoic acid (ALA), which 
displays poor thermal stability with respect to cleavage of the S-S bond, has been shown to be 
hosted within β-cyclodextrin. The resulting molecular complex was shown to increase the thermal 
stability of the ALA.  
Utilising the premise of hosting within benign cyclodextrin molecules, the second targeted molecule 
of the work presented in this Chapter was the antibiotic thiamphenicol, which displays poor 
hydrolytic stability. Initial evaporative crystallisations with thiamphenicol and the three native 
cyclodextrins (α-CD, β-CD and γ-CD) resulted in the formation of the molecular inclusion complex 
of thiamphenicol and γ-cyclodextrin (γ-CD). Initial evidence for inclusion of thiamphenicol inside 
the γ-CD molecule was provided by a change in the crystal structure; in its native state, γ-CD forms 
staggered chains, whereas once a molecule is included within its pore this changes to a channel 
structure. However, the thiamphenicol molecule was unable to be resolved from crystallographic 
data. As such, other methods for confirming inclusion were required and full NMR analysis on the 
system was conducted. Initial NMR analysis on single crystals screened to have the same unit cell 
parameters as the molecular inclusion complex showed both γ-CD and thiamphenicol to be present 
in the sample, providing further evidence of inclusion of the thiamphenicol into the cavity of the  
γ-CD molecule. The method of continuous variation, whereby shifts in peaks in an NMR spectrum 
upon changing the ratio of the two components whilst keeping the total concentration of the 
solution constant, was used in order to determine the binding ratio of the complex through 
formation of Job plots. The protons tracked during these titration experiments were those that 
would be involved in the interaction between the thiamphenicol molecule and the inner cavity of 
γ-CD. The mole fraction at which the peak in the Job plot is seen indicated the stoichiometry in 
which the two components bind; here it was determined that the two molecules bind in a 2:1  
(γ-CD : thiamphenicol) ratio. 
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Following full NMR analysis on the molecular inclusion complex, the effect of stressed conditions 
on the hydrolytic stability of the thiamphenicol was investigated. Samples were placed in a humid 
environment for a period of a month, analysed before and after with SSNMR. The stressed 
conditions resulted in the samples turning amorphous, characterised by broad peaks in the SSNMR, 
with the thiamphenicol sample melting under these conditions. However, all key peaks were still 
present after being subjected to humid conditions, indicating both compounds remain within the 
molecular complex. However, the small shifts that would be expected upon hydrolysis of the amide 
carbonyl in thiamphenicol to a carboxylic acid were unable to be tracked due to the broad peaks. 
As such, another method is sought in order to generate conditions for the examination of potential 
hydrolysis in the solid state; solution state methods are deemed inappropriate as the two 
components do not remain associated in solution (as confirmed through DOSY NMR) which would 
leave the thiamphenicol molecule exposed to hydrolysis. 
However, the observation that the samples turned amorphous under stressed conditions prompted 
analysis of the thermal stability of the inclusion complex. DSC analysis confirms an increase in the 
melting point of the complex in comparison to the thiamphenicol starting material (239 °C vs 
165 °C), indicating the thermal stability of thiamphenicol has been increased. The ability to increase 
the thermal stability of APIs through incorporation inside benign host molecules is of great interest 
if the pharmaceutical displays a low thermal stability; many downstream processes can require high 
temperatures that would be detrimental to the solid form of these APIs.  
Due to the evident improvement in physical properties achieved through complexation, the 
transfer to a cooling crystallisation environment for both the molecular inclusion complex of  
ALA: β-CD and thiamphenicol: γ-CD was targeted. Binding ratios from each of the Job plots were 
used to aid initial cooling crystallisation design. Both systems produced the desired formation of 
the inclusion complexes, but with samples that displayed poor crystallinity initially. However 
optimisation of crystallisation conditions such as cooling rate and solvent composition allowed the 
crystallinity to be improved. The cooling crystallisation of the molecular inclusion complex of ALA 
and β-CD was further optimised in two different solvent systems, using three cooling rates and 
scaled to volumes of 12 ml. The transfer of the synthesis of these hosting complexes, which increase 
the thermal stability of the API, to cooling crystallisation is a key first step in the transfer to 





7 Conclusions and Future Work 
7.1 Conclusions 
The work presented in this thesis has looked at obtaining solid form control of active 
pharmaceutical ingredients (APIs) through multi-component techniques; here solid form 
encompasses different polymorphic forms of the same chemical entity as well as the chemical and 
physical stability of single molecular components. This work was performed with a view of 
transferring systems displaying solid form control into a continuous crystallisation environment. 
The ability to control the polymorphic form of APIs is of great interest to both academia and 
industry with different polymorphic forms often displaying markedly different properties. 
Literature reports on large scale manufacture of metastable polymorphic forms are limited, with 
no reports on the continuous crystallisation of metastable APIs. In the work presented in this thesis 
a second molecular component is added to the crystallisation process to direct the formation of a 
metastable polymorphic form; this second molecular component is termed a template molecule.  
Work on controlling polymorphism through this templated approach has focussed on the API 
paracetamol (PCM). Two of PCM’s five polymorphic forms have been of interest in this work; the 
thermodynamically stable PCM-I and the metastable PCM-II. PCM-II displays a layered arrangement 
of molecules in the crystal structure, giving this form enhanced compressibility; PCM-II also displays 
an enhanced solubility in comparison to the stable PCM-I. As such it represents a desirable target 
for large scale production. 
Initial studies built on previous literature work that highlighted the possibility to template PCM-II 
with a variety of p-substituted benzoic acid derivatives in an evaporative crystallisation 
environment. The transfer to a cooling crystallisation environment, which is the principle on which 
many of the currently marketed continuous crystallisers operate, was targeted. Use of 4-
fluorobenzoic acid (4-FBA) as a template molecule in a 60:40 H2O:IPA solvent system allowed for 
the reproducible production of PCM-II on the 1 ml solvent scale. However, attempted scale up of 
this templated crystallisation was largely unsuccessful; it is postulated that this is due to the low 
solubility of the templating molecule combined with the poorer mass transfer that is experienced 
upon scaling to larger volumes and vessel sizes. Seeding experiments at the 50 ml scale in both the 
absence and presence of 4-FBA as a template molecule were also performed to investigate the 




The lack of success, in terms of scaling potential, with the substituted benzoic acids as additives 
prompted work with template molecules which display a structural similarity to PCM, which had 
only previously been studied in relation to their effect on the morphology of PCM-I. Small scale 
studies with magnetic bottom stirring were conducted with six structurally similar, size-matched 
template molecules: metacetamol (MCM), orthocetamol (OCM), 3’-amino-4-methoxyacetanilide 
(3A4MA), p-acetanisidide (PACN), 4-acetamidobenzoic acid (4ABA) and methyl paraben (MP).  The 
use of 2.4 % OCM combined with a cooling rate of 0.02 °C min-1 resulted in the reproducible 
production of PCM-II at the 1 ml scale. However, attempts at scaling beyond this volume were 
unsuccessful, owing to the low solubility of the template molecule and poor mass transfer, as was 
observed with the substituted benzoic acids. Higher percentages of 3A4MA (35 %) were required 
in order to direct the formation of PCM-II; however, use of this template molecule allowed for 
production at the 10 ml scale with a cooling rate of 1 °C min-1, a cooling rate which is more 
conducive to transfer to a continuous crystallisation environment. However all attempts at scaling 
beyond this volume have been unsuccessful and the presence of excess template molecule is 
detectable in the solid product through PXRD. 
Use of MCM as a template molecule has provided the most success, with the reproducible 
production of PCM-II observed initially up to the 20 ml solvent scale in two different solvent systems 
(60:40 H2O: IPA and ethanol) at three different cooling rates (0.02, 0.2 and 1 °C min-1). Percentages 
of MCM as high as 25 % were required in order to direct the formation of PCM-II, resulting in the 
crystallisation of metacetamol hydrate impurity alongside PCM-II in the final solid product when 
the crystallisations were cooled to a temperature of 5 °C. However, truncation of the cooling profile 
at a temperature of 20 °C resulted in elimination of this hydrated form from the final solid product. 
PCM-II samples produced from these small-scale additive experiments with both the substituted 
benzoic acids and the structurally similar template molecules are stable for a period of 24 months 
at the time of writing, indicating the high polymorphic purity of these samples. Investigations 
carried out in this thesis whereby samples of PCM-II were doped with varying quantities of PCM-I 
showed that the presence of 1 % or more of PCM-I within a PCM-II sample initiates the conversion 
to PCM-I within one month.  
Further investigations into the scaling potential of the PCM/MCM system were conducted at the 
100 ml scale utilising overhead stirring. A full factorial Design of Experiments (DoE) analysis with 
five factors was conducted at this scale in order to determine the conditions under which PCM-II 
could be produced in highest yield and both polymorphically and chemically pure (i.e. in the 
absence of any PCM-I or MCM.H2O). This DoE analysis highlighted the importance of stirring rate 
218 
 
and the temperature at which the cooling profile was truncated, for the production of PCM-II 
samples with a high degree of purity; a faster stirring rate and higher truncation temperature were 
required. Optimal concentrations of PCM and MCM were also highlighted to result in highest yields; 
as such for all future experiments a concentration of PCM of 300 mg/g coupled with a wt. % MCM 
of 25 % were used. Further batch scaling of the templated crystallisation of PCM-II with MCM as a 
template molecule was conducted at the 800 ml volume at the CMAC National Facility, housed 
within the Technology and Innovation Centre at the University of Strathclyde. The crystallisation 
was monitored with inline PAT: a Raman PhAT probe to monitor the polymorphic form produced 
and an FBRM probe to track nucleation events. This crystallisation allowed for the production of 
120 g of PCM-II in a single process run, one of the only reported examples of the scaled production 
of a metastable polymorphic form of an API. However, solid samples did contain small quantities of 
the metacetamol hydrate impurity that proved challenging to eliminate from large scale batch 
crystallisation experiments, likely due to inefficient mixing upon scale-up.  
The transfer of the templated crystallisation of PCM-II with MCM as a template molecule to three 
continuous crystallisation platforms was investigated. In order to mimic the stepped cooling profile 
utilised in a batch crystallisation platform, a two-stage MSMPR set-up at AstraZeneca in 
Macclesfield, operated in periodic mode, was employed.  Initial crystallisations resulted in the 
crystallisation of PCM-II, however some PCM-I was present in the solid product. SEM images of the 
dry solid product show two distinct crystal morphologies: hexagonal blocks attributed to  
PCM-II with small needle crystals postulated to be due to the presence of PCM-I. However, this 
PCM-I was eliminated from future experiments through alteration of the temperature profile, 
allowing more controlled crystallisation at a lower supersaturation ratio. This crystallisation 
platform eliminates the metacetamol hydrate impurity from the final PCM-II solid product, 
producing samples of high polymorphic purity that show the expected good stability with respect 
to the PCM-II to PCM-I solid state transformation.  
The continuous templated crystallisation of PCM-II was investigated in two tubular continuous flow 
platforms. A re-configurable continuous oscillatory baffled crystalliser (COBC), ranging from four to 
twelve straights, allowed for reproducible production of PCM-II; however elimination of the 
metacetamol hydrate impurity seen in batch crystallisations proved problematic. Varying 
temperature regimes and a reduction in the percentage of MCM were investigated in order to 
eliminate this hydrate impurity from the solid product. It was found that the system had to be set 
up to allow crystallisation at a sufficiently high temperature to ensure elimination of this hydrate 
phase, however the limited residence times experienced in the crystalliser meant lower 
219 
 
temperatures had to be used in order to induce any crystallisation in the system; the presence of 
MCM in the system has the effect of widening the MSZ, delaying the onset of nucleation. These 
relatively short residence times within the crystalliser resulted in incomplete desupersaturation of 
the system, causing detrimental filtration issues in many crystallisations. However, the superior 
mixing conditions seen in the COBC, owing to its baffled geometry with small volumes of fluid 
contained within each baffle, meant that the additive concentration of MCM could be considerably 
reduced from that used in batch crystallisation experiments (from 25 % to 18 %). With a need for 
high product purity, this reduction in template molecule concentration is highly desirable. 
The second tubular continuous flow crystallisation platform employed to investigate the 
continuous crystallisation of PCM-II was the kinetically regulated automated input crystalliser 
(KRAIC), an open tubular crystalliser that operates on the principle of segmented flow. A cold tube 
needed to be incorporated into the set-up to induce nucleation in the crystalliser, to account for 
the main coils not being able to be cooled below ambient temperature. Initial adjustment of the 
cooling profile was needed after nucleation before the mixer piece resulted in the crystallisation of 
PCM-I. Upon this adjustment and confining the controlled nucleation to the cold tube, PCM-II was 
produced. However, in all experiments performed in this platform solid yields were poor and so 
further optimisation of the cooling crystallisation is needed to improve these yields. As with the 
COBC, the poor yields can be attributed to the relatively short residence times within the system; 
as the residence time within the crystalliser is determined by a fixed length of tubing and limited 
by experimentally achievable flow rates, it cannot be increased and modification to the current set-
up would be required. 
Although the crystallisation of PCM-II has been successfully observed, for the first time, in three 
separate continuous crystallisation platforms, only one of these platforms (the PMSMPR) yields 
samples of PCM-II that display both high chemical purity, indicated by the absence of any 
metacetamol hydrate impurity, and high polymorphic purity, indicated by both the absence of any 
detectable PCM-I and by good stability with respect to the PCM-II to PCM-I solid state 
transformation. Operation of the MSMPR in periodic mode is more suitable for systems, such as 
the one investigated here, that display slow nucleation kinetics, as opposed to flow crystallisers 
where the residence time is dictated by experimental limits on flow rates and crystalliser length.  
Investigations were also conducted into the possible mechanism of action of the template molecule 
in the production of PCM-II. Slurrying experiments, whereby PCM-II was slurried in the chosen 
solvent system with varying percentages of MCM, showed inhibition of the solution mediated 
phase transformation from PCM-II to PCM-I at higher percentages of MCM, indicating solution 
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stabilisation of PCM-II in the presence of MCM. Analysis of the crystal structure of PCM-II and 
corresponding molecular structure of each of the template molecules allowed rationalisation as to 
why some template molecules were successful in the production of PCM-II, whilst others resulted 
in the crystallisation of PCM-I. 
The second approach to multi-component solid form control explored in this thesis was hosting of 
APIs which display poor stability, within benign host molecules. The antibiotic thiamphenicol, which 
displays poor hydrolytic stability, and α-lipoic acid (ALA), which displays poor thermal stability, were 
the API targets of this work. Previous literature work had shown that through incorporation inside 
β-cyclodextrin (β-CD), the thermal stability of ALA was increased. Utilising the premise of hosting 
within cyclodextrins, small scale evaporative crystallisations of thiamphenicol with the three native 
CDs yielded a new molecular inclusion complex of thiamphenicol and γ-cyclodextrin (γ-CD) which 
showed an increased thermal stability of the thiamphenicol molecule. Full NMR analysis was 
conducted on this new molecular inclusion complex to confirm inclusion of the thiamphenicol 
molecule, including the generation of a Job plot to show that the two components bind in a 2:1  
(γ-CD: thiamphenicol) ratio. Job plot analysis was also performed on the literature ALA: β-CD 
complex, confirming binding in a 1:1 ratio. The knowledge of these binding ratios was used to design 
successful cooling crystallisation routes to the molecular inclusion complexes, the first key step 
towards transfer to continuous crystallisation platforms.  
7.2 Future work 
7.2.1 Templating for polymorph control 
Much of the future work on the templated crystallisation of PCM-II would be directed towards the 
optimisation of the continuous crystallisation processes described in Chapter 5. It is clear that with 
the two tubular continuous flow crystallisers described (the COBC and the KRAIC) the limited 
residence time, due to fixed experimental parameters such as crystalliser length and flow rates, 
combined with a widening of the MSZ in the presence of MCM, were responsible for the small 
crystallisation yields observed in these systems. As such, further work would look to increase the 
residence time within these systems. For the COBC, it is highly likely that the addition of further 
straights would allow for the crystallisation of PCM-II in the absence of any metacetamol hydrate 
impurity. Therefore, a COBC set-up of increased length with the oscillation provided by either a full 
bellows set-up or a piston, to improve suspension of particles in later straights, would be targeted 
initially. Furthermore, sampling of the solution and operation in recycle mode would reduce the 
filtration problems experienced in many crystallisations as well as increasing operation times; the 
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latter would be of particular interest to observe whether the polymorphic form outcome could be 
retained over time. The KRAIC platform, which operates on much lower volumes than the COBC, 
highlights an interesting possibility for those systems outlined in Chapter 3, where the formation of 
PCM-II was only seen at much smaller volumes. As such, future work with the KRAIC set-up would 
look towards developing the continuous crystallisation of these systems.  
It would also be of interest to implement seeding approaches into the crystallisation of metastable 
PCM-II. The use of seeding may allow for a reduction in the concentration of MCM required to 
template PCM-II, a highly desirable objective with a need for product purity. However, 
considerations need to be taken into account regarding the suitability of conventional slurry 
seeding approaches as this would result in the solution mediated phase transformation from  
PCM-II to PCM-I. As such, investigations into dry seeding approaches in continuous crystallisation 
would need to be conducted.  
7.2.1.1 Assessing the transferability to the CMAC workflow 
A lot of work within the CMAC Hub consortium has been directed towards generating a workflow 
to aid in the development of a continuous crystallisation of a target compound. At the time of 
writing, the workflow consists of seven steps, outlined in the flow chart shown in Figure 7.1. The 
workflow has been applied to the development of a process for the continuous crystallisation of 
PCM-I, but is yet to be developed for a metastable polymorphic form. Owing to its enhanced 
physical properties, the development of this workflow for the metastable PCM-II would be of great 
interest. Some of the stages outlined have been wholly or partly covered by the work in this thesis 
(in particular Stage 1, Stage 5 and Stage 7). Future work should look towards developing the other 
stages in more detail. From the outset, owing to solubility data available at the time, a limited 
solvent selection was used in this work. It would be of interest to explore a variety of other solvents 
as this may also aid with the elimination of the hydrate impurity. The solvents could initially be 
screened for suitability based on solubility; if PCM is too soluble in a solvent the solution mediated 
phase transformation would be too rapid and stabilisation of the PCM-II would be difficult. These 
solubilities would have to be calculated by the use of ratios based on the solubility of PCM-I (see 
Chapter 3); this work is currently ongoing. This work on solubility and solvent choice encompasses 
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Stages 2-4 of the workflow. The PAT calibration subsection of Stage 4 has been conducted as part 
of the work presented in this thesis (Chapter 4). 
Much of the work presented in this thesis has given a strong system understanding (Stage 5), 
however further work in the understanding of agglomeration and fouling as well as measurement 
of both primary and secondary nucleation rates would be needed to complete this stage of the 
workflow. No work has currently been performed using model predictive control approaches, 
however their implementation into the crystallisation process could prove vital in obtaining optimal 
crystallisation conditions and would be very desirable for future work on the system. Proof of 
concept crystallisations, in the 60:40 H2O: IPA solvent system explored in this work, have been 
performed in three different continuous platforms, indicating a PMSMPR to be most amenable to 
the production of polymorphically and chemically pure PCM-II. However, the large scale continuous 
crystallisation of this templated crystallisation has yet to be investigated and would be the subject 
of future work. 





The subject of future work for the hosting compounds presented in Chapter 6 would be the 
determination of hydrolytic stability of the molecular inclusion complex of thiamphenicol and  
γ-CD. All methods currently investigated have proved unsuccessful in confirming whether, through 
incorporation inside a γ-CD host, the hydrolytic stability of thiamphenicol has been increased. A 
method of generating a humidity environment without subjecting the samples to high 
temperatures would reduce the tendency for the samples to become amorphous over time, as 
observed in this work; an example would be use of a K2SO4 tub at room temperature.  
The continuous crystallisation of the molecular of inclusion complex of ALA with β-CD and 
thiamphenicol with γ-CD will also be targeted, with the transfer of both systems to a cooling 
crystallisation environment demonstrated in Chapter 6 a key starting point. The continuous 
crystallisation of these systems is unprecedented in the current literature. Observations from 
cooling crystallisation experiments indicate that cooling to a temperature of 5 °C is required in order 
to induce significant crystallisation in the system. As such, it can be suggested that the COBC or an 
MSMPR crystalliser would be most suitable as initial targets for continuous crystallisation platforms 
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9.1 A3 (Chapter 3) 
Metacetamol crystallisations yields at 10 ml 
























% MCM Solvent Yield (%) 
5 EtOH 12.95 
10 EtOH 35.87 
25 EtOH 45.15 
10 60:40 H2O:IPA 71.98 
25 60:40 H2O:IPA 89.04 
Repeat 2 
% MCM Solvent Yield (%) 
5 EtOH 18.06 
10 EtOH 23.68 
25 EtOH 38.44 
10 60:40 H2O:IPA 76.66 
25 60:40 H2O:IPA 72.86 
Repeat 3 
% MCM Solvent Yield (%) 
5 EtOH 46.74 
10 EtOH 35.21 
25 EtOH 39.95 
10 60:40 H2O:IPA 73.79 
25 60:40 H2O:IPA 81.72 
Repeat 1 
% MCM Solvent Yield (%) 
5 EtOH 31.83 
10 EtOH 35.89 
25 EtOH 16.96 
5 60:40 H2O:IPA 65.98 
10 60:40 H2O:IPA 66.95 
25 60:40 H2O:IPA 70.72 
Repeat 2 
% MCM Solvent Yield (%) 
5 EtOH 43.26 
10 EtOH 42.71 
15 EtOH 48.94 
5 60:40 H2O:IPA 67.98 
10 60:40 H2O:IPA 66.82 
15 60:40 H2O:IPA 97.25 
Repeat 3 
% MCM Solvent Yield (%) 
5 EtOH 43.05 
10 EtOH 47.28 
15 EtOH 43.12 
5 60:40 H2O:IPA 78.75 
10 60:40 H2O:IPA 74.95 
15 60:40 H2O:IPA 74.00 
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5 Filtration problems meant the yields for the ethanol crystallisations could not be determined accurately 
Repeat 1 
% MCM Solvent Yield (%) 
10 EtOH 47.73 
25 EtOH 32.39 
10 60:40 H2O:IPA 69.48 
25 60:40 H2O:IPA 68.49 
Repeat 2 
% MCM Solvent Yield (%)5 
10 EtOH * 
20 EtOH * 
25 EtOH * 
10 60:40 H2O:IPA 65.76 
20 60:40 H2O:IPA 63.28 
25 60:40 H2O:IPA 64.52 
Repeat 3 
% MCM Solvent Yield (%)* 
10 EtOH * 
15 EtOH * 
20 EtOH * 
10 60:40 H2O:IPA 55.16 
15 60:40 H2O:IPA 61.76 
20 60:40 H2O:IPA 46.45 
Repeat 1 
% MCM Solvent Yield (%) 
10 EtOH 36.64 
20 EtOH 36.47 
25 EtOH 35.77 
10 60:40 H2O:IPA 58.64 
20 60:40 H2O:IPA 69.74 
25 60:40 H2O:IPA 55.26 
Repeat 2 
% MCM Solvent Yield (%) 
10 EtOH 21.59 
15 EtOH 37.24 
20 EtOH 30.91 
10 60:40 H2O:IPA 55.34 
15 60:40 H2O:IPA 65.88 
20 60:40 H2O:IPA 61.54 
Repeat 3 
% MCM Solvent Yield (%) 
10 EtOH 36.87 
15 EtOH 41.19 
20 EtOH 45.60 
10 60:40 H2O:IPA 68.68 
15 60:40 H2O:IPA 61.17 
20 60:40 H2O:IPA 58.53 
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